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Abstract 
This project focused on two facets of equine infectious anaemia virus (EIAV) 
biology; genomic characterisation and virus isolation. A lack of published full 
genome sequences has led to a poor understanding of genomic variation in 
the field and inability to design molecular detection methods. Equally the 
technically demanding nature of equine macrophages has led to much 
research EIAV being conducted using cell lines that cause viral adaption. Post 
mortem tissues from six and serum from one British outbreak cases were 
used to both sequence the full genome of novel field strains and develop a 
reproducible cell culture system that minimises adaption. Sequencing using 
primer walking and Sanger sequencing yielded the gag and pol of a 
symptomatic case but the high variability of the env prevented effective primer 
design. Next generation sequencing (NGS) was then used to avoid the 
requirement for sequence specific primers. The full genomes of the three 
symptomatic viruses were resolved. Two asymptomatic cases were also 
sequenced but no virus specific reads were returned. One symptomatic virus 
yielded a high coverage allowing a population analysis which showed the 
majority of variants localised to the gp90 glycoprotein. Each sequenced British 
genome added a new EIAV phylogenetic group with each group showing 
nucleic acid divergence of ~30% from the others. To develop a culture system 
that minimises adaption, primary monocytes were differentiated to 
macrophages using M-CSF and autologous equine serum, and successfully 
infected with the Wyoming strain. The system was used to successfully isolate 
virus from horses with clinical signs of infection. The activation of the 
macrophages had little effect on virus replication and dendritic cells appeared 
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to be unable to support efficient replication. Variation was seen between 
different monocyte isolations so the effect of single cytokines was tested, with 
IL-4 found to improve EIAV replication reproducibly. 
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1.0 Introduction: 
Equine infectious anaemia virus (EIAV) belongs to the lentivirus genus of the 
Retroviridae family, other lentiviruses include human immunodeficiency virus 
1 and 2 (HIV-1 & HIV-2), simian immunodeficiency virus (SIV), bovine 
immunodeficiency virus (BIV), feline immunodeficiency virus (FIV) and visna 
virus, all are of veterinary or human importance. EIAV is only known to infect 
members of the Equidae family, mainly equus caballus, which is a domestic 
subspecies of equus ferus (wild horse). EIAV is the aetiological agent of 
equine infectious anaemia (EIA), which is an episodic disease that persists for 
the life of the host, and is a notifiable disease of the Department of 
Environment, Food and Rural Affairs (DEFRA) and the World organisation for 
animal health (OIE). Although the clinical signs of EIA were first reported in 
1843 in France, it was not until 1904 that EIA was attributed to a ‘filterable 
agent’ (Vallee & Carre., 1904). Major interest in EIAV peaked during the 
1960s when EIAV was reported in high profile racehorses in the USA and 
Europe, causing major economic impact and was subsequently followed by 
several decades of intense research (Johnson, 1976). The advent and 
introduction of the Coggins agar gel immune diffusion test (AGIDT) as the 
‘gold standard’ provided a much needed standardised diagnostic test and tool 
to allow surveillance and control of the disease, heavily reducing the disease 
burden on many countries.  
 
With less concern about EIAV and the failure to discover a successful vaccine 
research interest in EIAV reduced with remaining efforts focusing either on 
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vaccine development or as a model for HIV (Cook et al., 2013). However, 
EIAV remains a worldwide problem with little understanding about its specific 
biology and evolution, most knowledge is based on HIV biology or studies 
using a clonal strain derived from an American (EIAVWYO) or Chinese 
(EIAVLIA) case (Dong et al., 2014; Dong et al., 2013; Cook et al., 2013). 
1.1 EIAV genome: 
1.1.1 The EIAV genome: 
The EIAV genome consists of approximately 8.2kb of single stranded RNA 
and contains the canonical lentiviral polyproteins gag (structural), pol 
(enzymes) and env (surface glycoproteins) flanked by long terminal repeats 
(LTRs) which are exact repeats of each other and contain the promotor 
regions (Figure 1.1). One of the simplest lentiviruses, EIAV also encodes 
three accessory genes: tat, rev and S2 (Fields et al., 2007).  
 
 
Figure 1.1.EIAV genome schematic. The LTR region contains the promotor region in U3. The 
gag polyprotein contains the matrix, capsid, nucleocapsid and p9 proteins. The pol contains the 
viral protease, reverse transcriptase, RNaseH, DUTPase and intergrase. The env contains the 
surface and transmembrane glycoproteins. Tat and rev are both produced by two ORFs. Adapted 
from Dong et al., 2012. 
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1.1.2 The gag polyprotein: 
The gag gene encodes the viral structural proteins, which are the matrix (MA, 
p15), capsid (CA, p26), nucleocapsid (NC, p11) and the p9 protein. These are 
responsible for viral assembly and budding. If expressed alone the gag 
polyprotein can initiate assembly and budding of non-infectious virus like 
particles from the cell membrane (Hatanaka et al., 2001). The MA binds the 
host lipid membrane and stimulates virus assembly (in its unprocessed gag 
form), the aggregation of gag precursors at the membrane then cause the 
membrane to bulge out and the virus buds (Fields et al., 2007). In the mature 
virion the MA binds the envelope to the capsid. The MA contains a leucine 
rich nuclear export signal similar to HIV-1 (Hatanaka et al., 2001), this signal 
is possibly required to counteract nuclear localisation of the MA and ensure 
cytoplasmic availability (Dupont et al., 1999). 
 
The viral CA is the main structural component of the virion that forms a 
proteinaceous shell around the genome and plays a role in uncoating, virus 
assembly and budding (Grund et al., 1994). Few functional motifs have been 
determined for the CA except a region of similarity to other lentiviruses termed 
the major homology region (MHR; Grundet al., 1994) and a number of 
possible high avidity cytotoxic T lymphocyte (CTL) epitopes (Chung et al., 
2005).  
 
The NC binds the genome forming a nucleoprotein complex and is involved in 
virus budding, nuclear importation and integration (Payne and Fuller, 2010; 
Jin et al., 2005a; Leroux et al., 2004). The NC sequence contains two zinc 
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binding domains of the CCHC type (CX2CX4HX4C) separated by a short 
linker sequence (Amodeo et al., 2005) allowing the NC to bind the viral 
genome in the mature virion via the phi packaging signal (φ) in the RNA 
sequence (Maury & Oaks, 2000). A table of amino acids and their single letter 
codes is included for reference in Appendix 5. The EIAV NC has also been 
shown to possess topoisomerase activity suggesting a role in integration and 
DNA transcription after viral entry (Matsrafi et al., 1996).  
 
EIAV encodes a further gag protein named p9, which is only present in EIAV 
(HIV encodes p6 which is of similar function; Jin et al., 2005). p9 encodes a 
short protein at the 3’ end of the gag whose specific function is unknown, 
however, it has been found to play an important role in proviral production and 
early infection the specificities  of which are still unknown (Jin et al., 2005). p9 
contains one known functional domain, the late YPDL domain, disruption of 
which abrogates viral budding. The p9 protein is otherwise highly variable so 
the conservation of YPDL through all EIAV isolates confirms its importance 
(Puffer et al., 1997; Puffer et al., 1998). 
 
1.1.3 The pol polyprotein: 
The pol gene encodes the viral enzymes required for virus replication. From 5’ 
to 3’ these are the protease (PR), reverse transcriptase (RT), RNaseH (RN), 
DUTPase (DU) and the integrase (IN). Since enzymes tend to be highly 
conserved, identification of important motifs is generally extrapolated from 
work with HIV and SIV since the lentiviral pol genes share a relatively high 
sequence homology (Cook et al., 2013; Dong et al., 2013). The viral aspartate 
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PR is responsible for processing the gag and pol polyproteins as well as 
cleaving the gag and pol polyproteins to form the mature virion. The protein 
contains three sets of functional residues: the substrate binding and the active 
site flap residues and the DTG catalytic motif, which are involved in the 
enzymes proteolytic activity (Weber et al., 1993; Eizert et al., 2008; Gustchina 
et al., 1996). 
 
The RT of EIAV has had little attention in the way of characterisation however 
it shares similar motifs with HIV-1 as well as a similar error rate 
(Bakhanashvili & Hizi, 1993). Whilst HIV-1 has a double aspartate catalytic 
motif and a DVGD motif essential for function, EIAVs RT maintains the DD 
motif but replaces the valine with an isoleucine for a DIGD motif, conserving 
amino acid type. Since this is conserved through all published EIAV field 
strains it is possible that it is important for function (Dong et al., 2014; 
Rungrotmongkol et al., 2007). 
 
The 3’ end of the RT encodes a RN domain which catalyses RNA degradation 
from the RNA:DNA hybrid intermediate produced during reverse transcription 
(Fields et al., 2007). HIV-1 RN contains a glycine rich motif 
(AWVPAHKGIGGN), which is highly conserved among lentiviruses. The only 
changes in EIAV are the second alanine and second glycine changed to a 
glycine and tyrosine respectively (Davies et al., 1991; Dong et al., 2014). As 
well as the glycine rich motif, a set of four acidic residues (D443, E478, D498, 
D549) that are possibly catalytic in nature and are highly conserved through the 
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lentiviruses are also present in each EIAV field strain (Dong et al., 2014; 
Davies et al., 1991). 
 
Uniquely among lentiviruses EIAV, FIV, caprine arthritis encephalitis virus 
(CAEV) and visna virus encode a dUTPase (DU) in the pol gene (Threadgill et 
al., 1993). The addition of the DU is important for EIAV due to its tropism to 
macrophages, which are non-dividing cells (Threadgill et al., 1993). 
Macrophages contain an environment rich in dUTP (the precursor to uracil) 
and dTTP (the precursor of thymine). This can lead to the incorporation of 
uracil into DNA resulting in deleterious effects on the viral genome. To combat 
this, the viral DU hydrolyses dUTP to dUMP and a pyrophosphate so that it 
cannot be incorporated (Dauter et al., 1999; Payne & Elder, 2001; Stegall et 
al., 1996). Structural work with the EIAV DU has highlighted multiple residues 
essential for function: binding of uracil by a 'uracil ring' composed of N67, 
G69, Q80 and I82. The binding of uracil induces a conformational change, 
which also brings G68 into contact with the uracil. A further binding pocket 
interacts with the pentose group of the uracil through A17, I71, N72 and Y75. 
Handling of the phosphate group is carried out through interactions with D26, 
S58, K56, E95 and K98. Metal ion binding possibly involves a number of 
residues some of which are also involved in phosphate binding (a cluster of 
R13, D20, K56, E95 and a negatively charged cluster of E15, D16, D72 and 
E73) (Dauter et al., 1999). A series of five conserved regions between 
lentiviruses has also been postulated but whether these confer function is yet 
to be tested (McGeoch, 1990). 
 
7 
 
Finally, the viral integrase (IN) similar to the RN, contains residues considered 
essential in HIV-1. It contains a HHCC motif for zinc binding (conserved 
across the lentiviruses in the form of H-X3-7-H-X23-32C-X2-C) and a set of 
catalytic core residues present in most lentiviruses (D64, D116 and E152) 
(Engelman & Craigie, 1992; Eijkelenboom et al., 1997). 
 
Translation of the pol polyprotein is from a full, unspliced mRNA, yet both the 
gag and pol are not in the same reading frame requiring a -1 frameshift. This 
is induced by a slippery sequence (AAAAAAC) and a five base CG paired 
region which can take the form of either a stem loop or pseudo knot structure 
and the disruption of either motif completely inhibits viral replication (Chen 
and Montelaro, 2003). 
 
1.1.4 The env polyprotein: 
The env produces two envelope glycoproteins; the surface (gp90, SU) and 
transmembrane (gp45, TM) forming the membrane-bound glycoproteins. The 
SU is responsible for immune evasion and shows a high amount of diversity. 
Previously eight variable regions were designated with the remaining 
sequence being broadly conserved. One variable region contains the principle 
neutralising domain (PND; Leroux et al., 1997) and several combinations of 
variable regions have been shown to confer varying extents of antibody 
neutralisation resistance (Howe et al., 2002). With the recent sequencing of 
geographically isolated field strains, it has been found that variation between 
such strains is spread through the whole gene, but the variable regions 
remain hot spots of variation (Dong et al., 2014). Due to its prominence on the 
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surface of the virion, SU is also heavily glycosylated to mask epitopes from 
the immune system. N-linked glycosylation sites tend to remain reasonably 
conserved by location but not sequence. Glycosylation sites are usually 
regarded as being denoted by a N-X-S/T motif where X is any amino acid 
except a proline, however it is possible that S or T can be a different amino 
acid and so without structural studies the designation of glycosylation sites is 
only prediction (Schwarz & Aebi, 2011). Similarly cysteine residues are highly 
conserved among unrelated strains which is unsurprising given that the 
resulting disulphide bridges effect the folding of the protein, and changing this 
could drastically affect protein folding and consequently receptor binding. 
Thus, cysteine residues and glycosylation sites are usually conserved by 
location (Dong et al., 2014).  
 
The TM glycoprotein, like SU also contains cysteines and glycosylation site, 
but since it is more shielded and inserted into the virion, TM contains far fewer 
cysteine residues and glycosylation sites. TM contains two hydrophobic 
regions; the N terminus proximal region, which may play a role in membrane 
fusion during cell entry and the transmembrane region that anchors the 
glycoprotein complex to the virion (Rice et al., 1990). 
 
1.1.5 The accessory proteins: 
EIAV is one of the simplest lentiviruses encoding only three accessory genes; 
tat (transactivator of transcription) and rev (regulator of expression of viral 
proteins) so termed for their functional homogeneity to HIV-1 tat and rev, and 
S2.  
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The EIAV tat protein is produced by two ORFs and is translated from two 
multiply spliced mRNAs similar to HIV-1 tat, one of which produces tat only 
and the other, which produces tat and rev (Carroll & Derse, 1993). Uniquely 
among the lentiviruses translation initiation of the EIAV tat protein is started 
from a leaky start codon CTG which is also responsible for the translation of 
rev; this is likely because the tat leader sequence precedes the major splice 
site so the translation of the other EIAV proteins require a leaky start codon. 
Changing the CTG to ATG leads to a major reduction in rev translation (Dorn 
et al., 1989; Carroll & Derse, 1992). A high degree of similarity exists between 
the different lentiviral tats enabling five structural motifs to be delineated: the 
amino terminus, cysteine rich region, core region, basic region and carboxy 
terminal. However, EIAV does not encode a cysteine rich region (Carroll et al., 
1991). The role of tat is to increase the transcription of viral RNA in trans 
through the binding of the transactivation response element (TAR) in the LTR 
region (Anand et al., 2008). The TAR of EIAV is smaller than its HIV 
counterpart and lacks a pyrimidine bulge (Carvalho & Derse, 1991), but 
despite these differences the tat-TAR interaction of both lentiviruses is a 
complex one. The tat interacts and activates the TAR using different regions. 
In both EIAV and HIV the basic regions play a major role in tat recognition and 
the core region in tat activation (Carroll et al., 1991). Similar to HIV and SIV 
tat, EIAV tat forms a complex with the positive elongation factor b (P-TEFb), 
which consist of cyclin T1 and a cyclin dependant kinase 9 (Cdk9). Tat binds 
the cyclin T1 subunit, activating Cdk9 which hyperphosphorylates the C-
terminal domain of RNA polymerase II, causing the polymerase to shift from 
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arrest phase to elongation phase, up regulating viral transcription (Anand et 
al., 2007; Anand et al., 2008). 
 
Rev is responsible for the nuclear export of un-spliced and partially spliced 
viral transcripts to the cytoplasm that would either be completely spliced or 
degraded (Harris et al., 1998; Malim & Cullen, 1993). Rev itself is translated 
from an mRNA containing all four tat and rev exons (Carroll & Derse, 1993). 
Of the lentiviruses that encode a tat and rev, EIAV is unique in that it is the 
only lentivirus in which tat and rev do not overlap (Harris et al., 1998). The rev 
protein promotes the skipping of the first rev exon by interfering with the splice 
site resulting in a tat only mRNA, giving rev a self-limiting effect (Lee et al., 
2008). The rev protein encodes a number of motifs required for its function. A 
nuclear export signal (NES) has been mapped to the carboxy terminus of 
exon 2 (amino acids 31-55) but the area can handle extensive mutation with 
only four residues appearing to be essential (L36, L45 and L49 and W41; 
Harris et al., 1998; Lee et al., 2006). Further to the NES, rev contains; two 
short arginine rich motifs involved in RNA binding and an arginine rich nuclear 
localisation signal at the amino terminus that is also involved in RNA binding 
(Lee et al., 2006). The central arginine rich motif ERLE has been shown to be 
moderately resistant of mutations with only the leucine of ERLE being 
essential for its function. The aspartate of RRDRW and lysines of KRRRK 
were also shown to be dispensable for rev action indicating the arginines to 
be the essential residues (Lee et al., 2006; Belsham et al., 1998). The mode 
of action of EIAV rev has not been studied fully and relies on information from 
HIV to fill in the gaps. Rev acts by binding the rev response element (RRE) of 
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the viral RNA, multimerises and then exports the RNA via a nucleoporin 
pathway before returning to the nucleus (Lee et al., 2006; Fridell et al., 1996). 
 
The rev protein interacts with the RRE to translocate partially spliced and 
unspliced RNA to the cytoplasm for translation. The RRE is approximately 
555 nucleotides (nt) long and located towards the 5' of the env gene and 
forms a complex secondary structure in order to bind rev (Lee et al., 2008).  
 
The function of S2 is currently undefined, but mutational studies have shown it 
to play a role in nuclear localisation and entry of the pre-integration complex 
(PIC) into the nucleus. In vivo, it is a major virulence factor whereas in vitro it 
is non-essential. Relating to its role in nuclear entry three putative domains 
has been noted: a nucleoporin domain (GLF), SH3 binding domain (PLLP) 
and a nuclear localisation domain (RKQETKK) (Li et al., 1998; Li et al., 2000; 
Payne & Fuller, 2010).  
 
1.1.6 Long terminal repeats: 
The long terminal repeat (LTR) region is responsible for transcription 
regulation, reverse transcription, integration and possibly encapsidation of the 
viral genome and can be divided into three regions designated U3, R, and U5. 
The complete LTR is only present in the proviral form. In free viral RNA form 
only the R and U5 region is present at the 5’ end of the genome and only the 
U3 and R region is present at the 3’ of the genome (Fields et al., 2007). The 
U3 region contains the viral promotor region, which binds cellular transcription 
factors and is considered hypervariable (Carpenter et al., 1990). The U3 
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region can contain various transcription factor binding sites such as PU.1, 
PU.2 and PEA1/AP1 binding site as well as a methylated DNA binding protein 
(MDBP) site and TATA box (Carvalho & Derse, 1992; Carvalho et al., 1993). 
The combination of promotor sites can affect the ability of the virus to replicate 
and so the U3 region is a determinate of virulence (Payne & Fuller, 2010). 
The R region is also required for transcription as it contains the poly A signal 
and TAR for tat binding (Cook et al., 2014). Compared to other lentiviruses 
the EIAV LTR has been poorly characterised. The HIV-1 LTR has been 
characterised to a much greater extent and contains a variety of cis acting 
elements that carry out a function that is also seen in EIAV, but the function 
has not been attributed to a specific sequence as of yet. For example, the HIV 
LTR downstream from the TAR stem loop contains a Poly A stem loop, primer 
binding stem loop (for reverse transcription) and four stem loops that make up 
the encapsidation signal (Ψ, interaction with the φ signal in NC results in 
packaging of the genome). These stem loops also contain the dimerisation 
initiation sequence responsible for the kissing loop interaction between the 
two packaged genomes, and the major splice donor sequence (McBride & 
Panganiban, 1996; Frech et al., 1996). These elements have not currently 
been defined in EIAV but considering the two genomes are still packaged and 
reverse transcription still occurs these elements are present in some form. 
 
1.2 EIAV replication cycle: 
Compared to its extensively researched relation HIV, relatively little is known 
about the replication cycle of EIAV. Unlike HIV, which targets CD4+ cells such 
as T-cells, EIAV is tropic to cells of the monocyte/ macrophage lineage 
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(Maury et al., 1994). An overview of the replication cycle is given in Figure 
1.2. Initial entry into the cell is through equine lentivirus receptor 1 (ELR-1), 
present on monocytes and macrophages though an unknown co-receptor 
may also be involved (Zhang et al., 2005). EIAV then enters the cell through 
clathrin mediated endocytosis (Jin et al., 2005b; Brindley and Maury, 2008) 
followed by a low pH dependant uncoating step releasing the genome into the 
cytoplasm (Brindley and Maury, 2005). Upon entering the cytoplasm the 
ssRNA genome is reverse transcribed into double stranded DNA (dsDNA) by 
the viral RT. Although not defined in EIAV, in other retroviruses such as HIV 
reverse transcription is triggered during virion uncoating (Flint et al., 2009). An 
overview is given in figure 1.3. A tRNA bound to the primer binding site in the 
U5 region of the LTR acts as the primer for negative strand synthesis which 
extends to the R region. The viral RN degrades viral RNA as the RT 
proceeds. A template exchange then occurs where the ssDNA R region and 
the bound tRNA primer bind the r region at the 3’ end of the ssRNA genome. 
The RT reverse transcribes the negative strand completing the 3’ LTR. The 
RN continuous to remove ssRNA but leaves a small polypurine tract located 
upstream from the 3’ LTR which primes positive strand synthesis. The positive 
strand is then synthesised until it reaches the tRNA primer and the RN 
removes both the tRNA and polypurine tract primers. This leaves a small 
positive DNA strand bound to the complete 3’ LTR and a near complete 
negative DNA strand missing the 5’ LTR. A second template exchange occurs 
in which the primer binding site of the negative and positive strands bind 
together effectively circularising the DNA. The negative strand then acts as a 
primer leading to the completion of the 5’ LTR and the positive strand acts as 
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Figure 1.2: The replication cycle of a simple lentivirus. After receptor binding EIAV is 
internalized by endocytosis (1) into an endosome where the acidic conditions cause fusion 
of the viral and cellular membranes (2). Whilst in the breaking down envelope the viral RNA 
is reverse transcribed and complexed with the viral integrase and other viral and cellular 
proteins to form the PIC which enters the nucleus (4) and is integrated (5) to form the 
provirus. This is then transcribed into full length mRNAs that are either used as new 
genomes (9) or translated to give gag and pol polyproteins (7, 8). Single spliced mRNAs 
containing the env are translated in the endoplasmic reticulum (ER; 10, 11) before being 
transported through the cellular export machinery and finally embedded into a cell 
membrane (12, 13). The gag polyprotein aggregates at the cell membrane recruiting the 
viral genome. The gag then aggregates causing the membrane to bulge and the virus to 
bud off (14, 15). Finally the viral PR cleaves the gag-pol and gag polyproteins which 
orientate and form the mature virion (16). The viral PR may also cleave the tail end of the 
TM glycoprotein to form the mature virion. (Taken from Flint et al., 2009). 
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the primer for the rest of the genome resulting in a dsDNA provirus containing 
identical LTRs (containing U3, R and U5) (Flint et al., 2009). The viral RT has 
no 3’-5’ exonuclease activity and so introduces errors into the progeny 
genomes. The EIAV RT has a similar error rate to other lentiviral RTs 
(Bakhanashvili & Hizi, 1993) equating to approximately one error into each 
progeny genome (Maury and Oaks, 2010). The viral RT can also carry out 
recombination between the two packaged genomes through copy choice 
recombination, which is when the viral RT switches viral templates generating 
a provirus with mixed ancestry (Simon-Loriere et al., 2011). Although not 
characterised in EIAV this is most likely to occur during one of the template 
exchanges or during positive strand synthesis (Flint et al., 2009). Some 
lentiviruses such as HIV contain multiple polypurine tracts enabling multiple 
locations to start positive strand synthesis as well as presenting more 
template switching opportunities (Flint et al., 2009).  
 
The viral dsDNA then complexes with the viral IN and other cellular proteins to 
form the pre-integration complex (PIC) which migrates to and enters the 
nucleus of the host cell using a nuclear localization signal on the S2 gene (Li 
et al., 1999) and integrates into the host genome by the viral IN to form the 
provirus. The host cellular machinery then interacts with the relevant 
sequences in the U3 region of the LTR and begins transcription of the viral 
genome. The full-length transcripts are then exported from the nucleus and 
translated into the viral gag and pol polyproteins. The env and S2 are 
translated from a singly spliced mRNA and the tat and rev are both translated 
from multiple spliced mRNA. Another multiple spliced mRNA produces a 
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Figure 1.3: Reverse transcription of a retrovirus. A. The tRNA primer is 
bound to the primer binding site (PBS) of the ssRNA genome. B. The viral RT uses the 
primer to synthesis the negative strand to the r region while the RN degrades the RNA. 
C. The ssDNA R region exchanges template, binding the r region at the 3’ of the RNA 
(D) allowing the RT to continue synthesizing the negative strand. The RN continues to 
degrade the RNA apart from the polypurine tract (ppt) (F) which is used to prime positive 
strand synthesis. H. The PBS is reverse transcribed (I) and the tRNA and ppt primers 
are removed (J) allowing the second template exchange to occur where the PBS of the 
negative and positive DNA strands to bind together (K) effectively circularizing the DNA. 
L. To complete the proviral genome the positive strand primers the completion of the 
negative and the negative strand primes the completion of the positive resulting in a 
provirus with identical LTRs. M. throughout this process dead end intermediates may be 
created where the provirus in ligated into a circle. (Adapted from Flint et al., 2009). 
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protein, ttm, of unknown function (Beisel et al., 1993). The viral tat enhances 
transcription by binding the TAR in the LTR and recruiting cellular proteins to 
enhance transcription (Anand et al., 2007; Anand et al., 2008). The viral rev 
binds the RRE of spliced mRNAs and exports them from the nucleus (Lee et 
al., 2008; Lee et al., 2006). The env glycoproteins are inserted into the cell 
membrane via the golgi. 
 
The gag polyprotein then aggregates at the membrane recruiting two full-
length ssRNA genomes bound by a kissing loop interaction. The clustering of 
the gag then causes the membrane to bulge and eventually bud off (Maury & 
Oaks, 2000). The location of budding for lentiviruses appears to be cell 
specific. In fibroblasts EIAV buds from the plasma membrane (Puffer et al., 
1998), whereas in macrophages, budding may occur from intracellular 
membranes (Maury & Oaks, 2000). Once packaged, the viral protease 
cleaves the gag/pol polyprotein to form the mature virion (Maury and Oaks, 
2010). 
 
1.3 EIAV pathogenesis and transmission: 
1.3.1 Pathogenesis: 
Infection with EIAV results in equine infectious anaemia (colloquially known as 
swamp fever). Initial infection results in an acute phase, which can last up to 
31 days (Leroux et al., 2001; Belshan et al., 2000). Symptoms can range from 
mild to fatal and can include thrombocytopenia, pyrexia, anaemia, depression 
and wasting but can also be asymptomatic. Although no specific mechanism 
for the drop in platelet count has been defined, it is believed to be a 
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combination of two factors. The suppression of megakaryocyte and platelet 
production in the bone marrow due to the effect of cytokines released from 
infected macrophages (Tornquist et al., 1997; Tornquist & Crawford, 1997); 
and the reduction of circulating platelets due to reduced life span and 
destruction due to immune dependant and independent factors (Crawford et 
al., 1996; Clabough et al., 1991). Similarly, if anaemia is present the reduction 
of erythrocytes is due to a reduction in longevity due to immune mediated 
destruction (McGuire & Henson, 1969; McGuire et al., 1969a; McGuire et al., 
1969b) and suppression of erythrocyte production in the bone marrow 
(McGuire et al., 1969c). The pathogenesis of EIAV is intrinsically linked with 
viral replication with the drop in platelets and rise in body temperature 
coinciding with the increase in viral replication (Figure 1.4; Maurey & Oaks, 
2010; Leroux et al., 2001). The use of macrophages as the primary cell of 
EIAV infection is believed to yield the host symptoms through the release of 
cytokines from the infected macrophage rather than through their destruction 
(Maurey & Oaks, 2010; Lim et al., 2005). 
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Acute disease is resolved between seven and thirty days post infection. It is 
believed that the resolution of the acute phase is brought about by the 
generation of a specific and effective cellular CD4+ and CD8+ cytotoxic T-
lymphocyte (CTL) immune response (Hammond et al., 1997; Perryman et al., 
1988; Mealey at al., 2001). The animal then enters the chronic stage 
characterised by irregular febrile episodes lasting approximately 3-5 days 
each, separated by days, weeks or months. Each episode represents the 
emergence of a new immune escape mutant that can replicate to the extent of 
crossing a genome copy threshold of 5x107 copies per ml of blood (Cook et 
al., 2003). During such episodes, the viral RNA and DNA can be found in 
most bodily tissues with the highest level of replication being found in the 
spleen. During asymptomatic periods viral RNA and DNA is still present in 
these tissues but at much lower levels (Harrold et al., 2000).  
Figure 1.4.Disease progression of EIAV showing the acute, chronic and inapparent 
carrier stages. The dashed line represents platelet count, the solid line represents body 
temperature and the dots show viral RNA molecules. The arrows indicate when the horse 
experienced a febrile episode. The first is the acute episode which is followed by a series 
of irregular episodes which characterise the chronic phase. The horse then 
immunologically controls viral replication preventing any more episodes. Episodes are 
triggered when viral replication passes a threshold. (Adapted from Howe et al., 2002) 
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Over the course of 12 months the episodes gradually reduce in intensity until 
eventually, the animal becomes asymptomatic and enters an inapparent 
carrier stage (ICS; Capomaccio et al., 2012). Resolution of chronic episodes 
does not correlate with a single immune parameter, both the cellular and 
humoral response mature to different levels in different horses; however both 
immune arms fully mature around 6-8 months post infection at which point 
they seem to successfully control the virus (Hammond et al., 1997). Despite 
appearing clinically healthy the virus is still present but under stringent control 
by the host’s immune system. The virus continues to replicate at a much-
reduced rate in its target tissues and generate quasispecies; with the env 
continuing to vary to a similar level regardless of the number of febrile 
episodes an animal has experienced (Leroux et al., 2001). This control can 
continue until the animals ‘natural’ death (Quinlivan et al, 2013). Both a high 
avidity antibody response capable of effective virus neutralisation and a 
targeted CTL response against the gag and env epitopes are thought to be 
responsible for this control (Hammond et al., 2000). The administration of 
immune-suppressants or high stress can cause the recrudescence of the 
febrile episodes, which can range from mild to fatal (Hammond et al., 1997; 
Kono et al, 1975). The disease progression of EIAV is not always linear as 
described above. The disease can progress in a non-linear fashion and 
infection with EIAV can result in an ICS straight after the initial acute infection 
with no chronic episodes; such cases are termed ‘non-progressor’. Similarly, 
infection can result in no acute episode followed by fatal episodes years later 
(Leroux et al., 2004; Leroux et al., 2001; Capomaccio et al, 2012).  
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1.3.2 Transmission: 
EIAV is a blood-borne virus and so excretion of the virus via urine and faeces 
is generally thought not to occur (Kono & Fukunaga., 1973) with horizontal 
transmission through blood  being the main route of spread, however vertical 
transmission does occur. In studies relating to breeding of infected parents, 
EIAV has been detected in aborted foetuses and live foals (Mims, 1981). 
Kemen & Coggins (1972) followed 52 foals from EIAV positive mares and 
found 12 were positive: seven born of a mare with clinical signs during 
gestation and five where the mare was clinically normal during gestation. 
Tashijan & Kittleson (1976) followed five foals born to EIAV positive stallions 
and negative mares as well as ten foals born to seropositive mares and 
negative stallions over 1-3 years, all of which remained negative for the period 
of study. Thus the chance of a foal becoming infected appears to be much 
smaller if the mare remained inapparent during gestation but clinical signs in 
the gestating mare are not a guarantee of transmitting the virus.  
Due to its blood-borne nature, horizontal transmission can occur through 
contaminated blood products and use of contaminated veterinary instruments. 
The origin of the 2006 outbreak in Ireland was traced to the use of 
contaminated horse serum imported from Italy and administered to foals. The 
subsequent outbreak was then fuelled by the use of contaminated veterinary 
instruments resulting in the outbreak revolving around two veterinary hospitals 
(More et al., 2008a; More et al., 2008b). EIAV has been shown to remain 
infectious on hypodermic needles for up to 96 hours (Williams et al, 1981). In 
addition, EIAV is able to transmit through a number of arthropod vectors 
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mainly members of the tabanidae family (horseflies and deerflies) but has also 
been shown to transmit via a member of the muscidae family (stable flies) 
(Issel et al., 1988; Hawkins et al., 1976). In Great Britain (GB) the most 
important vector is the horse fly; their concentration in swampy areas and the 
resulting prevalence of EIAV in these areas resulted in the colloquial name 
’swamp fever’. A number of transmission events in the 2006 Ireland outbreak 
were attributed to biting flies (More et al., 2008b). Although problematic, 
transmission by horse fly has many variables and overall is not a very efficient 
process. Transmission is associated with interrupted feeding on an infected 
host followed by movement to a susceptible host. Since horse flies are large, 
noisy insects that comprise ‘cutting/ slashing’ mouth parts they have a high 
chance of being interrupted, but disturbed flies are generally more likely to 
return to the same horse if it is the closest (Issel and Foil, 1984; Foil, 1983). 
Due to the short distance and time of survival on the mouthparts, biting flies 
are considered a risk for local dissemination of the disease rather than 
international spread (DEFRA, 2010; Issel and Foil, 1984). The disease state 
of the horse also has an impact on successful vector borne transmission. 
Horses experiencing clinical signs have a much higher virus load in the blood 
and so are far more likely to transmit a high enough titre to the fly for it to 
survive and infect a susceptible individual. Thus, vector transmission from 
clinically inapparent horses is of low risk (Issel et al., 1982; Coggins, 1984; 
Issel & Foil, 1984). 
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1.4 Diagnosis, treatment, vaccination and control of EIAV: 
There is currently no treatment or vaccine for EIAV limiting control methods to 
either destruction or lifelong quarantine of infected individuals. The success of 
such a programme however relies on the effective diagnosis of infected 
individuals. The current and first ‘gold standard’ diagnostic test for EIAV in 
most countries is the agar gel immunodiffusion test (AGIDT) commonly known 
as the Coggins test; which is a serological test developed in 1970 (Coggins & 
Norcross, 1970). It is based on the precipitation of the test subject’s 
antibodies when they bind purified p26 capsid antigen after migrating towards 
each other in an agar gel (OIE, 2008). Developed at a time when EIAV was 
rampant in the USA (>10,000 positives in 1976; Issel et al., 2013) it was seen 
as the best means of reducing virus prevalence. It proved successful and 
between 2008 and 2010, two hundred cases were detected in the USA, most 
of which were asymptomatic. A positive AGIDT is repeated and upon 
confirmation, the animal is euthanized or moved into quarantine.  
 
As the incidence of EIAV decreases, the low sensitivity of the AGIDT has 
caused some concern over false negatives and so recommendations have 
been made to use a ‘three-tiered’ test system; combining the AGIDT with an 
ELISA (Dong et al., 2012) and an immunoblot (Issel et al., 2013; Scicluna et 
al., 2013). Several ELISAs are currently available based on the p26 antigen 
but a number of false positives have been reported and so need to be 
confirmed by AGIDT (Dong et al., 2012). Since the above methods are 
serological in nature they require the generation of antibodies and so an EIAV 
carrier must seroconvert in order to produce a positive result; this takes 
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around 2-3 weeks on average, but cases have been recorded where 
seroconversion has taken several months (DEFRA, 2010b). In the UK, two 
tests 90 days apart are required to declare a site clear of EIAV and so it could 
be possible for slow seroconverting cases to evade detection (DEFRA, 
2010b). A further drawback of serological tests is their inability to distinguish 
between foals that are infected or only have maternal antibodies (Tashijan & 
Kittleson., 1976). A molecular test such as PCR negates these problems with 
the advantages of being faster, cheaper and simpler to perform. However, the 
lack of sequence data and the high genetic variability of lentiviruses relative to 
other viruses make the design of universal primers challenging. Indeed, 
previous OIE recommended primers fail to amplify many current strains (Dong 
et al., 2012). 
1.5 EIAV distribution: 
Since being first reported in France in 1843, EIAV has been reported on 
almost every continent in the world.  In 2014, EIAV was present in North and 
South America, Asia and Europe (Figure 1.5). It has also been previously 
reported in Oceania and Africa. Global prevalence is weighted towards South 
America with 4863 outbreaks in Brazil, 1914 outbreaks in Colombia and 160 
outbreaks in Paraguay in the year 2014 (OIE, 2012).  
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In Europe in 2014, there were EIAV outbreaks in France, Germany, Italy, 
Bosnia & Herzegovina, Croatia, Hungary, Latvia, Romania, Russia and Serbia 
with incidence weighted towards Eastern and Southern Europe (Fig 1.6). The 
disease is currently considered endemic in Romania with 3073 outbreaks in 
2011, 1970 outbreaks in 2012 and 817 in 2013 (OIE, 2012). A ‘continuing 
disease event’ has been ongoing in Italy for a number of years with 71 
outbreaks in 2011, 63 outbreaks in 2012 and 23 in 2013 (OIE, 2012). The 
source of the 2006 Irish outbreak (as discussed in 1.3.2) was serum from Italy 
and some Italian outbreaks are believed to of originated from Romania 
leading to an assumption that European strains are closely related, however 
more sequence data is required to verify this.  
Figure 1.5: Heat map showing the global distribution of EIAV in the first six months 
of 2015. Global prevalence is weighted towards South America. (OIE, 2016). 
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In Great Britain (GB) EIAV was first detected following the introduction of the 
‘Infectious Diseases of Horses Order, 1975’ that made EIAV a notifiable 
disease. A foal in Newmarket tested positive (Rossdale et al., 1975) followed 
by a second case and then in 1978 six horses tested positive and were traced 
from either South America or Europe (Lamont, 1979). There was then a long 
period of no disease detection until 2010 and 2012 when there were 6 and 2 
reported cases respectively (DEFRA, 2010b; DEFRA, 2011a; DEFRA, 2011b; 
DEFRA, 2013) (Figure 1.7; Table 1.1).  
 
Figure 1.6: Heat map of EIAV prevalence in Europe for the first six months of 
2015. EIAV is considered endemic in Romania and there is a ‘continuing disease 
event’ in Italy. (OIE, 2016). 
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Unlike the outbreak in Ireland, which was caused by contaminated blood 
products, the GB outbreaks were thought to be due to the importation of 
infected animals from Romania (Quinlivan et al., 2013; DEFRA, 2010b). In 
January 2010, two horses tested positive in Wiltshire after arriving from 
Romania via Belgium (DEFRA, 2010). Due to the endemic EIAV situation in 
Romania horses from this region are required to have a post-import AGIDT on 
arrival to GB. Subsequent notification resulted in the discovery of Belgium’s 
first cases in over twenty years and the resultant tracing programme identified 
seven positive horses all of which were culled (Caij & Tignon, 2012). This was 
followed by a single case in Northumberland which was tested due to 
document irregularities after import from The Netherlands (DEFRA, 2011a) 
and a single case in Devon, which presented with symptoms consistent with 
Figure 1.7: Map of England showing the locations of each 
outbreak of 2010 and 2012. (OIE, 2013b). 
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EIA (DEFRA, 2011b), both occurring in September 2010. Most recently, there 
were two cases in 2012, a horse tested positive in Cornwall after becoming 
symptomatic and subsequent tracing revealed a second positive 
asymptomatic horse in Devon (DEFRA, 2013). 
 
1.6 Sequence variation of EIAV and molecular detection: 
The low fidelity of the EIAV polymerases results in the generation of a diverse 
population of viruses, termed quasispecies. In a single host, this can give rise 
to multiple viral populations originating from the original infecting virus, which 
have accumulated various mutations due to the selection pressures of the 
immune system or conditions in different tissues. The ability to generate 
quasispecies is an important immune escape mechanism for EIAV since the 
immune system will eventually generate neutralizing antibodies. With time, a 
virus with mutations that prevents antibody binding arises and replicates 
without being neutralised by the immune system and can cause a vireamia 
and become the dominant viral population. This results in the observed 
sequential disease presentation where each episode represents the 
appearance of a new neutralization resistant viral quasispecies (Howe et al., 
Table 1.1. Details of cases - from the British outbreaks. The designation noting the 
location, date and clinical nature and whether they were symptomatic or asymptomatic is 
displayed as well as the shorthand version of which they will be referred to from here on in. 
Y: Yes; N: No. 
Year Location Clinical? Designation Shorthand 
1975 Newmarket Y EIAV/Newmarket/06/1975/S EIAVNEW 
2010 Devon Y EIAV/Devon/09/2010/S EIAVDEV 
2010 Northumberland N EIAV/Northumberland/09/2010/A EIAVNORTH 
2010 Wiltshire 1 N EIAV/Wiltshire1/01/2010/A EIAVWILT1 
2010 Wiltshire 2 N EIAV/Wiltshire2/01/2010/A EIAVWILT2 
2012 Cornwall Y EIAV/Cornwall/09/2012/S EIAVCOR 
2012 Devon N EIAV/Devon/10/2012/A EIAVDEV2 
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2002). The result is an ever-evolving viral population. The variation within a 
single infected individual varies between genes but tends to be low. A study 
involving one horse showed a nucleotide divergence of 2.6% in gp90 over five 
febrile episodes over one year with variation concentrated within seven 
variable regions, one of which contained the principle neutralising domain 
(PND) (Leroux et al., 1997). The LTRs on the other hand tend to remain 
highly conserved in respect to the infecting strain both through time and 
between tissue compartments (Reis et al., 2003; Lerouxet al., 1997 Maury et 
al., 2004). On the other hand, the rev gene develops into two distinct 
subpopulations, which display different phenotypes in regards to virulence. 
They then cycle in dominance with each disease state (Baccam et al., 2003). 
In env gp90 mutations appear to miss some episodes or appear once and 
then are lost entirely (Howe et al., 2002); indicating that even though the virus 
is gradually mutating there may be a proviral reservoir of the original infecting 
strain within the host. The slow progressive accumulation of mutations 
suggests a slow build-up of proviral reservoirs as the disease progresses. 
With each segment of the EIAV genome varying to different extents, the 
number of proviral quasispecies in a single host could be exceptionally high, 
with each quasispecies able to ramp up replication quickly should the fitness 
landscape change to its favour (Leroux et al., 2001; Belshan et al., 1998). 
Similarly, viruses from the same outbreak show high levels of conservation 
with gag sequences taken from a single Italian outbreak showing identities 
over 97% (Cappelli et al., 2011). Similar findings have also been reported for 
horses found in Shackleford banks region of North Carolina, USA 
(Capomaccio et al., 2011).  
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Until recently the only full genomes available for EIAV field strains were a 
Chinese (EIAVLIA) and American (EIAVWYO) strain or their derivatives. Thus 
most studies into gene function and diversity have utilised these strains (Cook 
et al., 2013). In comparison a fairly extensive catalogue of gag sequences 
exists due to a preference for use of this gene in phylogenetics. In 2013, full 
length strains from the 2006 outbreak in Ireland (EIAVIRE) and from feral 
horses in Japan (EIAVMIYA) were published and revealed a much higher level 
of diversity between geographically isolated strains than previously estimated 
(Quinlivan et al., 2013; Dong et al., 2014). The nucleic acid sequence of 
geographically distinct strains is much greater then within a host or single 
outbreak situation. Nucleic acid identity between the full length EIAVLIA, 
EIAVWYO, EIAVIRE and EIAVMIYA is between 75% and 80% (Quinlivan et al., 
2013; Dong et al., 2014). The variation is not equally distributed throughout 
the genome but varies between individual genes. For example, variation in the 
gag gene is weighted towards the p9 protein with only 50% nucleic acid 
homology; followed by p15 (75.8%), p11 (89.5%) and p26 (91.5%) (Quinlivan 
et al., 2007). In individual genes, variation is restricted to ‘hot spots’ between 
closely related strains but between geographically distinct strains, the 
variation is spread throughout the genome (Quinlivan et al., 2013; Dong et al., 
2014). The relatively consistent nucleic acid variation between the 
geographically distinct viruses has led to the proposition that the US, Chinese, 
Irish and Japanese strains each represent monophyletic groups. This raises 
the question of whether 75-80% is the lowest sequence identity between EIAV 
strains, or whether other more divergent strains are present somewhere in the 
world.  
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Although gp90 and gp45 are the only viral proteins exposed to the immune 
system as part of the free virus the immune system is still able to exert a 
selective pressure on the other viral proteins. The major histocompatibility 
complexes (MHC) are proteins embedded on the surface of cells that display 
proteins to the adaptive immune response. MHC type 1 proteins are present 
on all nucleated cells and present proteins that are generated within the cell to 
cytotoxic T-cells (CD8). If stimulated the CD8 T-cell initiates apoptosis in the 
affected cell (Fields et al., 2007). In the context of an infected cell, any virus 
peptide may be presented on the cell surface and so has the potential to be 
selected against. MHC type 2 receptors on the other hand are only presented 
on professional antigen presenting cells such as macrophages and dendritic 
cells. Type 2 receptors display peptides which were taken up by the cell from 
its external environment such as free virus (Fields et al., 2007). Again any 
viral peptide can potentially be displayed to the immune system and be under 
selective pressure. Type 2 MHCs interact with helper T-cells (CD4) which, 
when activated, proliferate and differentiate into effector, memory or 
regulatory T-cells and can stimulate an immune response against the virus 
(Fields et al., 2007). 
 
1.7 Sequencing EIAV: 
The variation of EIAV presents a challenge for genome sequencing as the 
high variation makes the design of primers difficult. With the advent of next 
generation sequencing technologies the sequencing chemistries and 
technologies have been improving exponentially. The use of next generation 
sequencing negates the need for sequence specific knowledge due to the use 
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of ligated adapters as primers for PCR as opposed to Sanger sequencing. 
This allows the sequencing of viruses with variable or unknown genomes. 
However, even though the sequencing technologies themselves are ever 
improving the bioinformatics analysis techniques lag behind presenting a new 
series of problems such as the ability to definitively ascertain the presence or 
absence of virus specific reads in a given data set. The issues, solutions and 
technologies are more fully discussed in chapter 3. 
 
1.8 EIAV tropism and adaption: 
A unifying trait of the lentiviruses is their replication in macrophages, but to 
varying extents (Fields et al., 2007). The primate lentiviruses; HIV and SIV for 
example, replicate in macrophages, but the majority of virus in an infected 
individual originates from infected CD4+ cells (Simon et al., 2006; Edinger et 
al., 1997). The non-primate lentiviruses are more reliant on macrophages, 
except FIV and BIV which replicates well in a variety of cells (St-Louis et al., 
2004; Brown et al., 1991). The small ruminant lentiviruses CAEV and visna 
virus replicate in cells of the monocyte macrophage lineage more than other 
cells types (Narayan et al., 1982; Narayan et al., 1983), as does EIAV (Sellon 
et al., 1992; Maury, 1994). EIAV is able to infect monocytes but the virus 
replicates far more efficiently once the cell differentiates into a macrophage 
(Maury, 1994). This gives rise to a Trojan horse phenomenon whereby the 
virus uses the monocytes to disperse itself throughout the body and begin 
replicating at a high level once the monocyte enters the tissue and 
differentiates, a feature seen in other lentiviruses (Gendelman et al., 1986; 
Narayan et al., 1983). Harrold et al (2000) showed that in an acutely infected 
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individual or an ICS individual the majority of proviral DNA and viral RNA is 
more abundant in tissues rich in macrophages such as the spleen and liver. 
However, the virus can also be detected in other tissues such as the brain, 
kidney, bone marrow and lymph nodes but replication seems to occur at much 
lower levels compared to macrophage rich tissues. In 1999 Oaks et al also 
demonstrated the presence of EIAV in the heart, intestine and blood vessel 
endothelial cells in vivo. To culture the virus in vitro, horse leukocyte cultures 
have been used for studies of EIAV infection since the 1960s (Kobayashi & 
Kono, 1966; Kobayashi & Kono, 1967; McConnell et al., 1977). However, their 
use was restricted because macrophages are usually isolated as monocytes 
and stimulated to differentiate into macrophages and the in vitro infection of 
macrophages with EIAV eventually results in cell death making the 
maintenance of such cultures technically demanding. As such, research with 
EIAV has utilised a number of other cell lines such as canine macrophages 
(Hines & Maury, 2001), equine endothelial cells (Maury et al., 1998), equine 
dermal cells (Maury et al., 2002) and other canine and feline fibroblasts 
(Maury et al., 2002).  
 
There has however been doubt over the use of immortal cell lines in regards 
to their relevance in vivo. Clinical strains have been found to infect 
macrophage cultures much more efficiently than fibroblast cell lines 
(Carpenter & Chesebro, 1989). Subsequent passaging in fibroblasts 
increases its infectivity for fibroblasts at the expense of infectivity in 
macrophages. This adaption also sees a reduction in virulence in vivo 
(Carpenter & Chesebro, 1989). One of the contributing factors in cell culture 
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adaption is the U3 region of the LTR. The hypervariable nature of the U3 
region can result in the deletion and introduction of transcription factor binding 
sites brought about by the selection pressures of the different transcription 
factors present in different cells, altering the viral tropism (Carvalho & Derse 
1993a; Carvalho & Derse 1993b). Most field strains contain three ETS motifs 
that act as PU.1 binding sites, which is a transcription factor mainly found in 
myloid cells such as monocytes and macrophages (Maury, 1994; Dong et al., 
2014). Further to these binding sites the U3 promotor of cell adapted strains 
has been found to contain binding sites for fibroblastic transcription proteins 
not found in myloid cells such as PEA-2, lvb, Oct, Cre and CAAT boxes 
(Maury et al., 1999; Hines et al., 2003). For example, in strain pSP19 two ETS 
motifs are removed and two PEA2 sites are inserted (Dong et al., 2014). 
Thus, the use of fibroblast systems to study EIAV may select for a specific 
sub-set of the viral population which would not be selected in vivo thus biasing 
the study. 
1.9 Monocytes: Precursors of macrophages and dendritic cells: 
Monocytes (Mo) are large, rounded cells with a horse shoe shaped nucleus 
and contain cytoplasmic lysosomes and various organelles in abundance to 
allow the quick production of proteins and the digestion of pathogens. They 
are of myeloid origin and originate from the bone marrow as a hematopoietic 
stem cell precursor that either self-renews or differentiates into a lymphoid 
progenitor that then gives rise to B-cells, T-cells, natural killer cells and 
dendritic cells (DC), or a myeloid progenitor cell (Geissmann et al., 2010; 
Figure 1.8). Myeloid progenitor cells differentiate into progenitor cells for 
erythrocytes, platelets, neutrophils, monocytes and other leukocytes. Mo then 
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migrate from the bone marrow to the blood where they circulate around the 
body (Shi & Pamer, 2011). Equine Mo populations have not been fully 
established, but in mice and humans there are two distinct Mo populations, 
one that migrates towards sites of infection and inflammation, and one that 
‘patrols’ around the body and enters non-inflamed/ infected tissues to 
replenish macrophage (MФ) and DC populations (Shi and Pamer, 2011; 
Serbina et al., 2008). Mo are also present in high numbers in the spleen that 
acts as a storage reservoir for immature Mo. In the absence of infection or 
any activation signal, they do not proliferate except at low levels to replenish 
tissue MФ and DC resting levels. When there is an infection, they migrate to 
the site of infection and phagocytose microbes, release tumour necrosis factor 
(TNF) and other chemokines attracting immune cells, enter the tissue and 
differentiate into a MФ or DC subset depending on the present cytokines and 
microbial signals (Geissmann et al., 2010). Initially the Mo develops into a Mo-
derived accessory cell, which is a Mo with DC characteristics, before 
differentiating into a MФ or DC (Peters et al., 1996). They can also migrate to 
a draining lymph node where they can prime the adaptive immune response 
(Shi and Pamer, 2011). 
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1.10 Macrophages and dendritic cells: 
MФ are approximately five times the size of their Mo precursors and contain a 
circular nucleus and a large number of lysosomes, vacuoles and granules. 
MФ are professional phagocytes due to their ability to efficiently engulf and 
break down microbes, debris and dead/ dysfunctional host cells (Murray and 
Wynn, 2011). They may also secrete regulatory cytokines that help shape the 
resulting immune response, attract neutrophils or promote wound healing. 
They can also function as an antigen presenting cell (APC) in which they 
display the antigens of a previously phagocytosed microbe on their cell 
surface and use it to prime T-cells and stimulate an adaptive immune 
Figure 1.8: Development of immune cells, Erythrocytes and platelets as well as their 
compartments (blue boxes). For example, monocytes generated from a stem cell progenitor 
in the bone marrow before circulating in the blood. They then enter a tissue and differentiate 
into macrophages or dendritic cells. (Adapted from Todar, 2012). 
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response (Mak & Saunders, 2005). They are not as efficient an APC as DC 
because they contain markedly less major histocompatibility complex (MHC) 
molecules and the majority of phagocytosed protein is directed to the 
lysosomes where it is broken down into amino acids. In DC, the proteins are 
broken down into larger peptide chains (Banchereau & Steinman, 1998).  
 
DC on the other hand are specialised APC, capable of ingesting a micro-
organism, breaking it down and displaying antigens on the cell surface before 
migrating to the nearest lymph node and stimulating a potent B-cell and T-cell 
response. There are various subsets of DC depending on the phenotype and 
location, such as inter-digitating DC, located in lymphoid organs heavily 
populated with T-cells, and interstitial DC, located in non-lymphoid organs 
(Mak & Saunders, 2005). Initially DC are ‘immature’ and reside in tissues 
where they are likely to encounter antigen such as the skin or digestive tract. 
They are star shaped with long thin dendrites that allow them to form a net 
and capture undesirable microbes and cellular debris. Once taken in, a DC 
breaks down the antigen into small peptides that are then bound to MHC 
class I molecules and displayed on the cell surface. This activates the DC and 
causes it to mature. The receptors involved in endocytosis are down 
regulated, they home towards draining lymph nodes, large stores of MHC 
molecules inside the cell are trans-located and displayed on the cell surface, 
MHC co-stimulatory molecules are expressed and a variety of cell surface 
receptors involved in T-cell signalling are up regulated within 24 hours of 
stimulation (Banchereau & Steinman, 1998). They also lose their efficiency at 
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phagocytosis and antigen capture completing the switch in skill set from 
antigen capture to adaptive immune activation (Geissmann et al., 2010). 
 
1.11 Aims: 
The testable hypothesis was that EIAV strains of European origin display a 
high degree of nucleic acid diversity from the US prototypes, which is 
reflected in their biological behaviour in vitro. 
 
Even though EIAV is present across the globe, full genome sequences only 
represent a single case from Japan and a small number of cases from Ireland, 
China and the USA. A larger number of gag sequences exist with the majority 
originating from either Romanian or Italian cases. The lack of sequence data 
makes understanding the extent of EIAV genome diversity in the field difficult 
and hinders outbreak investigation. The British outbreak cases offer a unique 
opportunity to increase the diversity of full genome sequences and allow a 
more detailed phylogenetic analysis of European EIAV strains. Sequencing of 
the British cases was initially carried out using conventional PCR and Sanger 
sequencing. Following this next generation sequencing was used to avoid the 
requirement for sequence specific primers. With the generation of full genome 
sequences from the outbreaks in Britain, phylogenetic analysis was then 
carried out to investigate the origins and diversity of the different European 
and global EIAV field strains. Sequence analysis was also carried out to 
assess any patterns and coding motifs in the genomes. Issues occurred with 
the asymptomatic cases due to low level virus. Virus culture could yield an 
isolate and increase the success of sequencing but the adaption of EIAV field 
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strains to cell lines used in in vitro virus culture negates this approach. The 
need for a culture system that utilises cells that are naturally infected in vivo to 
reduce adaption is high, not only for the isolation of field viruses, but also for 
their study and biological characterisation. Therefore a culture system using 
Mϕ was developed. A system of Mo isolation, differentiation and infection was 
implemented to study the Mo product which best supported EIAV replication. 
Variation in the virus genome was also examined to assess the extent of virus 
mutation in the Mϕ cultures used. 
  
In summary, the project was split into two halves: the molecular side, 
including the sequencing and phylogeny, and the cellular side, including cell 
system development and the infection studies. In summary, this study aimed 
to investigate: 
1. The characterisation of British EIAV strains by: 
a. Sequencing 
i. Sequencing by PCR of British strains 
ii. Investigate use of next generation sequencing for 
sequencing EIAV 
iii. Full genome sequencing and detailed phylogenetic 
analysis of GB viruses and other strains 
iv. Analysis of full genome sequences for trends and 
patterns 
b. Virus culture 
i. Set up Mo differentiation system 
ii. Set up EIAV infection system 
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iii. Study capability of Mϕ and DC cells to support EIAV 
replication 
iv. Investigate possible sequence adaption in the cell culture 
system 
 
 
 
41 
 
2.0 Materials and Methods: 
2.1 Viruses and tissues: 
EIAVIRE, EIAVWYO and the British outbreak samples (Table 2.1) were used in 
this study. EIAVWYO was originally isolated from a case in Wyoming, USA and 
has since been maintained in equine dermal cells and was obtained from the 
ATCC® (VIR-778™) in tissue culture supernatant (TCSN). Two EIAVIRE 
tissues were also used (EIAVIRE3300 and EIAVIRE1875) which were biopsied from 
two infected foals during the 2006 outbreak in Ireland (Central Veterinary 
Research Laboratory, Department of Agriculture and Food, Ireland). Tissues 
from the four 2010 and two 2012 British EIAV cases were provided by the 
Mammalian Virology Investigation Unit (MVIU, Animal and Plant Health 
Agency (APHA), Weybridge). 
Table 2.1: The British outbreak cases location and date with 
abridged name used in this thesis.  
Origin location Year of outbreak Reference 
Wiltshire 1 2010 EIAVWILT1 
Wiltshire 2 2010 EIAVWILT2 
Northumberland 2010 EIAVNORTH 
Devon 2010 EIAVDEV 
Cornwall 2012 EIAVCOR 
Cornwall 2012 EIAVDEV2 
Wyoming 1941 EIAVWYO 
Ireland 3300 2006 EIAVIRE3300 
Ireland 1875 2006 EIAVIRE1875 
 
2.2 Nucleic acid extraction: 
2.2.1 RNA extraction from tissues 
Tissues were homogenised by disruption of 50-100mg of tissue in 500µl of 
TRIzol® (Life technologies, Paisley, United Kingdom (UK)) with a hand held 
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homogenizer. The homogenate was then transferred to a plastic 2ml tube 
containing 500µl of TRIzol® and incubated at room temperature for 5 minutes. 
For phase separation, 200µl of chloroform (Sigma Aldrich, Dorset, UK) was 
added to the tube that was then mixed by vigorous agitation for 15 seconds 
and incubated at room temperature for 3 minutes before centrifuging at 
12,000xg, 4°C for 15 minutes. The upper RNA containing aqueous phase was 
then removed and mixed with 75% ethanol (Fischer Scientific, Loughborough, 
UK) in a 1:1 volume resulting in RNA precipitation. The RNA was purified with 
an RNeay Mini Kit (Qiagen, West Sussex, UK). 
 
The RNA ethanol mix was transferred to an RNeasy spin column and 
centrifuged at 8000xg, for 15 seconds to bind the precipitated RNA to the 
silica membrane. Contaminants were removed from the membrane by 
washing with 700µl of buffer RW1 followed by 500µl of buffer RPE, spinning 
both at 8000xg for 15 seconds and discarding the flow through of both. A final 
wash with 500µl of buffer RPE was then carried out, centrifuging at 8000xg for 
2 minutes. The column was then transferred to a sterile 2ml collection tube 
and centrifuged at 10,000xg for 1 minute to remove any remaining buffer and 
ethanol before transferring to a sterile 1.5ml plastic tube. Thirty µl of PCR 
grade water (Bioline, London, UK) was then applied to the column membrane, 
incubated at room temperature for 1 minute and centrifuged for 1 minute at 
8000xg to elute the RNA. Four more elutions were then carried out. The RNA 
yield was analysed by a nanodrop 2000 spectrophotometer (ND2000) 
(Thermo Scientific, Surrey, UK) and the RNA stored at -80°C until required.  
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2.2.2 RNA extraction from cell culture 
RNA was extracted from cells grown in culture using the RNeay Mini Kit 
(Qiagen, West Sussex, UK). Initially cells were disrupted by discarding the 
media, washing the monolayer once with PBS (phosphate buffered saline; 
Life Technologies-Gibco, Paisley, UK) and then adding 500µl antibiotic trypsin 
versene (ATV, 450ml deionised H2O, 50ml trypsin/ versene, 6.25ml penicillin, 
streptomycin, nystatin 104U/ml) to each well. The plate was then incubated at 
37°C for 5 minutes. The plate was then agitated and the cells removed to a 
sterile 1.5ml plastic tube. To inhibit the ATV, 1ml of fresh medium was then 
added and the cells pelleted by spinning at 300xg for 5 minutes. Following 
this, the supernatant was removed and 350µl high salt lysis buffer RLT was 
added. The cells were homogenized by vortexing for 1 minute and washed 
with 350µl of 70% ethanol. The mixture was then passed through an RNeasy 
spin column (8000xg, 15 seconds) binding the RNA to the membrane.  
 
To eliminate contaminant DNA carry over an on-column DNAse digest was 
also carried out. The column was washed with 350μl Buffer RW1, centrifuging 
for 15 seconds at 8000xg. Then 80µl DNase I incubation mix (RNase-free 
DNase set, Qiagen, West Sussex, UK) was added directly to the RNeasy spin 
column and incubated at room temperature for 15 minutes to digest the DNA. 
Finally, to remove the digested DNA from the column the RW1 buffer wash 
was repeated. Two washes with 500µl of buffer RPE were then carried out, 
both spinning at 8000xg but the first for 15 seconds and the second for 2 
minutes. To remove any residual buffers and ethanol the column was placed 
in a sterile collection tube and centrifuged at full speed for 1 minute. The RNA 
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was then eluted in 30µl of RNase free water by centrifuging at 8000xg for 1 
minute. The RNA yield was analysed by a ND2000 and the RNA stored at -
80°C until required. 
 
2.2.3 RNA extraction from TCSN 
To extract RNA from TCSN the Viral spin RNA kit (Qiagen, West Sussex, UK) 
was used. First, 140µl of supernatant was mixed with a 560µl aliquot of lysis 
buffer containing 5.6µg of carrier RNA and incubated at room temperature for 
10 minutes. To provide optimum binding conditions, 560µl 100% ethanol was 
added. The RNA was then bound to the Qiamp mini column by centrifuging at 
6000xg for 1 minute and discarding the run through. The column was then 
washed with 500µl of buffer AW1, spinning at 6000xg for 1 minute before a 
final wash with 500µl of buffer AW2, and spinning at 14,000xg for 3 minutes. 
The column was then placed into a clean collection tube and centrifuged at 
14,000xg for 1 minute to remove any residual buffer and ethanol from the 
column. To elute the RNA the column was placed into a sterile 1.5ml plastic 
tube and 60µl of buffer AVE applied to the column membrane, incubated at 
room temperature for 1 minute and then centrifuged at 6000xg for 1 minute. 
The RNA yield was analysed by the ND2000 and the RNA stored at -80°C 
until required.  
 
2.2.4 DNA extraction from tissues 
DNA extraction was carried out using the DNA Mini Kit (Qiagen, West Sussex, 
UK). 10mg spleen or 25mg of other post mortem tissue was immersed in 80µl 
1x phosphate buffered saline (PBS) and disrupted using a hand held 
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homogenizer. To lyse the tissue 100µl of buffer ATL was added followed by 
20µl of Proteinase K (Life technologies, Paisley, UK). The mixture was then 
pulse vortexed and incubated at 56°C for 3 hours or until the tissue had 
completely lysed. 200µl of buffer AL was then added and mixed by pulse 
vortexing before incubating at 70°C for 10 minutes. To bind the DNA to the 
column 200µl of 100% ethanol was then added to the solution and run 
through a QIAmp mini spin column at 6000xg for 1 minute. The column was 
then washed with 500µl buffer AW1, spinning at 6000xg for 1 minute and then 
buffer AW2, spinning at 14,000xg for 3 minutes. To remove any residual 
buffer and ethanol, the column was placed into a clean collection tube, 
centrifuged for 1 minute at 14,000xg, and then placed into a sterile 1.5ml 
plastic tube. For elution of the DNA, 200µl of buffer AE was applied to the 
membrane and incubated at room temperature for 1 minute before 
centrifuging at 6000xg for 1 minute. Three elutions were carried out in total. 
DNA levels were assessed using the ND2000. DNA was stored at -80°C until 
needed. 
 
2.2.5 DNA extraction from cell culture: 
To extract DNA from cultured cells in a 24 well plate the QIAamp DNA Mini Kit 
(Qiagen, West Sussex, UK) was use. Cells were trypsinised by discarding the 
medium and washing the monolayer once in PBS before adding 200µl of ATV 
to the wells and incubating for 10 minutes at 37°C. The plate was then 
agitated and the cells aspirated to a sterile 1.5ml plastic tube. The trypsin was 
diluted by adding 500µl of DMEM and the cells centrifuged for 5 minutes at 
300xg. The supernatant was then aspirated and the cells resuspended in 
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200µl PBS. To break down the cells 20µl of proteinase K and 200µl of buffer 
AL were added to the cells and the suspension was then incubated at 56°C 
for 10 minutes. The protocol for DNA extraction from tissues was then 
followed (Section 2.2.4), applying the DNA to a mini spin column before 
washing with 100% ethanol, buffer AW1, buffer AW2, then centrifuging in to 
an empty tube. The DNA was eluted into 200µl of buffer AE. The ND2000 was 
used to assess the quantity and quality of DNA extracted. DNA was stored at 
-80°C until needed. 
 
2.2.6 Quantification and quality control of nucleic acids: 
For applications where approximate quantification would suffice such as 
extracting RNA and DNA from tissues, the ND2000 was used. Where more 
accurate quantification was required such as for sequencing and library 
preparation an Agilent Bioanalyzer 2100 (Agilent Technologies, Wilmington, 
USA) was used. The RNA 6000 pico and nano kits (Agilent Technologies, 
Wilmington, USA) were used to analyse RNA, the pico kit has a quantitative 
range of 50-5000pg/µl and the nano 25-500ng/µl. For DNA the DNA 12000 
(quantitative range: 0.5-50ng/µl) and the high sensitivity DNA kit (range: 5-
500pg/µl) (Agilent Technologies, Wilmington, USA) were used. Samples were 
initially quantified using the ND2000 to assess which bioanalyzer kit to use. 
The following protocol was the same for all kits except for the requirement of 
5µl of conditioning solution into the well, labelled CS, for the RNA pico kit. 
After initial quantification, the RNA was denatured by incubating at 70°C for 2 
minutes and then placed on ice. The Bioanalyzer chip was set up by pipetting 
9µl of filtered gel dye mix into the designated well which was then 
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compressed by using the chip priming station by depressing the plunger so it 
was held by the clip for 30 seconds. Following this, 9µl of filtered gel dye mix 
was pipetted into the remaining gel wells. Finally, 5µl of RNA marker was 
pipetted into each of the sample and ladder wells followed by 1µl of ladder 
and 1µl of sample. The chip was placed in an adaptor vortex (IKA GmBH & 
Company, Staufen, Germany) and vortexed for 1 minute before placing the 
chip into the bioanalyzer and running the 2100 Expert software (Agilent 
technologies, V B.02.08.SI648(SR2)).  
  
2.3 Nucleic acid amplification: 
2.3.1 cDNA production/ reverse transcription: 
Prior to conventional PCR, RNA extracts were reverse transcribed using 
SuperScript® III Reverse transcriptase (Life technologies-Invitrogen, Paisley, 
UK) by carrying out three incubations. First, a 20µl reaction mix consisting of 
5µl extracted RNA, 0.5mM dNTPs (deoxynucleotide triphosphates; Promega, 
Southampton, UK) mix and 0.25µg hexamer primers (Promega, Southampton, 
UK) was incubated for 5 minutes at 65°C followed by 1 minute on ice. Seven 
µl of a superscript mix was added to the reaction mix resulting in 1x first 
strand buffer (Promega, Southampton, UK; final concentration of 37mM Tris 
HCl, 55mM KCl and 22mM MgCl2), 3.7mM DTT (Dithiothretol; Life 
Technologies, Paisley, UK), 40U RNaseOUT™ (Life Technologies, Paisley, 
UK) and 200U Super Script® III reverse trancriptase (Life Technologies- 
Invitrogen, Paisley, UK). The mixture was incubated for 5 minutes at 25°C, 60 
minutes at 50°C and 15 minutes at 70°C. Finally, to remove the remaining 
RNA, 2U RNase H (Life Technologies- Invitrogen, Paisley, UK) was added 
and incubated for 20 minutes at 37°C. 
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2.3.2 Detection Polymerase Chain Reactions (PCRs): 
To assess the presence of EIAV in the tissues, three PCRs were used, a 
realtime PCR (discussed in 2.3.4) and two conventional PCRs of which one 
was based on the gag gene (Cappelli et al., 2011) and the other based on the 
LTR-tat region (Dong et al., 2012). The primers were used with their published 
PCR profiles (Primer sequences shown in Appendix 1). Products were 
analysed on a 1.5% agarose gel (Promega, Southampton, UK) containing 
3.5µl per 100ml of agarose gel of SYBR safe (10,000x; Life Technologies- 
Invitrogen, Paisley, UK; final concentration 0.35x) using a 100bp ladder 
(Promega, Southampton, UK) standard for PCR product size verification. 
 
A quantitative PCR was used for visualisation of the relative viral abundance 
based on the Ct value for SBV. The primers are included in Appendix 1. The 
programme for the SBV qPCR was 50°C for 20 mins and 95° for 5 mins 
followed by 45 rounds of 95°C for 15 secs and 60°C for 30 secs. 
 
2.3.3 Sequencing PCRs: 
Initially a set of 12 primers based on Irish strains that spanned the length of 
the genome (Quinlivan et al., 2013) and a set of 3 primers designed on the 
Irish strains for use in EIAV detection (Boldbaatar et al., 2013) were tested for 
their ability to amplify the British samples. Subsequently primers were 
designed using an alignment of published full genomes with representatives 
from each of the supposed phylogenetic groups (American, Chinese, 
Japanese and Irish) from GenBank (Accession numbers: AB008196, 
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AB008197, AF033820, AF247394, AF327877, AF327878, GU385360, 
HM141911, HM141912, HM141923, JX003263, JX480631, JX480632, 
JX480633, JX480634, M16575, NC001450). The primer sequences are 
shown in Appendix 1. The primers taken from the literature were used with 
their corresponding published PCR programme. The programme used for the 
designed primers was taken from the recommendations of the Dream Taq 
polymerase (Thermo Scientific, Surrey, UK). That was 95°C for 5 minutes 
followed by 40 cycles of 95°C for 30 seconds, the specific primer annealing 
temperature for 30 seconds and 72°C for 1 minute, with a final extension step 
of 72°C for 10 minutes. The products were then separated on a 1.5% agarose 
gel containing 3.5µl SYBR safe per 100ml of agarose gel. A 100bp ladder 
standard was used for band size verification. Annealing temperatures for 
primers were calculated by deducting 5°C from the melting temperature given 
by the manufacturer. 
 
2.3.4 Real time Reverse Transcriptase PCR (RT-PCR): 
Detection and assessment of relative viral load of EIAV in post mortem 
tissues and cell culture was carried out using a commercial kit with primers 
based on the pol region (Primerdesign Ltd, Southampton, UK). First 5µl of 
RNA was added to a mastermix consisting of: 4µl PCR grade water, 10µl 2x 
Precision one-step mastermix (Primerdesign Ltd, Southampton, UK) and 1µl 
of EIA primer/probe mix to give a final reaction volume of 20µl. A one-step 
mastermix without the reverse transcriptase was also provided and was used 
as a control and for assessing the presence of proviral DNA. The PCR 
programme consisted of two segments: for reverse transcription, the reaction 
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was heated to 55°C for 10 minutes then 95°C for 8mins. For the PCR the 
reaction was heated to 95°C for 10 seconds then 60°C for 1 minute (at which 
point, 1 round of endpoint data collection was carried out), this cycle was 
repeated 50 times.  
 
2.3.5 Five prime (5’)random amplification of cDNA ends (RACE) PCR: 
In order to amplify the 5’ ends of EIAV for sequencing, a 5’ RACE PCR 
protocol was developed. Firstly reverse transcription was carried out to first 
strand only to generate a small DNA fragment. The 12µl RT reaction 
consisted of 5µl extracted RNA (1-5µg), 0.16µM gene specific primer (GSP1), 
0.83mM dNTP and PCR grade water (details of the primer sequences are in 
Appendix 1). The mixture was then heated to 65°C for 5 minutes then put on 
ice before adding 5x first strand buffer, 0.1M DTT and RNaseOUT™ (40 
units/µl) to a final concentration of 1x, 7.6mM and 40U respectively, . The 
mixture was incubated at 42°C for 2 minutes before adding 200U of 
SuperScript™ III reverse transcriptase (200U/µl; Life Technologies- 
Invitrogen, Paisley, UK). The reaction was carried out at 50°C for 50 minutes 
before heating to 70°C for 15 minutes for inactivation. Once first strand 
synthesis was complete, the DNA was purified by alkali hydrolysis by adding 
0.5M sodium hydroxide to a final concentration and volume of 0.1M and 73µl 
respectively (Sigma Aldrich, Dorset, UK) incubating at 50°C for 30 minutes. 
To neutralise the reaction for clean-up 1.8M acetic acid was added to a final 
concentration of 0.1M (Sigma Aldrich, Dorset, UK) was then added and the 
DNA purified using the Minelute PCR purification kit. This was carried out 
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using the same protocol used in section 2.4.2 except the final elution volume 
was 50µl. 
 
To allow the use of an anchored forward primer, A-tailing was carried out 
using the enzyme terminal deoxynucleotidyl transferase (TdT). The 24µl 
reaction mix contained 10µl purified DNA, 0.2mM dATP (Promega, 
Southampton, UK) and 1x tailing buffer (Promega, Southampton, UK) and 
was incubated for 3 minutes at 94°C and then placed on ice for 1 minute. 
Thirty U TdT (Promega, Southampton, UK) was added and the tailing reaction 
carried out for 10 minutes at 37°C followed by 10 minutes at 65°C. The added 
polyA tail allowed PCR using an anchored polyT primer (Life Technologies, 
Paisley, UK) and a second GSP (GSP2) that was situated down stream of 
GSP1. The anchored primer consisted of 20 deoxythymidyllic residues 
followed by bases AB where A was either dA, dC or dG and B was dA, dC, 
dG or dT. This allows the primer to bind the 5’ end of the DNA. The 50µl PCR 
reaction mix contained 10µl DNA, 0.4µM GSP2, 0.4µM anchored primer and 
1x DreamTaq mastermix. The profile used was an initial denaturation of 95°C 
for 2 minutes a main sequence of 95°C for 45 seconds, 55°C for 45 seconds 
and 72°C for 60 seconds for 35 cycles and a final extension of 72°C for 7 
minutes. A second nested amplification was then carried out using the same 
PCR profile and reaction mix except GSP3 was used instead of GSP2. GSP3 
was situated further upstream from GSP2. The products were then analysed 
on a 2% agarose gel.  
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2.4 Sequencing: 
2.4.1 Sequencing platforms: 
PCR products were sequenced using either a 3130xl (16 capillary) or 3730 
(48 capillary) Genetic Analyser (Applied Biosystems, California, USA) by 
APHA central sequencing unit (CSU; APHA, Weybridge, UK). Nucleic acid 
amplified by PCR was analysed by agarose gel electrophoresis (Section 
2.3.2) for product size approximation and if present was then cleaned (Section 
2.4.2) and sequenced by cleaning PCR products using Agencourt AMPure 
beads (Beckman Coulter, High Wycombe, UK), cycle sequencing using 
BigDye® Terminator v3.1 (Thermo Fisher, Surrey, UK), cleaned using 
Agencourt CleanSEQ beads (Beckman Coulter, High Wycombe, UK) and 
then analysed using either the 3130xl or 3730 genetic anlyser. 
 
The next generation sequencing platforms used were the Roche 454, illumina 
GAIIx, illumina MiSeq (CSU, APHA, Weybridge, UK) and illumina HiSeq 2500 
(Oxford Genomics, Wellcome Trust Centre for Human Genetics, Oxford, UK). 
Nucleic acid destined for NGS was extracted and analysed by 2100 
bioanalyzer (Section 2.2.6) and realtime PCR (Section 2.3.4) and then 
sequenced.   
 
2.4.2 Clean-up of PCR products for Sanger sequencing: 
If only the band of interest was present on the 1.5% agarose gel, the PCR 
product was cleaned using the MinElute PCR purification kit protocol (Qiagen, 
West Sussex, UK). First, 5µl of buffer PB for every 1µl PCR product was 
added to the PCR reaction product to provide optimum conditions (high salt, 
53 
 
pH <7.5) for membrane binding, and the mix applied to a kit column and 
centrifuged for 1 minute at 17,900xg. To remove contaminant enzymes and 
molecules the column was washed with 750µl of buffer PE, centrifuging for 1 
minute at 17,900xg. The column was then centrifuged for 1 minute at full 
speed to remove residual buffer. To elute the DNA, 10µl of PCR grade water 
was then applied to the membrane and incubated at room temperature for 1 
minute before spinning for 1 minute at 17,900xg. The DNA was stored at -
20°C until ready for submission.  
If other bands were present in the agarose gel the band of interest was cut out 
of the gel and cleaned using the MinElute Gel extraction kit protocol (Qiagen). 
The band was initially weighed and buffer QG was added in a 1:3 volume/ 
weight ratio (3µl buffer for every 1mg) before incubating at 50°C for 10 
minutes to solubilize the agarose whilst stabilizing the DNA. Isopropanol 
(Sigma Aldrich, Dorset, UK) was then added in a 1:1 volume ratio, and the 
mix was applied to a MinElute column and the DNA bound to the membrane 
by centrifuging at 17,900xg for 90 seconds. The column was then washed 
with 500µl buffer QG at 17,900xg for 90 seconds. To wash away the salt, 
750µl of buffer PE was added to the column and incubated at room 
temperature for 5 minutes before spinning at 17,900xg for 90 seconds. To 
reduce the chance of salt contamination during sequencing the PE buffer 
wash was repeated a second time. The column was then centrifuged in an 
empty collection tube at 17,900xg for 1 minute to remove all residual buffers. 
To elute the DNA, 10µl of PCR grade water was applied to the column 
membrane that was then stood at room temperature for 1 minute and then 
centrifuged at 17,900xg for 1 minute. The DNA was stored at -20°C. 
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2.4.3 PCR amplicon sequence construction: 
Sequences from Sanger sequencing were assembled using SeqMan Pro™ 
(Lasergene 11 core suite, V11.1.0, DNASTAR inc). The primer sequences 
were removed and the assembled sequences were adjusted (if necessary) 
based on a visual assessment of the raw traces. The standard nucleotide 
BLASTn (http://blast.ncbi.nlm.nih.gov/Blast.cgi?PROGRAM=blastn&PAGE_ 
TYPE=BlastSearch&LINK_LOC=blasthome) was used to confirm EIAV.  
2.4.4 Preparation of NA for NGS: 
The TRIzol/RNeasy RNA extraction method outlined in section 2.2.1 was 
used to extract RNA from tissue for NGS. In order to select which elution to 
sequence, the 5 elutions were analysed by Agilent 2100 Bioanalyzer (Agilent 
Technologies, Wilmington, UK; explained in 2.2.6) and the EIAV POL real-
time kit (see 2.3.4). The elution that contained the lowest overall nucleic acid 
concentration relative to lowest Ct value was selected for sequencing.  
 
2.4.5 In house RNA library preparation: 
In house RNA library preparation was carried out using the Truseq stranded 
illumina library preparation kit (illumina, San Diego, USA). Initially the sample 
to be sequenced was analysed by the 2100 bioanalyzer to accurately 
investigate RNA quality and quantity, and determine the length of time needed 
for fragmentation. The kit requires a starting RNA concentration in the range 
of 0.1-1µg of whole RNA. The kit includes the presence of a control for the 
end repair, A-tailing and adapter ligation steps. These controls each contain 
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dsDNA fragments whose presence or absence  in the final sequencing data 
indicates if the step was successful. 
 
2.4.5.1 DNAse digest 
Initially contaminant DNA was degraded using amplification grade DNAse I. 
The reaction mix consisted of 3µl RNA, 7µl PCR grade H20, 1µl 10x DNAse 
buffer (Life Technologies- Invitrogen, Paisley, UK), 1µl DNAse I (Life 
Technologies- Invitrogen, Paisley, UK). The reaction was mixed and 
incubated for 30 minutes at 37°C. The reaction was terminated by adding 1µl 
EDTA terminator (25mM; Life Technologies- Invitrogen, Paisley, UK) and 
incubated for 10 minutes at 65°C. 
 
2.4.5.2 RiboZero depletion and fragmentation 
For rRNA depletion 10µl RNA, 5µl rRNA binding buffer and 5µl rRNA removal 
mix was combined and incubated at 68°C for 5 minutes followed by 1 minute 
at room temperature. The rRNA was eliminated by adding 35µl of rRNA 
removal beads and incubating at room temperature for 1 minute. The tubes 
were then placed onto a magnetic stand for 1 minute and the supernatant 
removed, leaving the rRNA bound to the magnetic beads in the tube. The 
rRNA depleted RNA was then purified by adding 99µl RNAClean XP beads to 
the bound RNA and incubating at room temperature for 15 minutes. The RNA 
was then washed with 200µl of 70% ethanol for 30 seconds and air-dried for 
15 minutes. Finally, the RNA was eluted by adding 11µl of elution buffer and 
incubated at room temperature for 2 minutes before placing the tubes on the 
magnetic stand and incubating for 5 minutes. 
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For fragmentation 8.5µl eluate was taken and diluted with 8.5µl fragmentation 
mix and incubated at 94°C for a time appropriate for the RNA quality (as 
assessed by the initial bioanalyzer trace). 
 
2.4.5.3 First and second strand synthesis 
The reverse transcriptase mix was made up by adding 50µl superscript II to 
the first strand synthesis act D tube and adding 8µl of the mix to the RNA. The 
mix was then incubated with the following temperature profile: 10 minutes at 
25°C, 15 minutes at 42°C and finally 15 minutes at 70°C. 
For second strand synthesis, 5µl of a 1/50 dilution of an end repairing control 
was added, followed by 20µl second strand master mix. This was incubated 
for 1 hour at 16°C. 
 
Following the second strand synthesis the DNA was cleaned by adding 90µl 
AMPure XP beads, incubating at room temperature for 15 minutes and then 
placing the tubes on a magnetic stand for 5 minutes. The supernatant was 
then removed and replaced with 200µl of 80% ethanol. This was incubated for 
30 seconds before discarding the ethanol and repeating the ethanol wash. 
Finally after 15 minutes of air drying the DNA was eluted into 17.5µl 
resuspension buffer and 15µl was removed to a clean set of tubes. 
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2.4.5.4 Adenylation of the 3’ ends 
To adenylate the 3’ ends of the cDNA, 2.5µl of a 1/100 dilution of the A-tailing 
control was added to 15µl cDNA followed by 12.5µl A-tailing mix. This was 
incubated at 37°C for 30 minutes followed by 70°C for 5 minutes. 
 
2.4.5.5 Adaptor ligation 
To ligate adaptors to the cDNA, 2.5µl of a 1/100 dilution of ligation control was 
added, followed by 2.5µl ligation mix to the cDNA. Then 2.5µl of the desired 
RNA adapter index was added and incubated for 10 minutes at 30°C. To 
terminate the reaction 5µl stop ligation buffer was added. Finally the adaptor 
ligated cDNA was cleaned using 42µl AMPure XP beads as before (Section 
2.4.5.3) eluting the cDNA in 52.5µl of resuspension buffer. 50µl cDNA was 
then removed to a clean tube and 50µl AMPure XP beads were added again. 
The wash step was repeated as before, eluting in 22.5µl resuspension buffer 
and removing 20µl to a clean tube for enrichment. 
 
2.4.5.6 DNA enrichment PCR 
To enrich the DNA fragments, 5µl of PCR primer cocktail was added to the 
cDNA followed by 25µl PCR master mix. The PCR was then carried out with 
the following profile; an initial denaturation of: 98°C for 30 seconds, 15 cycles 
of 98°C for 10 seconds, 60°C for 30 seconds and 72°C for 30 seconds with a 
final elongation of 72°C for 5 minutes. The PCR mix was then cleaned using 
50µl of AMPure XP beads as before (Section 2.4.5.3), eluting in 32.5µl 
resuspension buffer. Thirty µl of supernatant was then transferred to a clean 
tube for validation. 
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2.4.5.7 Library validation 
 Library validation was carried out using a 2100 bioanalyzer using the high 
sensitivity DNA kit as described in 2.2.6. An example trace is shown below 
(Figure 2.1). The lower marker (green) and upper marker (purple) are both 
present with the majority of fragments being around 260bp. 
 
2.5.6 Construction of sequences from NGS: 
For Illumina data, mapping projects and sequence assemblies were carried 
out using SeqMan NGen (DNAstar Seqman NGen 11, v11.2.1(25)) and 
Seqman Pro™. The initial mapping project utilised multiple reference 
sequences including: AF327878, Vaccine; AF016316, University of Kentucky; 
AF033820, wyo; AF327877, Lia; JX480634, Ire; JX003263, Miya; EU240733, 
Ita-1; AB693823, Goshun; GQ229581, Rom-1; GU060664, Ita-6; JX193070, 
Ass-1 and JX193071, War-1 and the 2kb fragment from PCR sequencing of 
DNA from the Devon case.  This was to compensate for the variation between 
Figure 2.1: The expected bioanalyzer trace for a successful 
library preparation. The lower (green) and upper (purple) markers 
are visible and the majority of fragments are approximately 260bp 
in size. The left shows the electropherogram and the right shows 
the gel electrophoresis separation. (Taken from illumina, 2013) 
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currently published sequences and the British variants. The areas that 
mapped reads for each reference sequence were then cut out and formed 
together to create a single hybrid sequence which was then used as the new 
reference sequence. Following this each mapping project output would 
generate trimmed reads and consensus sequences skewed towards the input 
reference sequence, so this was manually altered in Seqman Pro™ by 
extending trimmed reads and adjusting the consensus to reflect the reads. 
This was carried out sequentially until reads covered as much of the 
consensus sequence as possible and so represented the sequenced virus 
genome. 
Table 2.2: The hybrid sequence makeup for the 
GB symptomatic cases. For each British virus, a 
series of reference sequences was mapped with 
the NGS data and the areas of each reference 
sequence that mapped the most reads were 
formed together to create a hybrid a sequence for 
the next round of sequence. 
Hybrid sequence Area Virus 
EIAVDEV 1-421 WYO 
 422-582 VACCINE 
 583-2602 DEV GAG 
 2977-3178 VACCINE 
 3179-3362 IREH3 
 3363-3484 LIA 
 3485-3609 WYO 
 3610-3806 UK 
 3807-3920 IREF4 
 3921-4150 LIA 
 4151-4406 WYO 
 4407-5296  MIYA 
 5297-5477 UK 
 5478-8400 LIA 
EIAVCOR 1-414 IREF2 
 415-1867 DEV 
 1868-5720 LIA 
 5721-7441 DEV 
 7442-8322 IREF2 
EIAVNEW 1-1465 WYO 
 1466-2083 IREF2 
 2084-3319 DEV 
 3320-5383 LIA 
 5384-8246 WYO 
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2.4.7 Phylogenetic tree construction: 
The sequences were then aligned by the Clustal W algorithm with other EIAV 
sequences in MEGA 5 (V5.03). Phylogenetic trees were constructed using the 
neighbour-joining and maximum likelihood methods and the Tamura Nei 
statistical model was used to calculate evolutionary distances with 
Bootstrapping to 1000 replicates. 
 
2.4.8 Bioinformatics: 
Reference guided assemblies to build hybrid sequences used SeqMan Ngen 
using the Metagenomics/ population assembly workflow. An initial minimum 
match percentage of 70% was used for the initial mapping projects but was 
raised to 80% when finalising the genomes. Ngen was also used to carry out 
de novo assemblies using the same workflow as reference guided 
assemblies. Further to Ngen a system using a Biolinux 7 (Ubuntu v14.04 LTS) 
operating system was also utilised. PRICE (v1.2) was used to try and 
elongate existing fragments through sequential extensions by aligning the 
fragment to all the reads. Bowtie (v2.2.6.2) was also used via a local instance 
of the Galaxy platform (v16.0) in order to test if linux based systems would 
have more success in extracting viral specific reads from the sequence data.  
 
2.5 Cell maintenance and acquisition: 
2.5.1 Cell lines & maintenance 
Equine Dermal cells (EDerms) were utilised to initially develop the viral 
infection protocols. They were sourced from European Collection of Cell 
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Cultures (ECACC, Salisbury, UK) and were maintained in Dulbecco’s 
Minimum essential medium (DMEM) with 10% heat inactivated foetal calf 
serum (FCS) and 1% penicillin/ streptomycin (Life Technologies- Invitrogen, 
Paisley, UK). Cells were split in a 1:2 ratio after achieving 90% confluence by 
covering the monolayer with ATV and incubating at 37°C for 5 minutes to 
allow the cells to detach, after which fresh media was added to the desired 
volume. The cells were aspirated in a 10ml pipette to break up large clumps 
and moved to a new flask. Cells were incubated at 37°C with 5% CO2. 
 
2.5.2 Animals used in this study:  
Three healthy horses (Equus caballus) were used in this study. The horses 
were monitored by trained veterinary staff (Animal Services Unit; ASU, APHA, 
Weybridge) each day for signs of ill health and if necessary treated 
accordingly. Blood was not taken during times of ill health. All horses tested 
negative for EIAV by the AGIDT. 
 
2.5.3 Monocyte isolation: 
Whole blood was collected from one of three healthy horses into 250ml blood 
bags containing 35ml of anticoagulant solution citrate phosphate dextrose 
(Baxter GmbH, Munich, Germany). The blood was then diluted 1:5 with PBS 
(5mM EDTA; Sigma Aldrich, Dorset, UK) and centrifuged at 754xg, 20°C for 
15 minutes. The buffy coat was then removed and layered onto 16ml of 
1.090g/ml Ficoll 400 (1 part PBS : 805 parts 1.10g/ml Ficoll 400; BiochromAG, 
Berlin, Germany) and centrifuged at 596xg, 20°C for 20 minutes to separate 
the erythrocytes and leukocytes. The leukocyte fraction was then collected 
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and diluted equal parts with PBS (5mM EDTA) and layered onto 16ml of 
1.077g/ml Ficoll 400. This was then centrifuged at 596xg, 20°C for 20 minutes 
to separate the PBMC and the granulocytes. The PBMC fraction was then 
removed and diluted 1:1 with PBS (5mM EDTA) and washed 3 times for 8 
minutes at 20°C at a speed of 596xg, 456xg and 335xg respectively. The cells 
were then resuspended in 20ml of PBS (5mM EDTA). The PBMC were 
counted using a MACSquant flow cytometer (Miltenyi Biotech, Bergisch 
Gladbach, Germany).  
 
2.5.4 Magnetic sorting of monocytes: 
To purify the monocytes from the PBMC, cells derived in section 2.5.3 were 
pelleted by centrifugation at 233xg, 20°C for 10 minutes and re-suspended in 
800µl of magnetically activated cell sorting (MACS) buffer (500ml 1x PBS, 2% 
FCS, 0.5mM EDTA) per 1x108 cells. Then 30µl of anti CD14 antibody (Big 
clone 10 or 13; Biometec GmbH, Greifswald, Germany) was added per 1x108 
cells and the solution was incubated for 30 minutes at 4°C. Afterwards the 
solution was made up to 15ml with MACS buffer and centrifuged for 10 
minutes at 233xg, 4°C. For the secondary antibody, the cells were 
resuspended in 500µl of MACS buffer per 1x108 cells with 150µl of goat anti-
mouse IgG microbeads (Miltenyi Biotech, Bergisch Gladbach, Germany) for 
every 1x108 cells and incubated for 15 mins at 4°C.  
 
To remove excess antibody the solution was made up to 15ml with MACS 
buffer and centrifuged for 10 minutes at 233xg at 4°C. The cells were re-
suspended in 500µl of MACS buffer per 1x108 cells.  The monocytes were 
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then purified using an LS separating column (Miltenyi biotech, Bergisch 
Gladbach, Germany) attached to a magnetic support as described in Figure 
2.2. The positive fraction was centrifuged at 233xg, 4°C for 5 minutes. The 
cells were resuspended in 1 ml of RPMI medium (Supplemented with 10% 
FCS and 0.1 mg/ml penicillin and streptomycin; Invitrogen) and the 
monocytes counted using the MACSquant flow cytometer. 
 
Figure 2.2: Magnetic separation of monocytes from PBMC. Initially to equilibrate the 
column 3ml of MACS buffer was run through the column and discarded. The labelled cells 
were applied to the column, and the flow-through reapplied twice more. The column was 
then washed by applying 3ml of MACS buffer to the column and letting it run through, then 
repeating twice more. The total flow-through was kept as the negative fraction. The column 
was then removed from its magnetic support and 5ml of MACS buffer was flushed through 
using the columns plunger to give the positive fraction. To reduce the loss of monocytes 
another column was attached to the magnetic support and 3ml of MACS run through the 
column and discarded. The negative fraction was then run through the column in the same 
fashion as the labelled cells previously followed by 3 rounds of 3ml MACS buffer washes. 
The flow-through was pooled with the negative fraction. The column was then detached 
and 5ml MACS buffer flushed through using the plunger and the resulting eluate pooled 
with the positive fraction. 
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2.5.5 Monocyte differentiation & macrophage activation: 
Monocytes were plated into a 24 well plate (Greiner Bio-One Ltd, Stonehouse, 
UK) at a density of 1x106 cells per well to be differentiated into EMDM (equine 
monocyte derived macrophages) and MoDC (monocyte derived dendritic 
cells). To drive MoDC differentiation 4µg IL-4 and 500U GM-CSF (R&D 
systems, Abingdon, UK) were used, to drive EMDM differentiation 10% 
autologous horse serum and 1µg M-CSF (R&D systems, Abingdon, UK) was 
used. EMDM were incubated at 37°C, 5% CO2 for 3 days and MoDC for 4 
days to differentiate. 
 
If activated EMDM were required 10ng of LPS (Enzo Life Sciences, Exeter, 
UK) and 100ng of IFN-γ (R&D systems, Abingdon, UK) or 10ng IL-4 was 
added to the cells 24 hours before infection for classical M1 or M2 activated 
macrophages respectively. Ten µg of water-soluble dexamethasome (Sigma 
Aldrich, Dorset, UK) was also added for each cell type. Macrophages were 
then incubated at 37°C, 5% carbon dioxide (CO2) for 24 hours to allow 
activation. 
Table 2.3: Cytokines used for individual stimulation of monocytes. 
Cytokine 
Concentration 
(ng/ml) 
Source Supplier 
ReM-CSF 1000 E. Coli derived R&D systems, Abington, UK 
Re-GM-CSF 500U E. Coli derived R&D systems, Abington, UK 
Serum 10% Horse In house 
IL-10 10 E. Coli derived R&D systems, Abington, UK 
IL-4 10 E. Coli derived R&D systems, Abington, UK 
IL-1β 10 E. Coli derived R&D systems, Abington, UK 
IL-6 20 E. Coli derived R&D systems, Abington, UK 
IFN-γ 1x10
6
 U/ml Mammalian cells R&D systems, Abington, UK 
TNF-α 20 E. Coli derived R&D systems, Abington, UK 
Lipopolysaccharide 10 
Salmonella 
Minnesota 
R&D systems, Abington, UK 
Prostaglandin E2 1000 Rabbit Enzo life sciences, Exeter, UK 
Dexamethasone 10 N/A Sigma Aldrich, Dorset, UK 
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If stimulating monocytes with individual cytokines, fresh monocytes were 
incubated with the desired cytokine (Table 2.3) overnight before infecting the 
cells. 
 
2.5.6 Cell freezing and thawing: 
Cells for long-term storage were centrifuged at 233xg for 5 minutes at 20°C to 
pellet the cells. The supernatant was then aspirated and the cells 
resuspended in 10% dimethyl sulphoxide (DMSO; Sigma Aldrich, Dorset, UK), 
90% FCS to give a density of 1x106/ml for monocytes. Ederms were frozen at 
a density of approximately 3x104/ml, due to the adhesive nature of the 
Ederms a large portion formed doublets and triplets making actual cell count 
difficult. The cells were then divided into 1ml aliquots in cryovials (Thermo 
scientific, Surrey, UK) and placed in a Mr Frosty container (Thermo scientific, 
Surrey, UK) with 100% isopropanol (Fisher Scientific, Loughborough, UK) and 
stored at -80°C overnight before transferring to cryostorage. 
 
Cells were thawed by defrosting the cryovial and its contents using a water 
bath set to 25°C. The cells were then resuspended by pipetting and added to 
4ml of prewarmed supplemented medium before centrifuging for 5 minutes at 
233xg. The cells were then resuspended in 1ml of the appropriate medium 
and analysed using the MACSQuant to assess the cell number before plating 
as appropriate. 
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2.5.7 Equine serum: 
Whole blood was collected from one of 3 healthy horses into 250ml blood 
bags, distributed into 50ml plastic tubes and allowed to coagulate for 2 hours. 
The blood was then centrifuged at 1800xg, 21°C for 10 minutes after which 
the serum was drawn off and pooled. As a further purification step, the serum 
was again centrifuged at 1800xg, 21°C for 10 minutes to remove residual red 
blood cells. The serum was then drawn off, aliquoted and stored at -20°C until 
needed. 
 
2.6 Cell infection & analysis methods: 
2.6.1 Equine Dermal cell infection/ creation of EIAVWYO viral stocks: 
EDerms were split 1:2 to 2 T25 flasks (Greiner Bio-One Ltd, Stonehouse, UK) 
which were incubated at 37°C, 5% CO2 overnight. The following morning the 
medium was removed leaving 2ml in the flasks, 100µl or 400µl of ATCC 
EIAVWYO tissue culture supernatent (TCSN) was added to a flask and 
incubated at 37°C, 5% CO2 for 6 hours, upon which 3ml of fresh media was 
added back into the flasks. The next day the media was removed (and stored 
for analysis with the RT-PCR, Section 2.3.4), the monolayer was washed 
once with PBS and 5ml of fresh DMEM was added back into the flask. 150µl 
was taken and stored at -80°C for use as a benchmark with the real time RT-
PCR. Then each day for 4 days 150µl of TCSN was removed to track viral 
RNA levels. On the last day all TCSN was frozen at -80°C as a viral stock. 
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2.6.2 Macrophage & dendritic cell infections: 
Upon differentiation, 800µl of media was removed from the wells and 20µl 
viral TCSN added. The cells were then incubated for 6 hours at 37°C, 5% 
CO2. After incubation, 800µl of fresh media was then added to each well and 
the plate incubated overnight. The next day the media was removed and 
saved for RT-PCR analysis (Section 2.3.4), the cells were washed with fresh 
media and then 1ml of fresh media was pipetted back into the wells. For viral 
load analysis with the RT-PCR, 150µl TCSN was removed. Each subsequent 
day for 3 days 150µl of media was removed for analysis of viral RNA levels 
and on the final day the remaining media was frozen at -80°C for later use. To 
passage the virus, the media from infected cells was made up to 1ml with 
fresh media and the whole volume was pipetted onto fresh cells. 
 
Where archived tissues were used 100mg of tissue was excised using forceps 
and scissors and cut into the smallest pieces possible. These tissue pieces 
and any blood were placed into a Griffiths tube containing 1ml of pirbright 
solution. Pirbright solution was made to 1mL with  9.5mg/ml sodium chloride, 
0.23mg/ml potassium chloride, 1.71mg/ml disodium hydrogen phosphate, 
0.01% phenol red, 0.23mg/ml potassium, dihydrogen phosphate, 5x102U/ml 
mycostatin/ nystatin, 2mg/ml streptomycin, 5x102U/ml polymixin B sulphate, 
5x103U/ml penicillin G and 0.7mg/ml neomycin (Biological products unit 
(BPU), APHA, Weybridge, UK), and enough sterile sand to cover the base of 
the tube. The tissue was then homogenised by grinding the tissue into the 
sand until no large pieces of tissue were visible. This was then left at room 
temperature in the dark for 45 minutes to allow the antibiotics to kill 
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contaminant bacteria and the sand to settle. The tissue homogenate was then 
removed from the Griffiths tube by pipetting into a sterile 15ml plastic tube and 
the contents were centrifuged for 10 minutes at 1000xg, 20°C. The 
supernatant was then taken off and stored at -80°C if not needed immediately. 
Otherwise, 150µl was inoculated onto cells and incubated at 37°C for 3 hours 
at which point 500µl of fresh medium was added and the cells were incubated 
overnight. The following morning the media was removed and the monolayer 
washed once with 1ml of media before 1ml of fresh supplemented media was 
added to the cells. The cells were incubated at 37°C with 5% CO2. 
 
2.6.3 EIAV immunoperoxidase (IPX) staining: 
After 1-3 days of infection, the media was removed from the wells that were 
then washed twice with PBS. To fix the cells 300µl of fixative was added to 
the cells and incubated for a time dictated by the fixative used (Table 2.4) at 
room temperature. The fixative was then removed and the cells were washed 
twice with PBS. If paraformaldehyde was used 300µl Triton X-100 (Sigma 
Aldrich, Dorset, UK) was added and incubated at room temperature for 30 
minutes to allow cell permeabilisation. The Triton X-100 was then removed 
and the cells washed twice with PBS. Initially plates were then blotted onto 
paper towel and dried under a bench lamp for 3-4 hours (dry staining) but this 
step was subsequently removed and replaced by an additional wash step (wet 
staining). 
 
The primary (1°) and secondary (2°) antibodies used are listed in Table 2.5. 
To stain the cells 300µl of 1:50 diluted 1o antibody was incubated with the 
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cells at 37°C for 30 minutes. This was then removed and the cells washed 3 
times with IPX wash buffer (one part Tween 80 to 20 parts PBS; BPU, APHA, 
Weybridge, UK). The plate was then blotted on paper towels to remove any 
residual liquid and 300µl 1:150 polyclonal rabbit anti-mouse immunoglobulins/ 
horse radish peroxidase conjugated 2o  antibody (Dako, Ely, UK) was added 
to the cells and incubated at 37°C for 30 minutes. The antibody was then 
removed and the cells washed 3 times with IPX wash buffer. Three hundred µl 
of freshly prepared ethyl carbazol (6mg/ml 3-amino-9-ethylcarbozole in di-
methyl formamide; BPU, APHA, Weybridge, UK) in substrate buffer (0.3ml 
ethyl carbazol solution, 5ml acetic acid and 5µl of 30% hydrogen peroxide; 
Sigma Aldrich, Dorset, UK) was then dispensed into each well and incubated 
at 37°C for 15 minutes to allow substrate conversion. After which the 
substrate was removed and the plate washed twice with wash buffer before 
analysing under a light microscope for staining. 
 
Table 2.4: Fixatives used and their incubation times as well as permiabilisation steps 
if used. N/A: Not applicable 
Fixative Incubation time Permiabilisation 
Acetone (20%) 10 minutes N/A 
Paraformaldehyde (5%) 5 minutes N/A 
Paraformaldehyde (5%) 5 minutes TritonX-100 (30 minutes) 
Ethanol (100%) 5 minutes N/A 
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Table 2.5: Primary and secondary antibodies used for IPX staining of EIAV. 
Antibody Supplier 1º or 2º Isotype Host Target 
MAB10206 Millipore 1º IgG1 Mouse P26 
EIAP6A1 VMRD 1º IgG1 Mouse P26 
Horseradish peroxidase conjugated 
anti mouse IgG 
Sigma 2º IgG Mouse Mouse 
IgG 
 
2.6.4 RNA staining: 
In order to show viral RNA was present at high levels in the differentiated 
monocytes, monocytes stimulated with IL-4 were fixed and incubated with 
fluorescent probes against EIAVWYO, and the presence of EIAV RNA 
visualised by flow cytometry. Initially cell media was aspirated and the cells 
washed and trypsinised as in Section 2.2.5 Cells were re-suspended in 1ml of 
PBS. If a viability stain was carried out 1µl of violet fluorescent reactive dye 
(Life technologies, Paisley, UK) was added to the cells and incubated at room 
temperature for 30 minutes.  
All reagents required for fixing and processing the cells were included in the 
PrimeFlowTM RNA assay kit (ebioscience, Hatfield, UK). The cell suspension 
was centrifuged for 5 minutes at 800xg to pellet the cells. The supernatant 
was then drawn off leaving 100µl of supernatant in the tube. The cells were 
then re-suspended in this ‘residual volume’. One ml of fixation buffer 1 (equal 
parts fixation buffer 1A and fixation buffer 1B was then added to the cells and 
incubated at 4°C for 30 minutes. The cells were then centrifuged and re-
suspended as before. One ml of 1x permiabilisation buffer with RNase 
inhibitors (100µl 10x permiabilisation buffer, 1µl RNase inhibitor 1, 10µl 
RNase inhibitor 2 and 889µl RNase-free water per sample per wash) was 
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then added to the cells, mixed, centrifuged and re-suspended as before. The 
permiabilisation buffer wash was then repeated twice more before adding 1ml 
of fixation buffer 2 (125µl 8x fixation buffer 2 and 875µl wash buffer per 
sample) and incubating for 60 minutes in the dark at room temperature. The 
cells were then centrifuged, supernatant aspirated and re-suspended as 
before. One ml of wash buffer was then added, the tube mixed and then 
centrifuged and re-suspended as before. The wash was then repeated once 
more.  
 
For target probe hybridization the target probes were pre-warmed to 40°C, 
diluted 1/20 in target probe diluent and 100µl was added to the cells before 
incubating for 2 hours at 40°C. The cells were then washed using 1ml of wash 
buffer. The cells were then washed using 1ml of wash buffer with 1µl RNase 
inhibitor 1 added and were stored overnight at 4ºC. 
 
To label the probes 100µl of pre-warmed (40°C) PreAmp Mix was added to 
the cells and incubated at 40°C for 1.5 hours. The cells were then washed 
three times using wash buffer before incubating the cells with 100µl of pre-
warmed (40°C) Amp Mix for 1.5 hours at 40°C. The cells were then washed 
twice using wash buffer before incubating the cells with 100µl of label probe 
(1µl of label probe and 99µl pre-warmed (40°C) label diluent) for 1 hour at 
40°C. The cells were then washed twice using wash buffer and once in 
storage buffer. The cells were then made up to 200µl final volume with 
storage buffer and analysed using a MacsQuant with the APC channel.  
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2.7 Safe working practices: 
The specified animal pathogens order (SAPO) categorises EIAV as a 
category 3 pathogen. Therefore it was handled in a class 2 microbiological 
safety cabinet, in a SAPO 3 laboratory. 
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3.0 Full genome sequencing and sequence analysis 
of the British outbreak cases: 
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3.1 Introduction: 
Equine infectious anaemia virus (EIAV), like its lentiviral relatives, is a highly 
variable virus. The different EIA viruses can be divided into four broad 
phylogenetic groups based on full genome sequences of Chinese, American, 
Japanese and Irish viruses (Quinlivan et al., 2012; Dong et al., 2013). The 
nucleic acid sequence of each of these groups differs from the other groups 
by approximately 30% with variation spread unevenly throughout the genome. 
This high level of variation is due to the viral RT, which is responsible for 
converting the viral RNA to DNA to allow integration of the viral genome into 
the host’s genome. The viral RT lacks any proof reading mechanism resulting 
in the insertion of errors (Bakhanashvili & Hizi, 1993). Over time this leads to 
a gradual build-up of different populations of viruses that differ slightly in their 
RNA sequence. The large pool of viral populations gives the virus a high 
flexibility in replication when under selection pressures (Leroux et al., 2001; 
Belshan et al., 2001). For example the generation of immune escape mutants 
give rise to the episodic disease presentation of EIAV (Howe et al., 2002).  
 
This high level of viral sequence variation in individual hosts is amplified 
between geographically separated viruses such as the four phylogenetic 
groups mentioned above. Globally few viral genomes have been sequenced 
compared to the number of outbreaks that occur each year. Until recently the 
only full genome sequences available for field strains were a Chinese case 
from Liaoning province (EIAVLIA; Tu et al., 2007) and a North American case 
from Wyoming, USA in 1941 (EIAVWYO; Cook et al., 2013; Kobayashi & Kono, 
1966). The majority of remaining full genomes published were clonal strains of 
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these two cases, for example, the Japanese V70 and V26 strains were 
originally derived from EIAVWYO (Dong et al., 2014a). In recent years more 
sequence data from Europe and Japan has become available in the form of 
Irish strains from the 2006 Ireland outbreak (EIAVIREF2; Cappelli et al., 2011; 
Quinlivan et al., 2013) and a strain from feral Toi Cape horses in Japan in 
2011 (EIAVMIYA; Dong et al., 2013). Other EIAV sequences exist but tend to 
cover individual genes or polyproteins. The majority of these sequences cover 
the gag gene to varying extents due to a preference of using the gag for 
phylogenetic studies. The most extensive of these gag sequences are; for a 
range of Canadian cases from 1999-2005 (EIAVCAN; Nagarajan & Simard, 
2007), a set of Italian cases from Italy in 2006 (EIAVITA; Cappelli et al., 2011), 
four partial Romanian sequences from 2009 (EIAVROM; Cappelli et al., 2011), 
and two Belgian sequences from a serological survey in 2010 (EIAVASS/WAR; 
Caij & Tignon, 2014). The gag sequence of a field virus from New Hampshire, 
USA (1947), Goshun, Japan and one from West Germany (Kobayashi & 
Kono, 1966; Boldbaatar et al., 2013) are also available. Gag sequences for 
other EIAV sequences from Argentina, Brazil, Slovenia, Russia and other 
places of interest exist, but these sequences only cover relatively small areas 
of the gag sequence, limiting their use in phylogenetic and sequence analysis 
studies. The preservation of tissues from the British outbreaks presented an 
opportunity to sequence more strains of EIAV and gain a greater 
understanding of EIAV diversity in Europe and the world. 
 
The high level of genetic variation makes molecular detection a challenging 
endeavour and indeed diagnosis has relied on the serological Coggins test 
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since its inception in the 1970s (OIE, 2008; Coggins & Norcross., 1970). 
Alignments of the small number of highly variable EIAV sequences contain 
few, if any conserved regions long enough to design robust primers against. 
PCR primers designed using one or even two phylogenetic groups of EIAV 
are likely to fail when used on more distantly related viruses. For example, the 
OIE recommended primers in 2012 failed to detect Japanese and Italian 
viruses (Dong et al., 2012; Cappelli et al., 2011). This difficulty in PCR primer 
design has also restricted the sequencing of new EIAV viruses, compounding 
the problem further. The sequencing of more EIAV strains would increase the 
overall diversity of published sequences making phylogenetic studies a more 
powerful tool for epidemiological investigations and allowing for the more 
accurate design of PCR primers for both diagnostics and sequencing. 
 
3.1.1 Sanger sequencing of EIAV: 
The majority of EIAV sequences have been published using conventional 
PCR and Sanger sequencing (Quinlivan et al.,2013; Dong et al., 2014). At its 
conception in 1977, Sanger sequencing revolutionized DNA sequencing by 
providing a rapid method of nucleotide determination compared to previous 
methods. It was with this method that the first complete DNA sequence was 
published for bacteriophage ϕ X174 (Sanger et al., 1977). Sanger sequencing 
went on to become the dominant method of DNA sequencing for almost 20 
years. Sanger sequencing has in itself come a long way since the original slab 
gel and radioactive labelling methods; and today involves the amplification of 
a DNA sequence using fluorescently labelled nucleotides in combination with 
dideoxynulceotide terminators at such a concentration to allow the generation 
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of fragments of various lengths (Shendure and Ji, 2008). These fragments are 
then separated by capillary gel electrophoresis and the base at each position 
read by laser. Sanger sequencing can generate around 900 base pair 
products in around 6 hours using gene specific primers (Shendure and Ji, 
2008). This generates an accurate nucleic acid sequence but the variability of 
EIAV makes the requirement of sequence specific primers problematic. 
 
A variety of PCR tests have been published using primers designed from 
various EIAV phylogenetic groups (Cook et al., 2002; Quinlivan et al., 2007; 
Nagarajan & Simard, 2001). Of importance in this study, are a nested PCR 
based on the gag gene (Cappelli et al., 2011) and a nested PCR based on the 
LTR-tat region (Dong et al., 2012). The gag PCR was developed using 
sequences of American, Chinese and Italian origin, whereas the LTR PCR 
was developed using North American and Chinese strains as reference. Since 
they are both used with success to detect strains of different geographical 
origins to the references, the primers were considered to have sufficient 
flexibility to detect the strains from the outbreaks in Britain. 
 
3.1.2 Next generation sequencing (NGS) as a tool for genetic 
characterisation: 
Next generation sequencing (NGS) is a term that encompasses a series of 
methods that can produce larger volumes of sequence data than Sanger 
sequencing without the need for target specific primers. The most popular of 
which were Roche’s 454 method which utilised emulsion PCR and 
pyrosequencing (Shendure and Ji, 2008) and Solexa’s illumina MiSeq which 
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works by bridge PCR and sequencing by synthesis with the use of reversible 
terminators (Shendure and Ji, 2008; Ansorge, 2009). The 454 platform can 
produce read lengths of around 800bp with approximately 700,000 reads per 
run (Roche, 2013), whereas the MiSeq can generate approximately 
25,000,000 reads with a read length of 2x300 bases (Paired end) (Illumina, 
2015; Ansorge, 2009). Both platforms utilise fragmentation and ligation of the 
sample DNA to adaptors which act as primers during the PCR stage. This 
removes the need for sequence knowledge and primer walking strategies.  
 
Viruses present a unique challenge compared to animal, plant and bacterial 
genomes due to their obligate parasitic nature, requiring a host cell in order to 
replicate. This means the quantity of viral nucleic acid relative to the nucleic 
acid of the host cell is usually very low and results in low numbers of viral 
specific reads (<0.1% out of approximately 25 million reads; Radford et al., 
2012). This can be problematic when full genome sequencing of an unknown 
sequence is the goal since it can result in fragmented sequences (if any) of 
low depth (Radford et al., 2012; Daly et al., 2012). During symptomatic 
periods RNA levels can reach around 108 copies per ml of plasma whereas in 
asymptomatic individuals it can be undetectable or around 100 copies per ml 
plasma, and in tissues such as the spleen the difference in virus level can be 
104 (Harrold et al., 2000; Leroux et al., 2001). This makes sequencing 
asymptomatic cases more difficult as the virus is likely to be represented in a 
much smaller proportion of NGS reads than the symptomatic cases. This 
means a method of virus or sequence enrichment may be necessary in order 
to obtain any sequence for asymptomatic cases. A method of shifting the host 
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to virus ratio is using sequence enrichment strategies to either enrich the 
target nucleic acid or deplete the background nucleic acid. Target enrichment 
strategies are available and include sequence capture using probes 
(Duncavage et al., 2011), but this requires sequence knowledge. Another 
method of ensuring high levels of viral RNA is using a viral isolate; however, 
this involves the isolation of the virus using tissue culture. Most tissue culture 
methods either use equine macrophages differentiated from monocytes, 
which is a laborious and lengthy procedure or cell lines of various origin, 
which may result in viral adaption to the cells (Carpenter & Chesebro., 1989). 
The use of cells not naturally infected by the virus may also result in the 
selection of a virus population that may not have been dominant in vivo 
(Carpenter et al., 1991). This problem and the development of an equine 
macrophage cell system is discussed in detail in Chapter 4. Sequence 
enrichment has generally been limited to modifications in extraction methods 
to reduce the background nucleic acids without eliminating the virus specific 
nucleic acids (Daly et al., 2011). In this work, an extraction method utilising 
multiple elutions was used to remove the bulk of the host nucleic acid 
(Rasmussen et al., 2008). Also, to maximise virus in the extraction, spleen 
tissue was used since it has been shown to be a major reservoir of EIAV 
(Harrold et al., 2000).  
 
The output of NGS is large data files, which can be processed and analysed 
using two main bioinformatics processes. These are either mapping of the 
reads to a reference sequence (reference guided assembly) or de novo 
assembly of all reads within the data file. Both have pros and cons; the use of 
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a reference sequence relies on the existence of a reference sequence that is 
highly similar to what is being sequenced in order to map the reads. Whereas 
de novo assembly is free of this constraint but is much more laborious in 
terms of computer processing power and locating the desired contiguous 
element within the output can be difficult (Radford et al., 2012). These two 
universal methods can be accomplished using a variety of programs. The 
majority of these programs are Linux-based requiring anywhere between a 
basic to advanced knowledge of command line interfaces. User-friendly 
windows based programs are available but sacrifice adaptability and power 
for user friendliness (Kumar et al., 2012).  
 
The tissues archived from the British cases offer an opportunity to expand the 
diversity of EIAV full genome sequences and thus gain a better understanding 
of EIAV diversity in the field. With each new field strain sequence published, 
the understanding of EIAV diversity, and whether a universal molecular 
diagnostic method is possible or not becomes clearer. Both PCR/ Sanger 
sequencing and NGS were used to sequence the British viruses. Primers from 
published PCRs and primers designed from an alignment of published 
genome sequences were used. Since the British 2010 and 2012 outbreaks 
may have originated from Romania it is likely that PCR primers designed from 
the four current phylogenetic groups will have difficulty in amplifying the British 
strains. Sequence is available for Romanian strains but only partial gag 
sequences. It is possible that the diversity of the strains may compensate for 
a lack of virus genomes that are closely related to the British cases. NGS was 
also used to sequence the British cases since it does not require sequence 
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specific knowledge. But since it is likely that the virus is at low levels in the 
tissues (this is especially the case for the asymptomatic cases) a method of 
RNA extraction using sequential terminal elutions was adopted to deplete host 
RNA to maximise the number of viral specific reads.  
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3.2 Results: 
3.2.1 Detection of EIAV in post mortem tissues: 
Three PCRs were tested for their ability to detect EIAV: a nested PCR based 
on the LTR-tat region (Dong et al., 2012), a nested PCR based on the gag 
gene (Cappelli et al., 2010) and a real time RT-PCR kit based on the pol gene 
(Primerdesign™). Initially EIAVWYO TCSN and the Irish cases were used as 
positive controls. 
Table 3.1: The detection profile of the three PCRs with each strain tested using 
splenic RNA unless otherwise stated. SR=Serum RNA, TCSN=Tissue culture 
supernatant, Y=Detected, N=Not detected. 
EIAV virus Real time RT-PCR Conventional PCRs 
Pol (Primerdesign™) LTR (Dong et al., 2012) Gag (Cappelli et al., 2010) 
EIAVWYO (TCSN) Y Y Y 
EIAVIRE3300,  Y  Y Y 
EIAVIRE1875,  Y Y Y 
EIAVDEV  Y  Y  N 
EIAVWILT1  N Y N 
EIAVWILT2  Y Y N 
EIAVNORTH  Y Y N 
EIAVCOR  Y Y Y 
EIAVDEV2  Y Y N 
EIAVNEW (SR) Y Y N 
  
Each PCR was used to detect EIAV in the two Irish cases, EIAVWYO and each 
of the British outbreak cases. The detection profiles are shown in Table 3.1. 
The pol real time RT-PCR detected all strains except EIAVWILT1, and provided 
an idea of the relative abundance of virus in each sample. The LTR PCR 
(Dong et al., 2012) detected all strains tested. The gag PCR (Cappelli et al., 
2010) failed to detect the majority of strains tested and only yielded bands 
with the Irish viruses, EIAVWYO and EIAVCOR. The LTR PCR was taken forward 
as the positive control for conventional PCRs where required. All British cases 
tested positive by at least one PCR. 
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A series of twelve overlapping PCRs (Region 1-12) that cover the EIAV 
genome and were designed to sequence the Irish 2006 outbreak strains 
(Quinlivan et al.,2013) were also tested. Region six and seven amplified 
EIAVIRE1875 and all but region eight amplified EIAVIRE3300. The only PCR to 
detect a British strain was region two and this only detected EIAVDEV. 
 
3.2.2 Viral RNA and proviral DNA use in sequencing: 
In order to assess which of the British cases to initially sequence and whether 
to start sequencing attempts on the viral RNA or proviral DNA, the pol real 
time RT-PCR kit (Primerdesign™) was used to evaluate the relative nucleic 
acid levels in joint DNA/ RNA extractions from the spleens of the 2010 cases 
based on the Ct values (Table 3.2).  EIAVDEV produced the lowest Ct value for 
both RNA and DNA suggesting the highest viral load. The only proviral DNA 
not detected was that of EIAVWILT1; only EIAVDEV RNA was detected. The 
RNA and DNA for EIAVDEV had similar viral loads (0.33 Ct difference).  
Table 3.2. The Ct values for the RNA and DNA extraction of the 2010 cases from 
spleen tissue. 
Nucleic acid Virus Ct 
RNA 
EIAVDEV 25.86 
EIAVWILT1 No Ct 
EIAVWILT2 No Ct 
EIAVNORTH No Ct 
DNA 
EIAVDEV 26.19 
EIAVWILT1 No Ct 
EIAVWILT2 27.52 
EIAVNORTH 31.77 
 
Interestingly, the symptomatic case contained more cell free virus than 
provirus, whereas provirus was present in the asymptomatic cases but cell 
free virus was undetectable. 
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3.2.3 Sequencing of EIAVDEV case DNA by PCR: 
Each of the four 2010 outbreaks occurred in different times and locations 
making it likely that a significant amount of sequence variation would exist 
between them. EIAVDEV being a symptomatic case and having the lowest Ct 
value for both RNA and DNA was used to test the possibility of sequencing by 
primer walking. DNA was used as the extraction generated larger volumes 
and so reduced the need to re-extract from the tissues. Initially, published 
PCRs designed using sequences from various phylogenetic groupings were 
used to amplify EIAVDEV and generate sequences, which could be used to 
design primers more able to detect the British viruses. Four sets of published 
PCRs were used; the nested LTR PCR based on the LTR-gag region (Dong 
et al., 2012), the nested gag PCR (Cappelli et al.,2010), the twelve 
overlapping PCRs designed to cover the genome of the Irish 2006 outbreak 
strains (Quinlivan et al., 2013) and  finally a primer set targeting the gag gene 
based on the Irish, American, a German and a Japanese strain (Boldabaatar 
et al., 2013). Together they include primers based on all current EIAV 
phylogenetic groupings (Dong et al., 2014). 
 
The LTR (Dong et al., 2012) and gag (Cappelli et al., 2010) PCRs generated 
two fragments, which covered the 3’ end of the 5’ LTR and the first 500 bases 
of the gag gene respectively. Region two of the Irish PCRs (Qunilivan et al., 
2013) produced an 800bp sequence of gag. The last set of published primers 
(Boldbaatar et al., 2013) failed to amplify EIAVDEV. This resulted in two 
contiguous fragments, one consisting solely of the LTR product, and one 
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containing the gag product with the second Irish PCR product, together 
forming 1kb of gag sequence (Fig 3.1). 
 
In order to complete the gag sequence and span the pol gene a series of 
primers based on an alignment of the published EIAV genomes were 
designed. Three over lapping PCRs were designed to cover the gag (F1 and 
F2 (nested PCRs) and F3 (conventional PCR)) and seven conventional PCRs 
to encompass the pol (Pol1- Pol7). Of these PCRs only F2, Pol1, Pol3 and 
Pol7 amplified viral sequence resulting in the LTR-tat, gag, Pol1, Pol3 and 
Pol7 products separated by gaps. Primers F74 and R1020 were designed to 
bridge the gap between the gag (Cappelli et al., 2010) and Irish region two 
(Quinlivan et al., 2013) sequences. The forward F3 primer was combined with 
the Boldbaatar Ire1879 reverse primer to try and cross the gap between Irish 
region two (Quinlivan et al., 2013) and Pol1. PCRs Pol2.1 and Pol2.2 were 
designed to close the gap between Pol1 and Pol3. F74 and R1020 did not 
amplify product. The F3/IRE1879 PCR generated a product which linked the 
end of the gag contiguous element with Pol1 completing the 3' of the gag 
sequence. Pol2.1, Pol2.2 and Pol3 produced a contig which when BLASTed 
did not appear to be EIAV specific product. Overall the resultant sequence 
covered 1282bp of gag and 534bp of pol (Figure 3.1).  
Figure 3.1: Schematic of EIAVDEV DNA PCR products. The three products are the 
LTR-tat PCR, cluster of gag-pol PCRs and Pol7, which encompasses the 3’ of the pol.  
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The PCRs used to amplify EIAVDEV were used to try and amplify the other 
British cases to see if any similarity was present but was not successful. A 
table of the PCRs and cases is shown in Appendix 1 and Table 3.1 
respectively. 
 
3.2.4 Comparison of NGS preparation methods and NGS platforms using 
Schmallenberg virus infected tissues:  
Since primer walking of EIAVDEV failed to yield additional sequence and 
primers used had failed to amplify the other British viruses, NGS was sought 
to complete EIAVDEV and sequence the other British cases. To decide which 
NGS platform to utilise in EIAV sequencing two NGS platforms and two 
extraction methods were tested for their ability in returning viral sequence 
from naturally infected tissues. Schmallenberg virus (SBV) was used due to 
the finite nature of the EIAV tissues. Two SBV infected tissue samples were 
used, one with a low Ct (sample 929, Ct: 19.2) and one with a high Ct (sample 
544, Ct: 35.0) to simulate a symptomatic and asymptomatic EIAV case 
respectively. These were both extracted by the TRIzol/RNeasy method and 
the standard TRIzol® method (Section 2.3.1). The extractions were analysed 
by the ND2000 and Bioanalyzer 2100 (Appendix 2 & 3).  
 
The TRIzol® extracted tissues had less RNA content compared to the 
TRIzol/RNeasy protocol extracted tissues (Table 3.3). The bioanalyzer band 
pattern was the same for each extraction (Appendix 2 & 3). The 544 sample 
TRIzol® and TRIzol/RNeasy elution one and elution two extractions contained 
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more RNA than their 929 samples counterparts, but the Ct decreased across 
the elutions before becoming undetectable in elution four. The 929 samples 
Ct values on the other hand remained relatively stable. After elution three the 
RNA was quickly lost from the 544 sample elutions whereas the 929 sample 
elutions showed a more gradual decrease. A SBV real time PCR was then 
performed on each extraction and the Ct values are displayed in Table 3.4. 
There was no clear pattern in the 929 sample elutions but the 544 sample 
elutions showed a gradual decrease in virus until elution four where virus was 
not detected. Based on the sequencing submission criteria at the time 
(>200ng/µl and >1.8 260/280) each individual sample, except elution five of 
544 was suitable for NGS. The third elution of the TRIzol/RNeasy method 
supposedly performs the best (Rasmussen et al., 2008) so elution three for 
both the 544 sample and 929 sample were sequenced, as was the TRIzol® 
extraction to allow comparison. Also sequenced was 929 sample elution four, 
since it contained less RNA and only a slightly higher Ct than 929 elution 
three so was sequenced for comparison. The samples were sequenced using 
the Roche 454 and illumina GAIIx platforms. 
 
The cumulative number of reads which mapped to the SBV genome for each 
extraction protocol and sample are shown in Table 3.4. Regarding the 454 
run, the TRIzol® extracted tissues returned no reads.  For the TRIzol/RNeasy 
extraction; 544 sample elution three returned no reads, but 929 sample 
elution three returned four reads generating 514bp of sequence and 929 
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elution four mapped three reads producing a 539bp sequence. The illumina 
run returned no  
Table 3.3: The spectrophotometer results and UV spectra for the SBV extractions. The 
E denotes elution, E.g. 544 E2 is the second elution of 544. Dash indicates no Ct detected. 
Extraction 
TRIzol® TRIzol/ RNeasy (544) TRIzol/ RNeasy (929) 
544 929 E1 E2 E3 E4 E5 E1 E2 E3 E4 E5 
RNA ng/µl 761 187.1 1544.9 237.3 42.1 21 8.7 799.4 113.4 164.4 97.6 156.2 
260/280 2.07 2.06 2.05 2.05 1.99 1.98 1.85 2.06 2.02 1.99 2 1.99 
Viral Ct 36.88 22.99 35.61 36.1 39.0 - - 19.71 21.17 20.94 21.27 20.02 
 
reads for the TRIzol® extracted 544 sample, but the 929 sample TRIzol® 
extraction generated 1495bp of sequence across 21 reads. 
 
The TRIzol/RNeasy extracted tissues returned 1 read for 544 elution three 
which was 119bp in length, 929 sample elution four generated 79 reads giving 
4949bp of sequence and the 929 sample elution three sample returned 
4887bp of sequence mapped across 93 reads. A summary of the Ct values, 
RNA yield, reads mapped and sequence length for each sample submitted for 
sequencing is shown in Table 3.4. The difference in extraction and 
sequencing profiles between the high and low virus titre samples indicated 
that the low virus level of the tissues could present a problem in regards to the 
asymptomatic EIAV cases. 
 
Table 3.4: The SBV extraction profile of the high (544) and low (929) Ct sample. Real 
time PCR Ct value, Bioanalyzer RNA yield, total number of reads and total unique sequence 
generated for each of the extracts by each NGS platform are shown. The low Ct sample 
generated more reads on both NGS platforms (ND: Not done). 
Sample Extract Ct 
RNA 
(ng/µl) 
illumina 454 
Reads Sequence Reads Sequence 
929 
TRIzol® 22.99 35.29 21 1495 0 0 
E3 20.94 128.83 93 4887 4 514 
E4 21.27 77.18 79 4949 3 539 
544 
TRIzol® 26.88 ND 0 0 0 0 
E3 39 28.45 1 119 0 0 
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Following on from the above findings, the increased number of reads and 
coverage observed from the TRIzol/RNeasy extraction method and on the 
GAIIx platform meant these methods were selected for the EIAV sequencing. 
During the PhD project, an illumina MiSeq became available for use. The 
GAIIx platform can generate paired end read lengths of up to 150bp but the 
run can take up to two weeks and result in between 85-95Gb of data. 
Conversely the MiSeq can perform a run with the same read lengths within 24 
hours generating data up to 6Gb. Currently the MiSeq can produce read 
lengths of 300bp (paired end), with the run taking approximately 56 hours and 
resulting in around 15Gb of data (illumina, 2015). Thus, the MiSeq was used 
instead of the GAIIx due to its reduced time and increased power.  
 
3.2.5 Nucleic acid extraction of British outbreak cases for NGS: 
RNA was extracted from each of the positive British cases to assess their use 
for NGS using the TRIzol/RNeasy method. The viral load and total RNA 
content of five elutions was measured to gauge the most suitable candidate 
for sequencing. Overall there was a large decrease in total RNA between the 
first and third elutions (Table 3.5); as seen with the SBV samples, ranging 
from a 2 to 29 fold decrease. Conversely Ct values dropped from first to third 
elutions indicating an increasing concentration of virus. The Ct values of the 
symptomatic cases tended to be lower than that of the asymptomatic cases 
(Table 3.5). Only serum was available from the Newmarket case and so the 
extraction was carried out using the Viral RNA spin kit resulting in a single 
elution. 
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Table 3.5: The detection profile of each British case showing the RNA 
content (ng/µl) and viral Ct of the elutions. Elutions highlighted were 
sequenced. Dashes indicate no Ct. ND: Not done. 
Elution 1 2 3 4 5 
EIAVDEV RNA 1862.6 1892.9 677.4 327.3 84.0 
 Ct 24.59 23.18 22.93 23.84 25.09 
EIAVCOR RNA 1874.3 737.0 826.7 173.4 56.4 
 Ct 32.61 29.38 25.10 27.78 27.82 
EIAVNORTH RNA 2110.1 870.1 72.3 19.2 11.3 
 Ct 33.55 31.30 31.56 33.62 34.00 
EIAVDEV2 RNA 750.6 164.5 23.1 12.3 30.2 
 Ct 33.69 33.67 - - - 
EIAVWILT1 RNA 3286.8 2728.5 1843.5 500.3 138.6 
 Ct - - - - - 
EIAVWILT2 RNA 3722.9 600.5 566.5 391.6 83.3 
 Ct 31.00 26.82 26.72 26.95 28.32 
EIAVNEW 
RNA 90.6 ND ND ND ND 
Ct 27.34 ND ND ND ND 
 
3.2.6 Sequencing of EIAV RNA using NGS: 
3.2.6.1 Symptomatic cases: 
The higher viral loads of the three symptomatic cases identified them as good 
candidates for generating viral reads. An RNA sample was extracted from 
splenic tissue and of the resultant five elutions, elution four and three were 
sequenced for EIAVDEV and EIAVCOR respectively (Table 3.5). RNA from the 
serum extraction of EIAVNEW was submitted. 
 
The first set of reference sequences combined mapped 923 reads for EIAVDEV 
and the EIAVCOR project mapped 565 reads. EIAVNEW mapped over 6000 
reads for each full genome reference, far exceeding the numbers mapped for 
the two more recent cases (Table 3.5). The sequential elongation of the target 
sequences successfully resulted in the full coding sequences of the three 
symptomatic cases with varying depth across the genome (Table 3.6). The 
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LTRs of EIAVDEV and EIAVCOR were partially recovered, EIAVDEV was missing 
255bp and 63bp from the 5’ and 3’ LTR respectively and EIAVCOR was 
missing 224bp and 289bp from its 5’ and 3’ LTR respectively (relative to 
EIAVIREF2).  
The EIAVDEV mapping project was carried out over five rounds resulting in a 
final coverage of 96.05% with 1345 reads (0.003% of the total reads) with an 
average depth of 22.73. The EIAVNEW was generated in six mapping projects 
resulting in 72037 reads mapped (0.178% of total reads), which covered 
100% of the reference genome with an average depth of 1166.50 reads. 
Mapping projects for hybrid five and six were carried out despite 100% 
coverage in hybrid four due to the existence of mismatches and the mapping 
of reads containing LTR and tat or env sequence to the 3’ or 5’ LTR 
respectively. The sequence of EIAVCOR was generated through five mapping 
projects resulting in 1550 reads (0.004% of total reads) covering 97.84% of 
the genome and an average depth of 22.36. The reduction in reads and 
average depth of the EIAVCOR project from hybrid two to hybrid three was due 
to the removal of contaminant sequences from the 3’ LTR (Table 3.7). The 5’ 
LTR of EIAVNEW was 220bp longer than that of EIAVCOR, which was 34bp 
longer than EIAVDEV. The 3’ LTR of EIAVDEV was 63bp shorter than that of the 
EIAVNEW, and EIAVCOR was 224bp shorter than that of the Devon sequence. 
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Table 3.6: Number of reads that mapped to the first mapping project for the Devon, 
Cornwall and Newmarket cases. Due to the poor performance of the gag reference 
sequences in the Devon project they were not used in the Cornwall project. For the 
Newmarket project a single representative of each phylogenetic group was used as a 
reference sequence. (ND; Not done). 
Reference sequence 
Number of reads mapped 
Devon project Cornwall project Newmarket 
Devon PCR 393 151 ND 
Wyoming (AF033820) 56 54 7013 
UK (AF016316) 62 52 ND 
Liaoning (AF327877) 138 70 7944 
Vaccine (AF327878) 86 74 ND 
Miyazaki (JX003263) 96 57 5581 
Irish F2 (JX480631) 40 56 6661 
Irish H3 (JX480634) 47 51 ND 
Goshun (AB693823) 1 ND ND 
Ita-1 (EU240733) 2 ND 1418 
Ita-6 (GU060664) 1 ND ND 
Rom-1 (GQ229581) 2 ND 988 
 
 
3.2.6.2 LTR determination and sequence reinforcement: 
Although the coverage was high, the complete LTR regions for both EIAVDEV 
and EIAVCOR were not extracted from the NGS data. To cover these regions 5’ 
RACE (Section 2.3.5) was carried out but despite several attempts was 
unsuccessful. The LTRs for EIAVDEV were lacking but the LTR-tat PCR (Dong 
et al., 2012) elucidated enough of the LTR to allow overlap between the 5’ 
and 3’ LTR sequences. Assuming complete complementarity as seen with 
Table 3.7: The number of reads mapped, reference coverage and average depth of 
each mapping project for the Devon, Cornwall and Newmarket cases. Initially a range of 
reference sequences were used to map reads against, these were then combined into a 
hybrid sequence and the mapping project re-run (hybrid 1). The output of each mapping 
project was adjusted to better represent the majority of reads before using as a reference 
sequence in another mapping project.  NA=Not Available. 
Mapping project (hybrid) 1 2 3 4 5 6 
Devon 
Reads 421 1283 1326 1334 1345 ND 
Coverage% 81.24 87.70 93.19 93.62 95.05 ND 
AveDepth 7.96 23.34 23.06 23.05 22.87 ND 
Cornwall 
Reads 655 1802 1416 1547 1550 ND 
Coverage% 72.35 87.76 91.78 94.77 97.84 ND 
AveDepth 14.80 25.67 20.76 22.10 22.36 ND 
Newmarket 
Reads 21904 63628 69730 71413 72178 72037 
Coverage% 72.11 NA 99.49 100 100 100 
AveDepth 468.88 NA 1073 1102.07 1204.05 1166.50 
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EIAVWYO, EIAVLIA, EIAVMIYA and EIAVIRE, the LTR could be deduced. 
Unfortunately, EIAVCOR was missing the entire R region and most of the U3 
and U5 regions preventing deduction of the whole LTR. Further to the LTRs 
EIAVDEV had two areas of low depth (<10 reads) between nucleotides 6285-
6855 and 7955-8225 and EIAVCOR had a gap present between nucleotides 
5904-5933 (Numbered relative to EIAVDEV full genome). Primers were 
designed to cross the gaps and the regions were successfully amplified and 
deduced (PCRs DevENVg1, DevENVg2 and CorENVg1). Primers (Appendix 
1) were designed in an attempt to sequence from the env into the R region to 
amplify the U3 region since it contains the EIAV promotors but were 
unsuccessful (PCRs CorLTR1, CorLTR2, CorLTR3 and CorLTR4). 
 
3.2.6.3 Asymptomatic cases: 
The asymptomatic cases were expected to contain much less virus than the 
symptomatic cases which was reflected in the real time Ct values (Table 3.5). 
No virus was detectable by real time PCR of EIAVWILT1 and only the first two 
elutions of EIAVDEV2 contained detectable RNA. EIAVWILT2 and EIAVNORTH 
however had detectable virus in all five elutions with EIAVWILT2 having similar 
levels to those of the symptomatic EIAVCOR. To investigate whether the viral 
load as denoted by Ct value has an impact on ability to sequence using NGS 
both EIAVNORTH and EIAVWILT2 were sequenced using the illumina MiSeq 
platform.  
 
No reads mapped to the references for the EIAVNORTH project. The EIAVWILT2 
project mapped two overlapping reads to the pol gene of the EIAVDEV full 
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genome sequence (FGS) and two overlapping reads to EIAVAss-1. Using the 
EIAVDEV FGS the two sets of reads were estimated to be 854bp apart from 
each other with the 5’ most reads being approximately 1.8kb away from the 
LTR PCR (Dong et al., 2012) product. PCRs were designed to cross these 
gaps and resulted in a 798bp fragment spanning the end of the gag and start 
of the pol. Further attempts to PCR sequence were unsuccessful. In case the 
lack of reads was due to a lack of similar reference sequences, a de novo 
assembly was carried out using the gag-pol fragment to recover any relevant 
contiguous elements out of the data, but no EIAV specific contiguous 
elements were found. The Wiltshire cases had pre-mortem serum taken prior 
to euthanasia and since the Newmarket case sequenced well from serum, 
serum from the second Wiltshire case was extracted in the same manner and 
sequenced. Using the same reference sequences as previously described, 29 
unique reads were mapped which were spread across the entire genome. The 
in house gag F2 and F3/IRE1879 PCRs were carried out on each of the 
asymptomatic cases to try and amplify extra sequence to use as a reference 
but did not amplify. The reference guided assemblies for both EIAVNORTH and 
EIAVWILT2 were repeated using Bowtie however no reads mapped to the 
reference sequences. 
 
3.2.6.4 Sequencing of EIAV proviral DNA using NGS: 
To investigate the extent of variation between proviral DNA and free virus 
RNA, whole DNA was extracted from the spleen of the 2010 Devon case 
(24.9ng/µl DNA, Ct 26.32) and submitted for sequencing using the illumina 
MiSeq platform. This returned no reads. Thus a Devon DNA spleen extract 
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was submitted for HiSeq sequencing as the increased coverage should have 
increased the chance of virus specific reads.  
 
The files were too large for Ngen to handle and so were mapped using 
Bowtie. Initially the files were BLASTed against the equus caballus genome 
and the remaining files mapped to existing EIAV sequences, but this returned 
no reads. Subsequently the original files were depleted using przewalski's 
horse genome in case sequences in the equus caballus genome were similar 
to EIAV and thus removing them. Using Bowtie on the depleted data 17 reads  
mapped to the EIAV sequences. These reads were then used as input to 
PRICE. At the time of writing this was unsuccessful.  
 
3.2.7 Phylogenetic analysis and sequence comparison: 
3.2.7.1 Full genome sequence: 
The three British sequences were analysed phylogenetically with the other 
EIAV field strain sequences. EIAVCOR (2012), EIAVDEV (2010) and EIAVNEW 
(1975) sequences were aligned and phylogenetically analysed. The neighbour 
joining method was used as it is the favoured method in the EIAV literature 
and shows the current full genomes present for field strains (Fig 3.2A). 
Nucleic acid identity between the full coding sequences of the field cases was 
75.1-79.0% (Fig 3.2C) and a tree based on full genomes displays the three 
British cases each forming their own monophyletic groups (Fig 2.A). However 
the neighbour joining method is a phenetic method as it only takes into 
account the genetic distance to build relationships. Thus a second tree was 
constructed using the maximum likelihood method. This method constructs an 
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initial tree using a basic model such as neighbour joining before creating 
topological variants based on a model (nearest neighbour interchange) to 
search for the topology that fits the data best. The topology of the two trees 
show a different arrangement of the most recent common ancestors for 
EIAVNEW, EIAVLIA and EIAVMIYA, however these nodes have low bootstrap 
values and so are of low reliability. However both trees show similar clustering 
of the British cases confirming the relationships. 
 
When the phylogenetic analysis was restricted to the gag region this allowed 
the inclusion of a greater number of sequences from Belgium, Romania, Italy 
and Canada (Fig 3.4). The Italian and Romanian sequences clustered with 
the Irish viruses and EIAVDEV respectively and the Canadian sequences with 
EIAVWYO. The two Belgian strains clustered with a different British case each 
and EIAVNEW clustered independently of any published sequence. Nucleic 
acid sequence homology tables are included in Appendix 4.  
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3.2.7.2 Long terminal repeats: 
Analysis of the LTRs (Fig 3.3) showed that conserved motifs were similar to 
those previously described (Quinlivan et al., 2013; Dong et al., 2014). It 
should be noted that since the British sequences are RNA genomes they lack 
the U3 region of the LTR on the 5' end and the U5 region on the 3' end (Fields 
et al., 2007). EIAVCOR was too short and did not cover the U3 promotors or the 
R region TAR stem loop. The methylated DNA binding protein (MDBP) 
binding site contained a 50% change in the seventh base, which was an  
 
Figure 3.2: Phylogenetics of field strain full genomes (excluding 
LTRs). A. Neighbor joining tree and (B) a maximum likelihood tree. Each 
new sequence sits distinct from the others forming individual 
monophyletic groupings. C. Nucleic acid sequence identity of the EIAV 
field strain full genomes. 
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adenine in EIAVMIYA, EIAVDEV and the EIAVNEW. A guanine was present in the 
other sequences. The three PU.1 sites, TATA box, TAR stem loop and polyA 
signal were present in all field strains bar EIAVWYO and were conserved 
through the British strains. The first nucleotide of PEA1/AP-1 was changed in 
EIAVDEV from guanine to adenine; however this binding site may be more 
relevant to in vitro replication and so may not impact on in vivo replication 
(Maury et al., 2000). Interestingly EIAVWYO was missing the 5’ most and 3’ 
most PU.1 binding sites, the 3’ of which is the most critical for LTR activity 
(Hines et al., 2004). EIAVWYO has been maintained using cell culture and so it 
is possible that the virus can better support mutations at these sites. 
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U5 
Figure 3.3: Alignment of LTR. The full genome field strains were aligned in MEGA5 
using the Clustal W algorithm and exported to Megalign for report creation. The blue line 
mark the boundaries of the U5, R and U3 regions. Red boxes mark motifs. Only a partial 
sequence for the LTRs of EIAVCOR was recovered.  
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3.2.7.3 The gag: 
The gag alignment (Fig 3.5) was extended to include field strains from Italy 
(EIAVITA1-5), Romania (EIAVRom-1), Belgium (EIAVAss-1 & EIAVWar-1) and 
Canada (EIAVCan1/7/10).  The sequence homology between viruses that 
clustered in the same group was much higher (89%-99.9%) than between 
viruses that were situated in different groups (77%-80.5%). Each additional 
gag strain adds to a grouping from Figure 3.2A instead of forming a new 
group (Fig 3.4). The same topology is seen if the maximum likelihood method 
is used. The Irish outbreak was closely related to the Italian strains which 
corroborates Italian serum as the source of the outbreak (Quinlivan et al., 
2012; More et al., 2008). Gag homology between these strains was between 
95% and 100% whereas for viruses that cluster separately the sequence 
identity did not exceed 81.2%. The p15 gene was 76-84% nucleic acid 
homology, p26 was 91-95% homology, p11 was 80-93% homology and the p9 
gene had the lowest homology with 34-73% nucleic acid homology.  
 
Figure 3.4. Alignment of field strains with full gag sequence. The viruses cluster into 
groups that show a geographic separation of EIAV with multiple groups present in Europe. 
Groups are shown with red dividers. 
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Despite the varied sequence homology, all previously noted amino acid motifs 
of the gag structural genes were present (Fig 3.5). The Matrix (p15) lysine rich 
nuclear export signal (LKKLEKVT) (Hatanaka et al., 2001) was conserved 
through all previous field strains and the British viruses (except EIAVCan7 
which has a threonine to isoleucine change). The major homology region of 
the capsid (p26) (Grund et al., 1994), which may be responsible for virus 
budding, contained mutations, which mostly exchange non-polar for non-polar 
amino acids, conserving the type of residue. The only exception is the tenth 
amino acid which was changed from a proline to glutamine in EIAVCOR and a 
serine in EIAVROM-1 and EIAVCAN-1 which are both polar amino acids. The 
nucleocapsid (p11) contains two zinc binding domains (Amodeo et al., 2006) 
which as with p26, contained several changes which conserve the type of 
amino acid. There was however, a high frequency change from glutamine to 
glutamate (36%) in EIAVROM1, EIAVCAN10, EIAVWAR, EIAVASS, EIAVMIYA, 
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Figure 3.5: Alignment of the gag polyprotein. Blue lines denote the boundaries 
between individual proteins and the red boxes highlight previously defined motifs. The 
MA contains a leucine rich nuclear export signal (NES), the CA contains the lentivirus 
major homology region (MHR), the NC contains two zinc binding domains (ZBD) and p9 
contains the late YDPL domain. Due to the large number of sequences residues that 
differ from the consensus are shaded blue. Figure continued on next page. 
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Figure 3.5 continued 
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EIAVCOR and EIAVDEV. The p9 protein demonstrated a very low level of 
nucleic acid sequence homology between strains which at its lowest is 34.8% 
between EIAVDEV and EIAVNEW. Despite this diversity, the late YPDL motif of 
p9 was completely conserved through all sequences confirming its importance 
in replication (Puffer et al., 1998; Jin et al., 2005). There was also an eight 
and four amino acid insertion in the p9 protein of EIAVDEV immediately 
upstream from the YPDL motif confirming the protein can handle large 
changes whilst maintaining function.  
 
3.2.7.4 The pol:  
The pol was the most conserved polyprotein with nucleic acid homology 
between 97.7% and 83.4%. The variation was more evenly distributed 
throughout the proteins (Fig 3.6) than in the gag, with nucleic acid identities 
between 88.7-91.3% in the PR, 84.7-91.7% in the RT, 79.1-88.7% in the RN, 
81.3-90.3% in the DU and 89.3-93% in the IN. Since the pol houses the viral 
enzymes, it is understandable that these would be highly conserved between 
the different viral phylogenetic groupings. Amino acid changes were generally 
restricted to specific residues rather than being randomly distributed 
throughout the sequences. The protease amino acids that form the substrate 
binding site, DTG catalytic motif and active site flap (Gustchina et al., 1996) 
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Figure 3.6: Alignment of the pol polyprotein. The blue lines denote the boundaries 
between the proteins and previously defined motifs and residues are boxed. The PR 
contains a series of residues involved in substrate binding as well as a catalytic motif and 
active site flap. The RT contains two motifs important in HIV (DIGD and DD). The RN 
contains a number of invariant residues boxed in red. The DU contains a number of 
residues involved in its activity which are boxed in red and named as in the text. The IN 
contains a number of residues that form the hydrophobic core (red boxes), zinc finger 
binding motif (green boxes) and which form the catalytic core (blue boxes).Figure 
continued on next page. 
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were all conserved through all field strains and the British cases. The only 
exception is position 54 in the substrate binding site which contained a 
leucine, valine or isoleucine, all of which were non-polar and structurally 
Figure 3.6 continued 
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similar, thus likely to have a similar effect on protein folding. Little work has 
been done to characterise the RT of EIAV and so motifs have been 
extrapolated from HIV (Dong et al., 2014) but the motifs noted, namely a 
double aspartate and DIGD motif (Davies et al., 1991) were both present in all 
sequences. The RN contained four conserved residues and a twelve residue 
glycine rich motif which are thought to be important for enzyme binding and 
function (Davies et al., 1991), all of which were conserved in all sequences 
except in EIAVNEW which contained a valine to isoleucine substitution in the 
glycine rich motif which maintained amino acid type. The DU contained four 
sets of conserved amino acids relating to function. Those involved in uracil 
ring binding (N67, G69, Q80, I82 and after a conformational change I82), 
deoxyribose interaction (A17, I71, D72 and Y75), phosphate interactions 
(D26, K56, S58, E95 and K98) and metal binding site (R13, D20, K56 and 
E95) (Dauter et al., 1999; McGeoch et al., 1990), all of which were conserved 
through the previous field strain and British virus sequences. The IN contains 
three sets of residues that form a zinc finger binding motif (H12, H16, C40 and 
C43), hydrophobic core motif (I5, A8, L22, A33 and I36) and central catalytic 
core motif (D64, D116 and E152) (Eijkelenboom et al., 1997; Engelman & 
Craigie, 1992) all of which are conserved through the sequences.  
 
3.2.7.5 The env: 
As the polyprotein responsible for immune escape it is understandable that 
the env (Fig 3.7) has the lowest sequence identity of the three polyproteins 
(67.5%-73.4%). The majority of variation was located in gp90; which had a 
nucleic acid identity of 58.9-66.8%, whereas gp45 had identity of 62.6-71.0%. 
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Gp90 is thought to contain eight variable regions (Leroux et al., 1997; Leroux 
et al., 2001) which are hot spots of variation. The majority of possible N-linked 
glycosylation sites are located within these variable regions with only one 
predicted site being conserved through all the sequences, with the others 
containing mutations that maintain, delete or shift the site up or down stream. 
EIAVLIA had 20 possible sites, EIAVMIYA had 19, EIAVIREF2, EIAVCOR and 
EIAVNEW had 18 predicted sites, EIAVDEV had 17, and EIAVWYO had 13. This 
variation in possible glycosylation sites could lead to marked differences in 
antigenicity. The presence of a serine or threonine at the terminal position 
may not be necessary for glycosylation (Schwarz & Aebi, 2011), so it is 
possible that more glycosylation sites are present. Another critical component 
of a surface glycoprotein is the disulphide bridge caused by the bonding of 
two cysteine residues. The cysteine residues in gp90 were highly conserved 
across the sequences highlighting their structural importance. There were 15 
sites at which a cysteine was conserved, indicating that each surface 
glycoprotein could form a similar folding structure. However, there are three 
cases where cysteines are not conserved; position 41 contained a cysteine in 
all but EIAVDEV which had a cysteine 23 amino acids downstream, and the 
cysteines at positions 258 and 362 were replaced by tyrosine in EIAVMIYA. 
Cysteine residues were also present singly at position 60 in EIAVNEW and 
position 216 in EIAVLIA, however they may not take part in protein folding. 
Gp45 was more conserved than gp90 and contained four possible 
glycosylation sites, one of which was entirely conserved and three of which 
were conserved by location (bar the second site in EIAVCOR which 
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Figure 3.7: Alignment of the env polyprotein. The boundaries of gp90 and gp45 are 
shown with blue lines. The variable regions of gp90 (V1-V8) and the transmembrane 
region of gp45 are boxed in green, cysteine residues are boxed in red and possible N-
linked glycosylation sites are boxed in blue. Figure continued on next page. 
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was four amino acids downstream). The transmembrane domain was mostly 
made up of non-polar amino acids and changes maintained this, except an 
isoleucine to threonine in EIAVMIYA and alanine to histidine in EIAVNEW.  
 
3.2.7.6 The accessory genes: 
Among the accessory proteins (Fig 3.8), tat was relatively well conserved 
(77.9%-87.6%), it was split into a central core and basic domain flanked by 
Figure 3.7 continued 
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the amino and carboxy terminals. The core, basic and carboxy terminals were 
believed to be responsible for TAR recognition and trans activation activity 
(Dorn et al., 1990; Carroll et al., 1991). The core region was conserved 
between all sequences except where a glutamine was changed to histidine in 
EIAVMIYA. A non-polar to non-polar change was also present in EIAVNEW. 
Interestingly the basic and carboxy terminal regions both contained a number 
of mutations that vary the types of amino acids. Position 60 in the basic region 
varied between an alanine in EIAVWYO and EIAVNEW, a serine in EIAVLIA and 
EIAVCOR, a histidine in EIAVMIYA and a proline in EIAVIREF2 and EIAVDEV. 
Position 70 of the basic region and position 72, 75 and 80 of the carboxy 
terminus also varied in this fashion. The number of arginines in the basic 
region varied slightly with four in EIAVWYO and EIAVCOR and five in the other 
sequences. The supposed importance of these regions indicates that critical 
amino acids may be conserved but the neighbouring amino acids are capable 
of mutations that conserve the amino acid properties, for example polar, 
basic, hydrophobic etc.   
 
S2 and rev conservation was much lower with sequence identities between 
37.3%-57.3% and 67.7-79.4% respectively. The S2 gene had been found to 
be highly conserved within a single infected host (Li et al., 1999) however; this 
was not the case between the different viral phylogenetic groupings. S2 had 
the lowest sequence identity of any EIAV protein with variation seemingly 
weighted towards the 3’ end. Domains previously noted in S2 were generally 
not conserved. The nucleoporin domain was present in all but EIAVMIYA and 
EIAVWYO, the SH3 binding domain was only present in EIAVWYO and EIAVNEW 
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and the nuclear localization domain was only present in EIAVWYO. The SH3 
domain was mostly conserved in that at least two of the four amino acids were 
present in each sequence however, the nuclear localization domain as not 
shared between most sequences and included a three and six amino acid 
insertion in EIAVMIYA and EIAVDEV respectively. Considering S2 has been 
shown to be a major determinant of virulence in infected horses (Payne & 
Figure 3.8: Alignment of the accessory proteins tat (A), S2 (B) and rev (C). Blue lines 
designate the boundary of the ORFs for tat and rev, and red boxes and lines designate 
previously defined motifs and regions. Tat contains an amino, core, basic and carboxy 
region. S2 contains a nucleoporin domain, SH3 binding domain and nuclear localization 
domain (NLD). Rev encodes a nuclear export signal (NLS) and three short arginine rich 
motifs which function in RNA binding.  
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Fuller, 2010; Li et al., 1999) it would seem that the S2 gene can continue to 
function with as little as 33.3% sequence similarity between viruses. Contrary 
to S2, rev undergoes significant variation within a single infected host 
(Belshan et al., 2000) and even more so between unrelated viruses.  
 
The rev protein contains four motifs responsible for nuclear localisation and 
export, RNA binding and tat splicing: a nuclear export signal, a short arginine 
rich motif (RRDRW), an RNA binding site (ERLE) and a nuclear localisation 
signal also involved in RNA binding (KRRRK) (Harris at al., 1998; Lee et al., 
2006). These motifs seem to be able to undergo a small degree of variation; 
for example the KRRRK motif has been shown to be fully functional providing 
there was no more than one mutation (Lee et al., 2006) and EIAVMIYA 
contained a histidine instead of the first arginine and so could be fully 
functional, but the motif is fully conserved in the other sequences. Similarly, 
the ERLE motif can lose all but the central leucine and still function (Lee et al., 
2006), it was present in EIAVWYO and EIAVNEW but the rest contained either a 
glutamine or threonine instead of the arginine whilst maintaining the central 
leucine. The arginines in the RRDRW motif on the other hand are thought to 
be essential however only three sequences (EIAVWYO, EIAVDEV and EIAVNEW) 
maintained the three arginines, with EIAVMIYA, EIAVIREF2 and EIAVCOR 
replacing the first arginine with a lysine, which maintains the basic residue. 
EIAVIREF2 also replaced the aspartate with a glutamate maintaining the acidic 
nature. EIAVDEV and EIAVLIA replaced a basic and polar residue respectively 
with a non-polar residue indicating the motif may be more able to handle 
mutations than previously thought (Lee et al., 2006). The NES was only 
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present in EIAVWYO but the region has been shown to be indispensable for 
nuclear export, and since the rest of the viruses are field strains and 
replication competent, the region must be able to handle significant mutations 
and still function (Lee et al., 2006). 
 
3.2.8 Viral populations of EIAVNEW: 
The high sequence coverage of EIAVNEW compared to the other EIAV cases 
allowed an analysis of the dominant viral populations present in the tissue 
samples taken from the horse at the time of death. There were 6637 single 
nucleotide polymorphisms (SNPs) in total. Of these, 6116 SNPs had a 
prevalence of <1%, 418 had a prevalence of between ≥1% and <10% and 
103 had a prevalence of ≥10%. The SNPs with a prevalence ≥10% were 
focused on for analysis. Overall 71% of the variants contained a non-
synonymous variant. 
 
 The R region of both LTRs (Table 3.8) contained a variant but this was not 
located in any known genome features. Both ORFs of tat contained two high 
frequency variants with ORF 1 containing a switch between polar threonine 
and hydrophobic alanine as well as between non-polar glycine and positive 
arginine; however they are not located in any known domains and so may not 
effect protein structure. The two variants located in ORF 2 are located within 
the basic region but both variants are synonymous. The gag polyprotein 
contained eight variants, most of which were located in p26. The variant at 
nucleic acid position 1324 was located in the MHR region of p15 but the 
difference between leucine and isoleucine is minimal. p9 contained a single 
variant located in the YPDL domain but the mutation was synonymous. 
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The pol contained more high frequency variants than the gag (Table 3.9). The 
majority of variants were located in areas lacking genome features except for 
three: one located in the active site flap of pro (NA positions 2091), one 
located in the glycine rich motif of RN (NA position 3821; but all variants are 
synonymous) and one present in a conserved region of the DU (NA position 
4274; all variants are synonymous). Twenty two of the twenty five variants 
either conserve the amino acid or exchange a non-polar residue for a similar 
non-polar residue again highlighting the conserved nature of the pol.  
 
 
 
 
 
 
 
Table 3.8: SNPs located in the LTRs, tat and gag sequences. The number of reads 
containing each base is shown with the resulting amino acid in brackets. Highlighted 
nucleotides represent the base called in the EIAVNEW genome. SNP locations are in reference 
to the EIAVNEW full genome. 
SNP 
position 
Location AA 
position 
Number of nucleotides at position (AA) Depth 
A G C T Delete 
236 5' LTR ( R ) N/A 91 356 0 0 0 447 
8160 3' LTR ( R ) N/A 43 248 0 0 0 291 
328 5' LTR/ gag linker N/A 26 0 926 87 0 1039 
434 tat ORF 1 29 1326 (T) 218 (A) 1 (P) 0 0 1545 
450 tat ORF 1 31 236 ( R ) 1314 (G) 2 ( R ) 0 0 1552 
5195 tat ORF 2 28 5 (A) 665(A) 0 335 (A) 0 1004 
5219 tat ORF 2 36 292 (Q) 682 (Q) 0 0 0 682 
616 gag p15 56 1042 (I) 375 (V) 0 0 0 1417 
1047 gag p26 200 852 (K) 0 215 (D) 56 (D) 0 1123 
1255 gag p26 269 1131 (I) 221 (V) 0 0 0 1351 
1324 gag p26 292 871 (I) 0 30 (L) 504 (L) 0 1405 
1420 gag p26 324 352 (T) 1037 (A) 0 0 1 1390 
1546 gag p11 366 47 (T) 2 (A) 335 (P) 1256 (S) 0 1640 
1701 gag p11 417 2 (K) 0 1187 (N) 156 (N) 0 1345 
1827 gag p9 459 1 ( E ) 0 1107 (D) 201 (D) 0 1309 
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Table 3.9: The location of SNPs in the pol gene. The number of reads containing each 
base is shown with the resulting amino acid in brackets. Highlighted nucleotides represent 
the base called in the EIAVNEW genome. SNP locations are in reference to the EIAVNEW full 
genome. 
SNP 
position Location 
AA 
position 
Number of nucleotides at position (AA) 
Depth A G C T Delete 
2013 pol pro 35 284 (I) 830 (V) 0 0 0 1114 
2091 pol pro 61 226 (T) 401 (A) 2 (P) 1 (S) 0 630 
2129 pol pro 73 324 (G) 172 (G) 0 0 0 496 
2288 pol RT 126 132 (K) 367 (K) 0 0 0 499 
2420 pol RT 170 166 ( R ) 0 10 ( R ) 809 ( R ) 0 987 
2504 pol RT 198 186 (G) 871 (G) 1 (G) 1 (G) 0 1059 
2538 pol RT 210 892 (N) 0 181 (H) 0 0 1073 
2672 pol RT 254 201 (L) 1767 (L) 0 1 (F) 0 1969 
2726 pol RT 272 1 (I) 1 (M) 513 (I) 1207 (I) 0 1722 
2876 pol RT 322 684 (P) 445 (P) 0 0 0 1129 
2879 pol RT 323 696 ( E ) 454 ( E ) 0 0 0 1150 
3044 RT/ RN linker 378 515 (G) 678 (G) 1 (G) 0 0 1194 
3137 RT/ RN linker 409 649 ( E ) 241 ( E ) 0 0 0 890 
3198 RT/ RN linker 430 571 (I) 117 (V) 0 0 0 688 
3201 RT/ RN linker 431 579 (I) 2 (V) 0 113 (L) 0 694 
3316 RT/ RN linker 469 4 ( E ) 0 1033 (A) 193 (V) 0 1230 
3473 RT/ RN linker 521 202 (S) 0 1083 (S) 4 (S) 0 1289 
3662 pol RN 584 310 (Q) 610 (Q) 0 0 0 920 
3737 pol RN 609 604 (T) 141 (T) 1 (T) 0 0 746 
3821 pol RN 637 126 (A) 1 (A) 2 (A) 671 (A) 0 800 
3891 RN/DU linker 661 236 (I) 853 (V) 1 (L) 0 0 1090 
4274 pol DU 788 1 (G) 0 514 (G) 324 (G) 3 842 
4292 pol DU 794 775 (I) 173 (M) 3 (I) 0 0 951 
4499 pol IN 863 644 (I) 689 (M) 1 (I) 0 0 1334 
4682 pol IN 924 449 (L) 991 (L) 0 0 1 1441 
 
The majority of variants located in the gag, pol or accessory genes are either 
synonymous or maintain the type of amino acid. Even though each position 
has the potential of being occupied by any of the four nucleotides, each 
position tends to only have two major variants, and if a third or fourth is 
present, it is only present on a small number of reads. For example, at NA 
position 2726 the major variants are thiamine (1207 reads) and cytosine (513 
reads) whereas adenine and guanine are only present in one read. 
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The majority of SNPs analysed fall inside gp90 (Table 3.10). This is 
unsurprising given its role in immune evasion and selection pressure. A large 
number of variants in the gag and pol genes involve non-polar residues but a 
much higher proportion of charged residues are involved in the variants in 
gp90. Of the forty one variants only fourteen maintained the amino acid or 
replaced them with similar residues. Over half of the variants occurred within 
previously defined variable regions or close to them. Two codons contained 
two variant locations, which could drastically increase the number of possible 
amino acids at these positions (env amino acid 197 and 365). Also of interest 
is the effect of the variants on the possible structure of the protein. Multiple 
variants interfere with the possible N-linked glycosylation sites mentioned 
previously (Section 3.2.7.5). The variants at position 5892 and 5893 both 
affect amino acid 197, which is an asparagine in an NST motif and so may 
remove possible glycosylation at this site. Similarly, variants at positions 6265 
and 6337 also remove the asparagine in a glycosylation motif. A variant at 
position 6355 may potentially remove a glycosylation site by changing a 
threonine to a lysine. There is also a lysine to threonine variant at NA position 
which may introduce a glycosylation site. Also the first ORF of rev overlaps 
with the 5' end of gp90 in the same reading frame. A single variant is located 
in this area (position 5503) and involves the change of a valine to a glutamate, 
but since this is not located in a possible genome feature, it may be of low 
impact. 
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Table 3.10: The location of SNPs in gp90. The number of reads containing each base is shown 
with the resulting amino acid in brackets. Highlighted nucleotides represent the base 
incorporated in the EIAVNEW genome. Highlighted boxes represent a variant located outside of 
the designated variable regions. The SNP and AA positions are in reference to the EIAVNEW full 
genome. 
SNP 
position 
AA 
position 
Number of nucleotides at position (AA) Depth Variable 
region 
A G C T Delete 
5503 67 412 ( E ) 1 (G) 1 (A) 1039 (V) 10 1454   
5596 98 1 (K) 0 150 (T) 1101 (I) 0 1252   
5654 117 1050 (Q) 1 (Q) 411 (H) 0 0 1462   
5795 164 877 (T) 0 2 (T) 589 (T) 0 1468   
5810 169 0 1 (T) 1265 (T) 271 (T) 0 1537   
5878 192 141 (D) 980 (G) 1 (A) 0 10 1132 V3 
5892 197 765 (N) 402 (D) 171 (H) 2 (Y) 0 1340 V3 
5893 197 869 (N) 370 (S) 90 (T) 35 (I) 0 1364 V3 
5904 201 176 (N) 1188 (D) 2 (H) 0 0 1366 V3 
5911 203 310 (K) 663 ( R ) 293 (T) 0 84 1350 V3 
5914 204 980 (K) 3 ( R ) 377 (T) 10 (M) 0 1370 V3 
6006 235 1516 (S) 205 (G) 0 0 2 1723 V4 
6157 285 804 ( E ) 1468 (G) 1 (A) 1 (V) 0 2274 V5 
6176 291 792 ( E ) 2 ( E ) 0 1517 (D) 0 2311 V5 
6187 295 1508 (N) 747 (S) 2 (T) 0 0 2257 V5 
6265 321 970 (N) 534 (S) 1 (T) 0 0 1505 V6 
6271 323 3 (K) 543 ( R ) 933 (T) 0 0 1479 V6 
6337 345 440 (N) 0 402 (T) 1 (I) 0 845   
6341 346 0 85 (W) 0 757 ( C ) 0 842   
6351 350 741 (I) 121 (V) 0 1 (L) 0 863   
6355 351 92 (K) 0 774 (T) 0 0 866   
6371 356 109 ( E ) 0 1 (D) 764 (D) 0 874   
6372 357 110 (T) 0 764 (P) 0 0 874   
6397 365 726 ( E ) 81 ( E ) 0 0 0 807   
6398 365 624 ( E ) 2 ( E ) 171 (D) 4 (D) 0 801   
6400 366 426 (N) 366 (S) 0 4 (T) 0 796 V7 
6401 366 72 (K) 14 (K) 0 711 (N) 1 798 V7 
6403 367 719 (N) 5 (V) 98 (T) 0 1 820 V7 
6405 368 724 (N) 84 (D) 0 0 0 808 V7 
6427 375 397 (N) 308 (S) 4 (T) 0 0 709 V7 
6430 376 45 (N) 0 363 (T) 0 9 417 V7 
6434 377 0 84 (K) 1 (N) 311 (N) 0 396 V7 
6435 378 64 (N) 291 (D) 41 (N) 0 0 396 V7 
6452 383 121 (Q) 885 (Q) 0 0 0 1006 V7 
6507 402 1033 ( R ) 316 (G) 2 ( R ) 2 (STOP) 0 1353 V8 
6510 403 1147 (N) 67 (D) 0 104 (Y) 0 1318 V8 
6517 405 168 (K) 1146 ( R ) 0 0 0 1314 V8 
6580 426 1 (STOP) 0 893 (S) 524 (L) 0 1418   
6615 438 1379 (I) 269 (V) 1 (L) 0 0 1649   
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6631 443 1369 (K) 0 292 (T) 2 (I) 0 1663   
As well as SNPs, seven high frequency insertion/ deletions (INDELs) were 
present, all of which were located in gp90 (Table 3.11). Six were located 
together in variable region 7 and so could represent the insertion of two amino 
acids. The remaining INDEL is located in variable region 4. This flexibility of 
gp90 to vary at such a level with both SNPs and INDELs within a single tissue 
highlights the issues with sequencing the virus. 
 
Finally gp45 (Table 3.12) varies to a much lesser extent than gp90. Gp45 
contains fourteen variants of which eleven maintain the amino acid or replace 
with a similar residue. This is the case for a variant in the transmembrane 
domain (position 7199) which replaces a methionine with an isoleucine. Also, 
similar to gp90, gp45 contains three codons that contain two variant positions 
increasing the number of possible residues at those positions. 
 
The second ORF of rev overlaps with gp45 and contains five variants, two of 
which are synonymous, one maintains the amino acid type and two change 
the amino acid charge. They are all outside of defined genome features 
Table 3.11: The Indels located in gp90. All high prevalence INDELs are present in a variable region. 
INDEL postions are in reference to the EIAVNEW full genome. The INDELs highlighted in blue and 
orange represent a single codon. 
INDEL position Variable region 
Number of nucleotides at position 
Deletion Depth A G C T 
6008 V4 2 0 159 1 1309 1471 
6433 V7 0 0 8 58 325 391 
6433 V7 51 0 1 11 328 391 
6433 V7 0 51 0 0 340 391 
6435 V7 41 0 5 0 350 396 
6436 V7 0 0 11 46 334 393 
6436 V7 45 0 0 10 336 393 
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except one variant at position 7648, which is in the lysine rich domain, but is a 
synonymous change. 
Table 3.12: The location of SNPs in gp45 and the second ORF of rev. The number of reads 
containing each base is shown with the resulting amino acid in brackets. Highlighted nucleotides 
represent the base incorporated in the EIAVNEW genome. SNP and AA location are in reference 
to the EIAVNEW full genome. 
SNP  
position 
Location AA position Number of nucleotides at position (AA) Depth 
A G C T Delete 
6766 env gp45 488 168 (N) 0 1196 (T) 4 (I) 0 1367 
6767 env gp45 488 0 172 (T) 2 (T) 1180 (T) 0 1354 
7199 env gp45 632 227 (I) 1263 (M) 0 0 0 1491 
7474 env gp45 724 204 (K) 939 ( R ) 0 0 0 1143 
  rev ORF 2 74 204 (Q) 939 (Q) 0 0 0 1143 
7547 env gp45 748 174 ( E ) 548 ( E ) 1 (D) 1 (D) 0 724 
  rev ORF 2 99 174 (N) 548 (D) 1 (H) 1 (Y) 0 724 
7601 env gp45 766 0 0 677 (N) 180 (N) 0 857 
  rev ORF 2 117 0 0 677 (P) 180 (S) 0 857 
7613 env gp45 770 117 (G) 775 (G) 0 0 0 892 
  rev ORF 2 121 117 (I) 775 (V) 0 0 0 892 
7648 env gp45 782 440 (N) 573 (S) 0 0 0 1013 
  rev ORF 2 132 440 (K) 573 (K) 0 0 0 1013 
7658 env gp45 785 0 0 460 (D) 583 (D) 0 1043 
7743 env gp45 814 95 (I) 885 (V) 4 (L) 38 (L) 0 1022 
7755 env gp45 818 213 (T) 737 (A) 0 2 (S) 0 952 
7756 env gp45 818 0 1 (G) 641 (A) 298 (V) 0 940 
7769 env gp45 821 149 (A) 783 (V) 4 (L) 0 0 936 
7770 env gp45 821 0 0 169 (A) 759 (V) 0 936 
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3.3 Discussion: 
3.3.1 EIAV molecular detection and sequencing by PCR: 
The initial stage of the molecular characterisation was an investigation into the 
use of PCR in detection and sequencing of EIA viruses. All tissues used were 
from horses that tested positive with the Coggins AGID test. Initially three 
different PCRs were tested for their ability to detect the two Irish cases, 
EIAVWYO and the British cases. Spleen was used since it has been shown to 
contain the highest virus burden in acute animals and one of the highest in 
asymptomatic animals (Harrold et al., 2000). Tissue culture supernatant was 
used for EIAVWYO since it is maintained in tissue culture and due to the 
historic nature of EIAVNEW, only serum was available. The gag PCR (Cappelli 
et al., 2011) detected only four of the ten strains tested; the LTR PCR (Dong 
et al., 2012) on the other hand detected every strain tested. Following this a 
series of 12 overlapping PCRs (region 1-12; Quinlivan et al., 2013) were used 
on all strains except the Cornish case due to finite tissue amount. Except R2 
with EIAVDEV none of the British strains amplified. A commercial qRT-PCR 
was also tested and detected EIAV in all cases except EIAVWILT1, which is 
likely due to a primer mismatch considering EIAVWILT2 was positive when 
tested with conventional PCR and is likely compounded by a low viral load. 
 
After subsequent testing of the viral RNA and proviral DNA present for each of 
the 2010 British cases, the RNA of EIAVDEV was selected for sequencing by 
PCR since it had the lowest Ct value and the largest sequence from which to 
design primers. In total twenty eight PCRs were used of which seven 
amplified viral sequence. This resulted in the whole gag and 534bp of pol. The 
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low success rate of primer walking to complete the pol made the method time 
consuming and laborious, and the high diversity of the env made primer 
placement difficult. Unlike other viruses such as HIV, there are few published 
sequences of EIAV , the genomes that are published are highly divergent and 
so the placement of primers to create a suitable product size and maintain a 
similar melting temperature are difficult. Also the likelihood that novel 
genomes are highly divergent from currently published genomes is high, 
making the design more problematic. The use of degenerate primers can 
overcome these issues but can also result in poor primer specificity. An 
increase in available sequences from different geographical locations and 
outbreaks would allow an alignment more representative of EIAV in the field. 
This could be used to design better primers and molecular detection methods. 
Thus, sequencing efforts were refocused on NGS. 
 
3.3.2 EIAV sequencing by next generation sequencing: 
Next generation sequencing was used because it avoids the requirement for 
sequence specific primers. Since the viral RNA can be present at low levels 
relative to host RNA, two extraction methods and two NGS platforms were 
compared. The TRIzol/RNeasy method provided a more flexible extraction 
procedure generating a series of five terminal elutions. The total RNA content 
decreased over the eultions whilst the virus level (measured by Ct value) 
remained relatively constant over the first two/ three elutions. This allowed the 
choosing of a sample, which had a large reduction of total RNA but 
maintained virus load. Interestingly RNA and viral load was higher in the 
earlier elutions but was lost quickly over the later elutions. Virus was 
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undetectable in the later elutions. The RNA content and Ct values of the 
elutions containing a low viral load by comparison remained relatively stable, 
a pattern also observed in the EIAV tissue extractions. The illumina MiSeq 
platform was chosen because it generated more sequence data than the 454 
and detected the high Ct SBV sample whereas the 454 did not. Also, the 
withdrawal of Roche’s 454 platform and support in 2016 from the market 
reinforced this decision. The extractions of the symptomatic cases (EIAVDEV, 
EIAVCOR and EIAVNEW) contained similar Ct values and relatively low total 
RNA content and were successfully sequenced. The asymptomatic cases 
were screened to identify the cases that had the best chance of sequencing 
success. The asymptomatic cases generated higher Ct values compared to 
the symptomatic cases and so EIAVNORTH and EIAVWILT2 were selected for 
sequencing. EIAVWILT1 and EIAVDEV2 were undetectable and produced the 
highest Ct respectively and so were not used. EIAVNORTH was detectable in all 
five elutions but had a Ct of 31.56 (6.46 Ct values higher than EIAVCOR 
equating to approximately a 100 fold difference). EIAVWILT2 on the other hand 
had a Ct only 1.62 cycles higher than EIAVCOR. The total RNA content 
seemed to vary regardless of disease state but the bulk of total RNA was lost 
earlier in asymptomatic cases than symptomatic cases. 
 
EIAVDEV and EIAVCOR cases mapped a total of 1345 and 1550 reads 
respectively to their final backbone with an average depth of 23 and 22 
respectively. The error rate of the illumina MiSeq is ~0.8% per base (Quail et 
al., 2012), given this low coverage the bases were assumed accurate 
providing ten or more reads were present at a given position. This depth 
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allowed assurance of the full genome sequence however both genomes had 
areas of low coverage (<10 reads) as well as small gaps, which were 
successfully covered by PCR and Sanger sequencing. The lowest coverage 
depth used for SNP discovery is ~15-20x and so was not applicable to the 
data of these two genomes (Bentley et al., 2008; Quail et al., 2012). The 
resultant genomes lacked the LTRs, which are difficult to sequence by NGS 
(Wang et al., 2011). To retrieve the LTRs, they were deduced by overlapping 
both LTRs, assuming both LTRs are identical (similar to the other published 
full genomes). EIAVNEW on the other hand mapped 72037 reads to the final 
backbone with an average depth of 1167. This allowed a population analysis 
and more confidence in the sequence accuracy of the dominant population. 
As a percentage of the total reads, EIAVDEV and EIAVCOR mapped 0.003% 
and 0.004% respectively whereas EIAVNEW mapped 0.178%. This difference 
could be due to a number of factors. The historic nature of EIAVNEW case 
meant only serum was available. However, the serum was from the second 
extraction of serum from whole blood, possibly by manually squeezing the clot 
to extract serum. This could result in an increase in virus if infected myeloid 
cells were present. However, sample type alone would probably not be 
sufficient if the animal was asymptomatic since the amount of virus in the 
blood depends on the disease state of the horse. The Newmarket case 
presented with a comparatively intense disease than the Devon and Cornwall 
cases, possibly a combination of the young age of the Newmarket case and, a 
higher virus burden. The Cornwall case presented with a comparatively 
moderate set of symptoms (lethargy, pyrexia, tachycardia, pale mucous 
membrane, perpetual oedema, depression, constipation, profound anaemia 
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and jaundice) whereas the Devon case presented with a comparatively milder 
set of symptoms (lethargy, pyrexia, tachycardia, pale mucous membranes, 
ventral oedema and weight loss). The Newmarket case on the other hand 
presented with all of the above symptoms as well as hind leg oedema, harsh 
staring coat and liver and spleen enlargement. The differences seen in the 
viral load and sequencing success of the different cases is probably a 
combination of virus load and sample type. The euthanasia of horses by 
barbiturates prevents blood being taken post mortem and blood was not taken 
pre-mortem for the Devon and Cornwall cases making serum or tissue viral 
load comparison of these cases impossible. 
 
Regarding the asymptomatic cases, EIAVNORTH failed to map any reads. 
EIAVWILT2 mapped two sets of two overlapping reads. These were used to 
design primers against the genome and allow PCR. This resulted in a 798bp 
fragment of the pol gene before primer walking was abandoned. Since the 
Wiltshire cases were the first EIAV cases in Britain for over thirty years the 
post mortem was thorough and included pre-mortem serum. Due to the 
success of EIAVNEW sequencing possibly being due to the use of serum, 
serum from the second Wiltshire case was extracted and sequenced. The 
serum was more successful than the spleen and mapped 29 reads to the 
same reference genomes used in the spleen mapping projects. The reads 
were spread across the genome making primer design a possibility to 
sequence more of the genome. Even if the gag alone could be sequenced it 
would allow phylogenetic comparison with the other viruses. Serum could be 
a useful alternative to spleen in carrying out NGS. It is likely that the lack of 
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host RNA reduces the background contamination, increasing the chance of 
virus specific reads even if there is little virus present. Also considering the 
same reference sequences were used for the serum and spleen mapping 
projects, the relative failure of the spleen is likely due to virus being at a low 
level in the tissue. Regardless, the best approach to sequencing the 
asymptomatic cases seems to be a combination of NGS and PCR/ Sanger 
sequencing. 
 
To allow comparison of the dominant population of free viral RNA and proviral 
DNA, DNA from EIAVDEV was extracted and sequenced. This however 
mapped no reads. The relative failure to sequence proviral DNA is possibly 
because the free virus is produced by relatively few ‘viral factories’ so it is 
assumed there is much less provirus. Thus, a more powerful sequencing 
platform was sought to sequence the proviral DNA. The illumina HiSeq was 
used as it can produce over 300 million reads compared to 25 million reads 
generated by the MiSeq, thus greatly increasing coverage. Unfortunately, the 
SeqMan NGen software was unable to process HiSeq data files due to their 
large size and so specialist bioinformatics support was sought. To reduce the 
file sizes reads were removed based on their similarity to equus caballus 
(95% of reads were horse genome), but interrogation of the resulting 5% of 
reads yielded no EIAV sequences. The original data files were then depleted 
using an alternative horse genome to reduce the impact of sequences similar 
to EIAV, this yielded 17 sequences spread through the genome. No more 
reads  could be recovered. The lack of EIAV sequences is likely due to a 
combination of a small number of proviral insertions and the extraction 
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method not being optimised for viral NGS. However with the full RNA 
sequence, primers could be designed to sequence the dominant proviral 
population in the tissue, whilst population analysis could be carried out by 
carrying out NGS with the PCR products there may be bias of which products 
are amplified most efficiently in the PCR. 
 
3.3.3 The British full genomes each represent a new group of EIAV: 
The generation of full genome sequences from the three symptomatic cases 
allowed phylogenetic and sequence comparison to the other field strains 
available. Analysis of the full genomes of published field strains revealed that 
EIAVDEV, EIAVNEW and EIAVCOR are as distant as EIAVMIYA, EIAVLIA, EIAVWYO 
and EIAVIREF2 are from one another and even when the phylogeny is 
restricted to the gag gene the same groupings can be observed. This leads to 
the assumption that the above seven strains each represent a single EIAV 
phylogenetic grouping or clade, with each strain being separated by an almost 
equal distance in the tree and all the strains showing a nucleic acid identity of 
approximately 77% (Figure 3.2). The British strains represent the first EIAV 
sequences from Britain as well as full genome sequence from the same 
country that diverge to the same extent to the previously suggested groups of 
American, Chinese, Irish and Japanese viruses. The Devon and Cornish 
cases were in the same consignment of horses from Belgium in 2008 as the 
other 2012 case in Devon, and a negative horse that was present on the farm 
in Wiltshire during the 2010 outbreak. Tracing postulated that the horses were 
infected before entry into GB and their separation on the tree seems to 
support the hypothesis that they were imported. The Wiltshire cases were 
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themselves imported from Belgium and their discovery prompted the Belgium 
government to screen horses imported from Romania between 2007 and 
2009. This screening programme lead to the discovery of EIAVASS and 
EIAVWAR. Both EIAVASS and EIAVWAR were separately imported into Belgium 
in 2009 from Romania (Caij & Tignon, 2012). The Belgian strains clustered 
separately with strains of Romanian origin from 2009. The clustering of 
EIAVDEV with EIAVWAR and EIAVROM1, and the clustering of EIAVCOR with 
EIAVASS and EIAVROM4 despite the two British cases being in the same 
consignment implies that there are (at least) two separate groups of EIAV in 
Romania that have been brought together at least twice and transported 
through Belgium. Considering this is based on two partial sequences from 
Romania in a year there were 544 outbreaks and two sequences from 
Belgium from a year there were seven cases, it is possible that many more 
EIAV phylogenetically distinct groups are active in Romania and other 
European countries. Also it is possible that individual groups may have spread 
further than anticipated. For example, EIAVNEW does not cluster with any 
current strains. This could be due to its historical nature but EIAVWYO is from a 
case in 1941 and clusters loosely with the recent Canadian viruses, thus it is 
more likely that its relations are extinct or have not been located/ sequenced, 
similar to equine arteritis virus (Steinbach et al., 2015). The cases in Britain in 
1975 and 1978 were traced to either South America or Europe and 
considering the small number of European sequences available and that the 
only South American sequences available are partial gag sequences it is 
possible that the relations of EIAVNEW are still circulating somewhere. 
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The difficulty in tracing horses lends a risk to undetected EIAV in many 
countries. For example, four of the horses from the consignment that 
contained the Devon and Cornwall cases were never found. During the 
Belgium tracing programme of horses from Romania, 1730 horses had left the 
country and so were not followed up and 224 horses could not be found due 
to identification problems. This combined with the difficulty in identifying 
asymptomatic cases highlights a risk that EIAV could go undetected for long 
periods of time before being discovered resulting in its spread. The most 
common symptoms of thrombocytopenia and pyrexia are also non-specific 
aiding in the disease remaining under the radar. 
 
3.3.4 EIAV sequence analysis: 
The majority of sequence motifs shown to be important in EIAV were 
conserved through the different viruses e.g. the YPDL motif in p9. The two 
regions considered to contain the most variation are the LTR and ENV genes. 
Despite high levels of variation in the LTR (72.2%-83.9% nucleic acid identity) 
all field strains (except EIAVWYO) contained three PU.1, one PEA1/AP1, a 
TATA box, TAR and poly A signal confirming their importance in replication. 
The env also contains a high level of variation, but the majority was contained 
within gp90 in the previously defined hypervariable regions (V1-V8), which 
also contain most of the possible glycosylation sites. Interestingly the number 
of glycosylation sites is relatively conserved with 17-18 glycosylation sites in 
each virus (except EIAVWYO which contains 13). However, it is important to 
point out that the glycosylation sites are only sequence based predictions  and 
so require confirmation in vivo. The cysteine residues are almost entirely 
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conserved in gp90, and given their importance in protein folding, changes in 
cysteine residue position and number could impact on protein folding and 
consequently receptor binding. The env gene shows 31-38% nucleic acid 
divergence which is of major importance considering vaccine protection is 
reduced from 100% to 40% against strains with as little as 13% divergence in 
the env gene (Craigo et al., 2013). The existence of multiple groups 
circulating in Europe hampers development of a single EIAV vaccine to 
control disease in Europe, especially since there appear to be multiple 
phylogenetic groups circulating simultaneously in individual countries. 
Although a vaccine is credited with reducing the EIAV burden in China in the 
1970s (Cook et al., 2013; Issel et al., 2014) it was live attenuated and part of 
an extended campaign to reduce a massive EIAV burden and so not suitable 
(or legal) for use in Europe as a prevention.  
 
Motifs in the gag and pol were highly conserved such as the leucine rich NES 
in the MA, the YPDL motif in p9 and the functional amino acids in DU and IN. 
Their conservation further highlights the importance of these motifs. The 
individual proteins that displayed the lowest sequence identity were p9 of the 
gag and the accessory protein S2, which had between 34.8%-72.7% and 
33.3%-57.3% amino acid identity respectively. Interestingly the lowest identity 
of both proteins is between EIAVDEV and EIAVNEW and the highest is between 
EIAVNEW and EIAVWYO for S2 and EIAVLIA and EIAVIREF2 for p9. The lack of 
sequence similarity between the British cases further shows that they were 
imported. The phylogeny of the full genomes and gag closely mirror one 
another but the addition of other field strain sequences are required to confirm 
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this. The S2 protein also provides an example of issues with generalising 
motifs between distant viruses. The domains of S2 were noted in HIV and 
extrapolated to EIAVUK, a clonal relation of EIAVWYO. The nucleoporin domain 
(GLF) is present in the majority of viruses with mutations exchanging amino 
acids for similarly structured amino acids (e.g. L replaced with V). The SH3 
domain (PLLP) and the NLD (RKQETKK) on the other hand are only present 
in a minority of viruses with the NLD only being present in EIAVWYO. Whilst the 
mutations may abrogate activity it is possible that, similar to the rev RNA 
binding motifs, non-critical residues can be changed or a threshold of 
mutations has to be reached to abrogate activity. At least three residues of the 
SH3 domain are conserved (except in EIAVDEV which changes the prolines to 
a histidine and serine) and most strains have a high abundance of lysines in 
the 3’ area (except EIAVNEW which only has two), which could allow function. 
The issue of identifying motifs is similar with the viral RT, RN and p26 in that 
until functional studies are carried out using EIAV (preferably using viruses 
from different groups) it is difficult to assign a function to a motif with full 
confidence.  
 
The gag provides an opportunity to look at viruses that are from similar 
outbreaks and locations enabling a look at close and distantly related viruses. 
For example, EIAVITA1, EIAVITA2 and EIAVITA3 are from an outbreak in 2006 in 
Italy whilst EIAVITA4 is from the same year but a different outbreak. EIAVITA5 is 
from Italy in 2007 and EIAVITA6 is from Italy in 2008. There were also five 
Romanian viruses (EIAVROM1-5), but they were mostly partial sequences 
missing the p9 protein and some of the NC, excluding them from the 
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phylogenetic analysis. But the alignments showed that the viruses that 
originated from the same outbreak could have as much as 100% sequence 
identity, even if they were separated by a year (EIAVITA1, EIAVITA2 and 
EIAVITA4 share 100% identity of their p9 protein).  
 
The viruses that are currently sequenced are either very close or very distant 
indicating that EIAV could be separated into groups similar to HIV, but unlike 
HIV there are very few sequences available. The ability to trace outbreaks 
would rely on ancestral viruses already being sequenced otherwise the 
sequence provides information similar to EIAVNEW in that it is the only 
sequence of its lineage. 
 
3.3.5 EIAVNEW population analysis: 
The high coverage of EIAVNEW allowed for an analysis of the various 
quasispecies present in the serum taken from the horse at death. The majority 
of the SNPs and indels were prevalent in less than 1% of the reads covering 
their position. Whilst the sequencing error is ~0.05%, the lack of quality 
checking software (discussed in 3.3.6) makes the identification of low level 
variants error prone (Quail et al., 2012). Whilst there are a large number of 
methods to identify errors in the sequence through alteration in sample 
preparation and bioinformatics (Isakov et al., 2015), the main aim of this 
sequencing was to sequence the full genome of the British EIAV strains. 
Considering the low number of viral specific reads generated, the removal of 
reads based on quality can be dangerous as it could potentially remove a 
large proportion of the viral genome. As a buffer to compensate for the lack of 
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quality checking, only SNPs with a prevalence >10% were analysed. The 
majority were located in gp90, which also contained the only indels which had 
a prevalence of >10%. Also of interest in the env were four instances of a 
single codon containing two variants increasing the possible bases at those 
positions. The env is capable of not only mutations but also changes in length 
within an individual animal. The majority of variants in the gag, pol, accessory 
genes and even gp45 were either synonymous or exchanged amino acids for 
a similar amino acid in structure or charge. The majority of variants in gp90 on 
the other hand were non-synonymous. Both EIAVDEV and EIAVCOR had 
average depths that potentially allowed the identification of high level variants 
in parts of the genome. However, only looking for variants in regions with 
enough coverage skews the findings and the information would be biased 
towards areas of the genome with a higher depth. The lower depth would 
need a higher prevalence cut off to remove false positives. Thus many true 
variants would be filtered out.  
 
A drawback of this type of analysis is that it only yields information regarding 
the location and prevalence of SNPs with no way of linking mutations to the 
same genome. For more information regarding the full genomes of the 
different viruses longer read technology would be required to allow the SNPs 
to be pieced together to form the different virions. Previously this was an area 
that the Roche 454 pyrosequencing platform excelled but its low coverage 
restricted it to samples containing a high viral load or minimal host material. 
The inclusion of quality control and/or an increased depth would allow 
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increased mutation linking and allow population analysis of the other British 
cases. 
 
3.3.6 Next generation sequencing evolution: 
Next generation sequencing technology is a fast developing area. During the 
time of this project the Roche 454 pyrosequencing platform has been 
discontinued and multiple sequencers that were in their infancy in 2012 are 
now more refined and widely adopted.  Current sequencers include; the 
SOLiD and Ion Torrent personal genome machine (PGM) from Applied 
Biosystems and Life Sciences respectively and the HiSeq and MiSeq from 
Illumina (the specs of which are compared in Table 3.13). Sequencing 
technology has also continued to advance to so called third generation 
sequencing which differs from second generation by not requiring a PCR step 
priop to sequencing and then sequencing in real time (Liu et al., 2012). Two 
examples of thirds generation are the SMRT RSII system by Pacific 
Bioscience which can produce read lengths upwards of 20Kb, and the MinION 
from Oxford nanopore Technologies with read lengths anywhere up to 200Kb 
(Oxford Nanopore Technologies, 2015; Thermo Fisher Scientific, 2015). The 
MinION is memory stick sized sequencer capable of producing 80,000 reads 
in four hours and can run longer to produce more reads if needed (Wei et al., 
2016). Considering the sequencing of EIAV, the low virus level in the clinical 
tissues requires a high coverage sequencing approach in order to maximise 
viral reads in the absence of an efficient viral enrichment method. The use of 
the Ion Torrent or the SOLiD platforms, which produce over three times and 
just under a thousand times more reads than the MiSeq respectively could 
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prove more successful at sequencing asymptomatic cases. Regarding the 
third generation sequencing technologies, their high price puts them beyond 
most laboratories and they still have some time to go in development before 
they come to rival the other sequencing technologies (Quail et al., 2012). With 
the continued advancement of both the sequencers themselves and the 
chemistry used, new opportunities for sequencing EIAV will become available. 
 
Table 3.13: Comparison of current NGS platforms.  
Sequencer Company 
Max output 
(Gb) 
Max 
reads 
Max read 
length 
Scale up with single 
machine?  
MiSeq illumina 15 25M 2x300bp N/A 
HiSeq X 
series 
illumina 1800 6B 2x150bp N/A 
SOLiD 
Life sciences 
(Thermo Fisher) 
160 2.4B 75x35bp 
can run two cells in 
parallell 
Ion Torrent Thermo Fisher 15 80M 400bp N/A 
SMRT (RSII) Pacific Bioscience 1 55000 >20kb 
can run 16 cells in 
parallell 
 
3.3.7 Bioinformatics limitations: 
A lot of focus is put into getting the maximum amount of data out of the 
sequencing whilst not entirely considering the effect this will have on the 
subsequent stage, the bioinformatics/ data analysis. An integral part of the 
sequencing pipeline, the bioinformatics processing of NGS data has been a 
major obstacle in sequencing EIAV. The use of the SeqMan NGen 
programme to carry out reference guided assemblies to map reads is one of 
the least demanding approaches to both the computer and the operator. As 
such, it is not necessarily the most efficient approach in extracting virus 
specific reads from the data files as it sacrifices much flexibility in the name of 
user friendliness. Approaches that would be considered a 'better' approach of 
interrogating the data is the use of programs such as bowtie and other 
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programs based on a Linux operating system. Programs based on a Linux 
system in general are much more flexible allowing mapping projects to be 
better tailored to individual project requirements. This comes with a trade-off 
in user friendliness that at its easiest requires knowledge of command line 
interface and Linux systems, and at its most difficult, a knowledge of 
programming and ability to write programming commands, both of which are 
beyond the knowledge of most laboratories (Kumar et al., 2012). Alternatives 
which maximise user friendliness and flexibility are slowly being developed 
but many of these are based on external servers which could not be used 
here due to the firewalls and computer policy present in a government 
agency.  
 
A part of this project was to assist in the set-up of an 'in workgroup' 
bioinformatics pipeline in an effort to develop the capability and expertise 
within the laboratory and reduce the need and reliance on external 
bioinformatics providers which can be costly and lengthy allowing a more 
flexible approach. SeqMan NGen was used as a starting point due to its user-
friendly nature, but since it is still in development itself it has had limitations in, 
for example, its inability to handle HiSeq data. Other issues have included the 
ability to carry out de novo assemblies. Since this requires greater computing 
power than reference-guided assemblies, de novo assemblies have been 
problematic with memory leaks leading to programme crashes. Alternative 
approaches have been the removal of the host genome (using the equus 
caballus genome on genbank) to reduce the burden on the computer. 
However, processing of completed de novo assemblies has been carried out 
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using seqman pro, and the size of the assemblies usually lead to programme 
crashes. The system has lead to the successful completion of three EIAV 
genomes but improvements are required if asymptomatic viruses are to be 
sequenced (Kumar et al., 2012). Very few viral specific reads have been 
recovered from the data files for asymptomatic cases. It is possible a more 
tailored approach will yield more reads.  
 
The above relates to the assembly of the desired sequence which is only half 
of the process, the other half being SNP calling and quality control. SNP 
calling for EIAVNEW was done using SeqMan Pro. Each individual SNP was 
assessed based on prevalence, and to reduce the chance of false positives, 
10% was used as the cut off. Currently software exists to carry out quality 
control of SNPs which has the effect of both filtering out false positives as well 
as retaining low level variants that might be filtered out by eye. Most of these 
programs take into account many factors including read length, depth, 
reference to SNP ratio and quality scoring and have proved useful in lentiviral 
population analysis (Zagordi et al., 2010). However many of these programs 
such as SAMtools (Li et al., 2009) and ShoRAH (Zagordi et al., 2010), are 
linux based presenting the same problems as outlined above. Further to this, 
each read generates a quality score and these can be filtered from 
alignments, mapping project and SNP calling (with the right software) but a 
possible problem with EIAV and other viruses of a low level are that they 
generate very few sequences. This is especially true for the asymptomatic 
cases where rejecting reads based purely on quality score may result in the 
loss of many viral reads.  To overcome these obstacles, a minimum depth 
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was used for sequence assembly and low coverage regions were reinforced 
by PCR, and population analysis used a relatively high cut off of 10%. Whilst 
this filters out true low level variants, it prevents the inclusion of false 
positives.   
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4.0 Development of eqMoMϕ culture system for EIAV 
isolation: 
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4.1 Introduction: 
During the 1960s, the identification or production of EIAV required the 
infection of a horse (Kobayashi & Kono, 1966). This was and still is a 
laborious and expensive method of viral production. Also, alternative methods 
of accurately studying EIAV align with the aim to replace, reduce and refine 
the use of animals in research (NC3Rs, 2016). The drive to develop cell 
culture methods led to the use of equine leukocyte cultures and subsequently 
cells of the monocyte-macrophage lineage. Monocytes (Mo) can be 
differentiated along two general pathways to become either a macrophage, 
which is a known target cell for EIAV, or a dendritic cell. Macrophages are 
difficult to isolate from tissues and are short-lived making their isolation and 
maintenance relatively labour intensive compared to other cells (Matheka et 
al., 1976). Other methods of obtaining macrophages are to isolate monocytes 
from the blood and differentiate them, but cell purity and variability remained a 
problem until recently. As such many in vitro EIAV experiments avoided using 
primary cells and utilised cell lines susceptible to EIAV, for which viral 
adaption to these cells has been discovered prompting the development of 
primary cell systems that more closely mirror the in vivo infection environment 
(Maury et al., 2005). 
 
4.1.1 EIAV culture using fibroblasts: 
In vitro experiments with EIAV have used various cell lines such as equine 
endothelial cells, feline embryonic fibroblasts (FEA), canine DH82 cells and 
canine macrophage (Cf2Th) cell lines, but equine foetal kidney (EFK) and 
equine dermal (ED) cell lines were the most widely used (Bouillant & Vineer, 
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1988; Benton et al., 1981; Matheka et al., 1976; Maury et al., 1998; Oaks et 
al., 1999; Maury et al., 2002; Hines & Maury, 2001). Infection of these cells 
with EIAV results in non-cytopathic replication so their maintenance is much 
easier compared to macrophage primary cell cultures (Hines & Maury, 2001; 
Maury et al., 2002).  
 
Strains that were virulent in the field such as the original EIAVWYO, are 
macrophage tropic in vivo and grow poorly in cell lines. If passaged 
repeatedly through fibroblasts however, their tropism will eventually shift 
towards fibroblasts and they will begin to infect macrophages with much less 
efficiency than originally (Gradinaru et al., 1981; Maury et al, 2002). This shift 
can also result in a loss of virulence when infecting horses (Carpenter & 
Chesebro, 1989). A number of the ‘fibroblast tropic’ virus strains used are 
derived from the original EIAVWYO strain (e.g. WSU5, MA-1, EIAVPR; Figure 
4.1 ) and the shift in tropism can be seen in as few as five passages through 
fibroblasts (Cook et al., 1997; Maury et al., 1998). This effect has led to a 
gradual shift away from cell lines to improving the ease of use and 
reproducibility of equine leukocyte cultures to reduce the adaption impact of in 
vitro study of EIAV. During the 2000s, the equine macrophage like (EML-3C) 
cells were developed by spontaneous immortalisation of cultured equine 
PBMCs (Fidalgo-Carvalho et al., 2009). However, previous work in this 
laboratory found them difficult to maintain and unable to support replication of 
GB EIAV field strains (Falko Steinbach, personal communication). 
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4.1.2 EIAV monocyte culture; from leukocyte to macrophage: 
EIAV equine macrophage cultures originally used leukocyte cultures obtained 
by layering leukocytes onto a plate or in a bottle and incubating overnight, 
relying on the adherence of monocytes to a solid surface in order to separate 
them from the other cells that would be washed off (Kobayashi & Kono, 1966). 
This was also carried out in the presence of high serum concentration (Moore 
et al., 1970). However, these cultures were very short-lived and by no means 
pure, making them difficult to maintain and to reproduce (Raabe et al., 1997). 
Thus, the technique was eventually improved by isolating monocytes only. 
Removing the other immune cells. This was done by extending the adherence 
incubation from one to twelve hours and more aggressive washing in order to 
better filter out lymphocytes and granulocytes that adhered to the surface, but 
are less adherent then monocytes (Raabe et al., 1998). The method of 
isolation and differentiation by adherence has been widely used to obtain 
Figure 4.1: The different strains of EIAVWYO. EIAVWYO has been passaged, cloned and 
attenuated to produce a range of viral strains that are widely used in EIAV research. The 
above figure shows the most widely used and their origin. 
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macrophages (Basta et al., 1999; Maury, 1994; Lim et al., 2005). Other 
methods of monocyte differentiation have included incubation of monocytes 
with high levels of serum or with gelatin and serum treated plates but the 
isolation still utilises adherence to separate the cells (Raabe et al, 1997; 
Carvalho et al., 2008; McConnell et al., 1977).  
 
More recently, whilst not carried out in the context of EIAV research before, 
the differentiation of equine monocytes has been improved by separating cells 
by density gradient centrifugation instead of separation by adherence. Two 
density gradient centrifugation steps first allowed collection of PBMC and a 
second allowing the removal of granulocytes. This was followed by multiple 
washes in PBS to remove platelets and other small contaminants (Mauel et 
al., 2006). The subsequent increase in commercially available antibodies and 
the characterisation of immune cell populations further streamlined the 
process, and following density separation, the monocytes could be purified 
from lymphocytes using magnetic bead separation of CD14 positive cells to 
yield highly pure monocyte cultures (Moyo et al., 2013). The production of a 
pure monocyte culture however is only one of the challenges, as the 
monocytes can then be differentiated into one of a plethora of cells, which 
may support EIAV replication in vivo. 
 
Differentiation of monocytes into equine monocyte derived macrophages 
(eqMoMϕ) can be achieved with the use of cytokines to produce specific cell 
populations. eqMoMϕ differentiation can be achieved through incubation of 
monocytes with macrophage colony stimulating factor (M-CSF) and serum. 
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The eqMoMϕ (technically an inactivated macrophage; M0) can then be 
activated to become either an M1 (classical) or M2 (alternative) macrophage 
by stimulation with lipopolysaccharide (LPS) and interferon gamma (IFNγ) or 
interleukin 4 (IL-4) respectively (Section 1.9; Mantovani et al., 2005). Another 
differentiation product of monocytes is the monocyte derived dendritic cell 
(MoDC). Since MoDC also differentiate from monocytes, and monocytes can 
be infected with EIAV it is more than likely that EIAV is capable of infecting 
them (Rivera & McGuire, 2005). MoDC can be generated by incubating 
monocytes with granulocyte macrophage colony stimulating factor (GM-CSF) 
and IL-4 (Mauel et al., 2006; Rivera et al., 2005; Moyo et al., 2013).  
 
4.1.3 Macrophage diversity and EIAV replication: 
The host contains numerous environments made up of varying concentrations 
of different cytokines in order to differentiate the monocyte or macrophage 
into the cell displaying the phenotypes most suited for the situation. Different 
cytokines can stimulate different phenotypes in the same cell type meaning 
the macrophage population in the body is by no means homologous (Martinez 
& Gordon, 2014). Although M-CSF and serum may produce a 'classical' 
macrophage, it may not be the macrophage most capable of replicating EIAV. 
As well as IL-4, GM-CSF, M-CSF and serum, other macrophage related 
cytokines may influence the phenotypes of the terminal cell and affect the 
efficiency of EIAV replication in the cell. Macrophages infected with virulent 
EIAV strains produce higher levels of IL-1α, IL-1β, IL-6, IL-10, interferon alpha 
(IFNα), transforming growth factor beta (TGFβ) and tumour necrosis factor 
alpha (TNFα), whereas avirulent strains do not (Lim et al., 2005; Tornquist et 
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al., 1997). The increase in these cytokines, while contributing to disease 
pathogenesis, may also have an effect of the ability of a macrophage to 
support EIAV replication. It is also possible that other cytokines and chemical 
signals relating to immune and macrophage activation and modulation may 
also up-regulate EIAV replication such as LPS, IFNγ, poly I:C and 
prostiglandin E2 (PGE2). It should be noted that it is possible that these 
factors could also have a negative effect on virus replication, but the aim of 
this study is to develop a system that maximises viral replication whilst 
maintaining an environment as close to in vivo as possible. 
 
There is still much work to do in order to assess the cell types most capable of 
supporting EIAV replication and so allowing a system to study EIAV. The 
previous systems of monocyte isolation and differentiation are difficult to 
reproduce, and have mainly been used with either EIAVWYO or one of its many 
molecular clones (Lim et al., 2005; Cook et al., 2013). Similarly, virus 
detection methods and proof of virus replication often relies on the use of 
antibodies and serum developed in house with the use of an infected horse 
which is beyond the capabilities of many laboratories (Schiffer Evans et al., 
1984; Leroux et al., 2001). These restrictions limit most laboratories to the cell 
systems and commercial antibodies that are tested and optimised for use with 
EIAVWYO limiting their effectiveness with novel field strains. The creation of a 
equine macrophage cell system that can reproducibly support EIAV 
replication without the need for specialist and laborious techniques would 
allow wider study of EIAV. A wide variety of EIAV viruses could then be used 
to study EIAV and massively increase understanding of EIAV and its 
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replication cycle. If possible to grow the virus with minimal mutation and 
growth bias the aim would also be possible to culture asymptomatic cases, 
making their sequencing easier. However, whilst this would provide the 
asymptomatic full genome sequence, the population SNP data should be 
treated with caution as the different populations present in the host may 
change in proportion in cell culture due to the removal of immune 
suppression. 
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4.2 Results: 
4.2.1 Cytokine titration for monocyte differentiation: 
To generate an effective culture system for EIAV, a system for differentiating 
Mo was required. In order to differentiate Mo into eqMoMϕ and MoDC the Mo 
were incubated with either M-CSF and equine serum or IL-4 and GM-CSF 
respectively as described (Section 2.5.5). To achieve cells that resembled 
those in vivo and support EIAV replication, cytokines were titrated over Mo 
and monitored for 72 hours for morphological changes. Monocytes destined 
for MoDC or eqMoMϕ were seeded at a density of 2x105/ml or 4x105/ml 
respectively. All experiments with primary cells were carried out in 24 well 
plates with well volumes of 1ml. 
  
For MoDC, GM-CSF was titrated at 100U, 500U and 1000U. Cells 
characteristic of MoDC could be seen at 72hrs, with 500U being sufficient to 
drive the differentiation. IL-4 was titrated at concentrations of 10ng/µl, 20ng/µl, 
40ng/µl and 200ng/µl. All concentrations induced clustering of the cells and 
dendrite formation by 24 hours, so IL-4 was then titrated at 0.2ng/µl, 2ng/µl 
and 10ng/µl with 500U of GM-CSF. Two ng/µl induced MoDC formation and 
GM-CSF (500U) combined with 0.2ng/µl IL-4 produced well-formed, clustered 
MoDC (Figure 4.2C) compared to the control Mo (Figure 4.2A).  
 
For eqMoMϕ, autologous serum was used at a 5% and 10% concentration 
and M-CSF at a concentration of 0.1ug/µl and 0.2ug/µl. Both concentrations of 
M-CSF caused the formation of large granular cells and possibly some 
proliferation as the media became acidic during the differentiation period and  
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the cells appeared to be stacked; 0.2ug/µl appeared to be sufficient without 
causing overgrowth. The 10% serum on the other hand appeared to cause a 
greater proportion of Mo to differentiate and the cells to spread out more. 
When 10% serum was used with 0.2ug/µl M-CSF the majority of Mo 
differentiated into large granular cells by 72hrs (Figure 4.2D) compared to the 
control Mo (Figure 4.2B). 
 
4.2.2 Establishment of EIAV infection system using EIAVWyo and equine 
dermal cells: 
Ederm cells can be reliably propagated and maintained in vitro and EIAVWYO 
was cultured and has been shown to replicate well in Ederm cells (Malmquist 
et al., 1973). Thus the EIAV infection system was first set up in Ederm cells to 
both test the system and create a stock of EIAVWYO for further use. Initially 
Ederm cells were sourced from the cell and tissue culture unit (CTC, APHA, 
Weybridge) and were cultured in DMEM (10% FCS, 1% pen/ strep) but only 
one batch was available and repeated attempts to grow cells from this batch 
failed (data not shown). Cells were then sourced from the European collection 
of cell cultures (ECACC; PHE; Salisbury) and again cultured in DMEM (10% 
FCS, 1% pen/strep) with success. Infection was carried out using 100µl or 
400µl of inoculum of EIAVWYO TCSN from the ATCC (VIR-778™). One 
hundred and fifty µl of supernatant was taken from the flask to test for viral 
replication on days 0, 1 and 2. At each time point after seven days the 
supernatant was removed and layered onto a new T25 of fresh Ederm cells, 
1ml of supernatant was frozen at -80°C for testing and use as a stock. The 
remaining supernatant was then made up to 5ml with fresh medium. Viral 
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replication was measured by testing the supernatant at each time point using 
the pol RT-PCR (Section 2.3.4) as shown in table 4.1.  
Table 4.1: Ct values and changes of EIAVWYO infection of equine dermal cells over a 53 
day period. Cells were infected with either 100µl or 400µl of virus inoculum. Supernatant 
was taken from the medium after inoculation (virus medium; VM). The medium was then 
removed the monolayer washed and replaced with fresh media (Day 0). At each time point 
after 2 days the media was passaged onto fresh cells in a T25 and made up to 5ml with 
fresh media. DPI: Days post infection.  NA: not applicable. 
DPI 
100ul inoculum 400ul inoculum 
Ct 
Overall Ct 
change 
Ct 
Overall Ct 
change 
VM 22.24 NA 20.92 NA 
0 29.47 NA 28.72 NA 
1 30.19 0.72 27.15 -1.57 
2 29.55 0.08 26.91 -1.81 
7 25.65 -3.82 24.34 -4.38 
15 23.54 -5.93 22.24 -6.48 
36 19.41 -10.06 20.24 -8.48 
42 19.86 -9.61 20.33 -8.39 
53 19.55 -9.92 19.53 -9.19 
 
The greatest change in threshold cycle (Ct) for both inoculum volumes was 
between days 2 and 36. The 100µl inoculum showed a marginally greater 
drop in Ct value. Both inoculum volumes gave a final Ct of 19.54±0.01 cycles 
indicating a maximum level of virus for one batch of cells. From 18 days post 
infection the cells began to detach and appeared ‘unhealthy’. Toxic products 
may have begun to build up in the passaged material, and combined with the 
viral infection may have contributed to the cessation in cell growth. The final 
three flasks of Ederm cells also appeared less healthy then previous flasks, 
with more cells detaching earlier in each consecutive flask indicating a 
gradual reduction in health of the Ederm cells. EIAVWYO TCSN from the last 
passage of 100µl was used in subsequent infections. 
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 4.2.3 Infection of monocytes and macrophages with EIAVWYO: 
4.2.3.1 Viral RNA replication in Mo and eqMoMϕ 
With the successful infection of the Ederm cells and creation of a freshly 
isolated EIAVWYO stock the next step was to try and use the method on 
eqMoMϕ. Since the isolation and differentiation of primary cells is laborious 
this initial infection of Mo and eqMoMϕ was carried out over a single passage. 
Also considering the similar results of the 100µl and 400µl EIAVWYO TCSN 
inoculum (Table 4.1), a reduced inoculum of 20µl or 50µl EIAVWYO TCSN was 
used to try and reduce the usage of the virus stocks. Monocytes and three 
day old eqMoMϕ from horse 1 were infected with either 20ul or 50ul of virus 
TCSN EIAVWYO. The primary cells were expected to have a shorter lifespan 
than the Ederm cells so the cells were infected for four days and the Ct was 
taken to measure the overall change in virus load (Table 4.2).  
 
The Ct values at day three were comparable to those on day 36 in Ederm 
cells (Table 4.1) indicating the virus replicates better in primary horse cells 
than Ederm cells. The change in Ct value between day 0 and day 3 was 
between 10.22 and 13.88 cycles giving a high likelihood of viral replication. 
Table 4.2: Ct values for Mo and EMDM infected with either 20µl or 50µl inoculum over 
3 days of infection. Mo and eqMoMɸ were incubated with either 20µl or 50µl of EIAVWYO 
TCSN for 6 hours, the media was then removed (VM), the monolayer washed once with 
PBS and then 1ml of fresh medium was added and 150µl taken for RT-PCR analysis (Day 
0). 150µl TCSN was taken each day for three days for RT-PCR analysis. The overall Ct 
change is the difference between Day 0 and the final day.  
Cell  
VM Day0 Day1 Day2 Day3 Overall Ct 
change Ct Ct Ct ΔCt Ct ΔCt Ct ΔCt 
Mo20 25.51 37.62 29.17 -8.45 26.86 -2.31 23.74 -3.12 -13.88 
Mo50 24.17 30.68 27.14 -3.54 24.89 -2.25 20.46 -4.43 -10.22 
eqMϕ20 25.65 32.27 27.7 -4.57 24.94 -2.76 20.73 -4.21 -11.54 
eqMϕ50 25.99 32.06 24.48 -7.58 21.09 -3.39 19.59 -1.5 -12.47 
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Virus replication was not confined to a specific time point nor did it follow a 
regular pattern between the cell types or inoculum volumes. There was no 
clear difference between Mo and Mϕ or inoculum volume, so 20µl inoculum 
was used for EIAVWYO TCSN inoculum to reduce its use and eqMoMϕ cells 
were taken forward since they are considered the in vivo target cell. The 
success of the eqMoMɸ infection also negated the use of Ederm cells, 
considering a EIAVWYO stock has been created (from the infection of Ederm 
cells) and the eqMoMɸ cells are the cells of interest. 
 
4.2.3.2 Detection of EIAV protein in eqMoMϕ: 
The significant decrease in Ct value strongly suggested viral replication. To 
further show evidence of viral replication, IPX staining of p26 was tried to 
demonstrate viral protein production. This was done using 20% acetone or 
5% paraformaldehyde and the cells were dried after fixation. The eqMoMɸ 
(from horse 1) were infected as before for two days to maximise the fitness of 
the cells to survive the fixing process with EIAVWYO TCSN.  
 
Unfortunately, the fixation removed all cells from the monolayer (data not 
shown). To try and overcome the cell loss the monocytes were subsequently 
seeded at a higher density (1x106 /ml) whilst allowing three days for infection 
to provide more time for virus to accumulate in the cells. Further to these 
changes, the drying period was removed from the (Section 2.6.3). Three 
fixative methods were used to determine the best one; ethanol, 
paraformaldehyde and, paraformaldehyde with triton X-100. The infection was 
then repeated with cells from horse 2 and Ct values determined again. 
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The cells remaining after fixation produced a largely non-specific stain with all 
cells being coloured faint pink (Figure 4.3). The use of primary cells lends 
variability to each infection because their condition and state depends entirely 
on the condition of the specific horse at the time the blood was taken. This 
would account for the Ct variation between each replicate; but overall the Ct 
results (Table 4.3) follow a similar pattern as the initial Mo and eqMoMϕ 
infection (Table 4.2).  
Table 4.3: Ct values for eqMoMϕ infected with EIAVWYO destined for IPX staining. Cells 
from horse 2 were infected for three days, seeded at 1x10
6
 and the drying period of the 
staining protocol was removed. To maximize the amount of virus only the supernatant from 
two wells was taken daily for RT-PCR. The cells in A1 were fixed with acetone and those in 
B1 were fixed in ethanol. 
Cells VM Day0 Day1 Day2 Day3 Overall change 
A1 25.91 33.19 26.51 21.66 19.25 -13.94 
B1 25.99 33.95 27.71 22.12 20 -13.95 
 
 
 
 
 
Figure 4.3: Picture of Horse 2 eqMoMϕ fixed with paraformaldehyde. eqMoMϕ were 
infected for three days with EIAVWYO before staining for EIAV p26. A, EIAVWYO infected 
cells. B, mock infected cells. 
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The failure of the IPX staining may have been due to cell detachment being 
biased towards infected cells. It is possible that a productive infection is 
orchestrated by a few productively infected cells. If these detach and are lost 
during fixation no virus will be visualised. The infection was repeated with 
cells from horse 2 but the virus inoculum was not washed off in an attempt to 
encourage viral entry into cells increasing the number of infected cells, and 
cells were fixed after two days to try and process them before the cells began 
to die off. This method resulted in far more cells being fixed to the wells 
however the nonspecific staining in all cells remained a problem (Table 4.4; 
Figure 4.4).  
 
Table 4.4: Ct values at day 2 of EIAVWYO infection of macrophages. To maximise the 
virus on the cells no TCSN was removed during the infection, it was only at the point of 
staining that the TCSN was removed and then virus replication measured by RT-PCR. Each 
well shows a similar final Ct value. 
Well A1 A2 A3 A4 B1 B2 B3 B4 
Ct 28.69 28.53 28.58 28.66 28.22 28.56 28.72 28.84 
 
 
 
 
Figure 4.4: Picture of horse 2 eqMoMϕ stained with paraformaldehyde and triton X-
100. Cells were infected with EIAVWYO for two days before fixing with paraformaldehyde 
and triton X-100 after a two day infection. A, EIAVWYO infected cells. B, mock infected 
cells. 
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The failure of the staining is likely due to the virus not being abundant enough 
to detect. An infection was carried out over three passages of virus culture 
each seven days long to try and encourage the virus to replicate in the 
culture. Mo were isolated from fresh horse blood (horse 3) and then seeded 
for passage one and separated into two cryovials for passage two and three 
which were frozen in liquid nitrogen. The inoculum was not washed off and 
the entire volume was transferred to the next passage and made up to 1ml 
using fresh medium (Table 4.5). Interestingly there was little variation within 
the same experiment but between experiments there were high levels of 
variation, likely due to the variation between the cells from each of the 
isolations.  
 
The third passage resulted in a very small number of cells staining darker 
(Figure 4.5A) than their negative counterparts (Figure 4.5B). The stained cells 
appeared to be ‘giant cells’ or syncytia like in structure. These structures were 
very few in number but did not appear to be present in the negatives and so 
may be products of virus infection. However, there were only a few 'giant cells' 
present in the well, which makes it difficult to discount that it could be an 
artefact in the culture. The Ct value of 23.01 is higher than the final Ct of 
previous staining attempts (Table 4.2 & 4.3) so the passage may not have 
been successful in encouraging the virus to replicate in eqMoMϕs to visualise 
Table 4.5: Ct values at end of each passage for macrophages infected with EIAVWYO 
on the day the cells were fixed for staining. Three passages were carried out, each 
lasting seven days. To avoid reducing the virus on the cells no supernatant was removed 
during each passage. Fifty µl was taken at the end of each passage for analysis by RT-PCR. 
Wells P1 END P2 END P3 END 
1 26.72 24.67 23.01 
2 26.69 25.47 22.99 
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Figure 4.5: Picture of horse 3 eqMoMϕ fixed using paraformaldehyde and triton X-
100.  Cells were infected with EIAVWYO for three passages of seven days each. A, 
EIAVWYO infected; B, mock infected. 
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the viral protein in cells. The background staining of each stain was high and 
so would have made it difficult see the virus. 
 
4.2.4 Isolation of British field viruses from macrophages: 
4.2.4.1 Isolation of EIAVDEV: 
With EIAVWYO successfully used to infect eqMoMϕ, attention was shifted to 
isolating a British case. EIAVDEV contained the most virus of the British cases 
according to the pol RT-PCR (Table 3.5, page 85) so was the first British case 
to be used for virus isolation. One hundred mg of spleen tissue was 
homogenized in 1ml of Pirbright solution and 150µl of this homogenate was 
inoculated onto eqMoMϕ from horse 3 and washed off after six hours. An 
infection with EIAVWYO was run in parallel as a comparison. Three replicates 
of each virus (Dev1-3 and Wyo1-3) were carried out over 3 passages of 
seven days each (Figure 4.5). Again cells were isolated and seeded for 
passage one or frozen for use in passage two and three. 
 
The EIAVDEV homogenate gave a Ct value of 23.74. Over the first and second 
passage, EIAVDEV did not show any significant decrease in Ct value until the 
third passage when the Ct of each replicate began to drop. Dev2 (Figure 4.6) 
dropped below the inoculum Ct value suggesting viral replication. The Ct 
value of EIAVWYO dropped by at least 5 Ct in passage 1 and passage 2, again 
showing it is fully capable of replicating in eqMoMϕ. 
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The EIAVDEV infection was repeated using the original tissue homogenate and 
macrophages from horse 1 or 2. However due to the precious nature of EIA 
positive tissues and the low volume of the remaining homogenate, only two 
wells were inoculated, one with 150µl homogenate as before and one with 
50µl homogenate to see if a decreased inoculum would still result in a similar 
level of infection (Figure 4.7). 
 
Unlike the first infection (Figure 4.6) the virus was only detected intermittently. 
There was no pattern between volumes of inoculation or between horses but 
there was a large Ct decrease in both horses in one of the last two passages. 
There were issues with defrosting monocytes from cryostorage. The die off 
Figure 4.6: Replication profile of EIAVWYO and EIAVDEV. Using cells from horse 3, 
three wells were infected with either EIAVDEV or EIAVWYO. TCSN was taken for 3 days 
post infection as well as the start and end of passage 2 and 3. Since supernatant was 
removed each day during the start of passage 1, the whole volume was transferred 
over to passage 2 to maximize the chance of infection. The inoculum for passage 2 
and 3 was made up to 1ml with fresh medium resulting in a slight increase in Ct 
between the end of one passage and the beginning of the next. Passages were 7 
days long. TCSN for the first passage of the second virus replicates was not 
tested.P2S: Passage 2 start, P2E: Passage 2 end, P3S: Passage 3 start, P3E: 
Passage 3 end. 
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varied between wells and horses making comparison problematic, therefore 
Mo were no longer frozen down for passaging after this point but were 
isolated from fresh horse blood when required. 
 
 
4.2.4.2 Isolation of the EIAVNORTH: 
Following the success of detecting isolating EIAVDEV infection in eqMoMϕ an 
asymptomatic case was chosen (EIAVNORTH) to try and isolate in the 
macrophage system. Since EIAVNORTH was asymptomatic and the Ct for the 
virus was lower than the other asymptomatic horses when tested (Ct 31.56; 
Section 3.2.5), 100mg of spleen was homogenized in 1ml of Pirbright solution 
of which 200µl was inoculated onto the cells (from horse 2) to maximise the 
amount of virus on the cells. The homogenate and cells were incubated for six 
hours before washing off the homogenate to avoid the homogenate killing the 
cells. The infection lasted for three passages of four days each. The inoculum 
Figure 4.7: Replication profile of EIAVDEV in macrophages from horse 2 and 3. 
eqMoMϕ from horse 2 or 3 were infected with EIAVDEV for three passages. Due to the 
finite volume and tissue amount, cells were inoculated with 50µl or 150µl of TCSN. 
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produced a Ct of 35.00 and the subsequent cell TCSN from the start of 
passage one to the end of passage three generated no Ct.  
 
It is possible the virus was too dilute to start a productive infection before 
being washed off. Following the attempt to isolate EIAVNORTH an attempt at 
concentrating EIAVNORTH was carried out using 150mg of tissue which was 
homogenized and concentrated using a centrifuge filter. This resulted in a Ct 
reduction from 36.00 (homogenate) to 34.86 (post concentration). A Ct less 
than 30 would more closely match the symptomatic cases.  
 
4.2.5 Effect of macrophage activation on EIAVDEV replication: 
To further refine the culture system and produce cells that better support EIAV 
replication, EIAVDEV was used to investigate the effect of eqMoMϕ activation 
on EIAV replication. eqMoMϕ were further activated by the addition of LPS 
(10ng/ml), porcine IFN-γ (100ng/ml) and dexamethasone (10ug/ml) for M1 
macrophages and, eqIL-4 (10ng/ml) and dexamethasone (10ug/ml) for M2. 
The cytokines were added 18 hours prior to infection. Porcine IFNγ was used 
as it is cross-reactive. TCSN from Dev2 of the EIAV isolation was used to 
infect (Figure 4.5). Dendritic cells were also used and differentiated as 
described (Section 4.1.1). Passage one and three were six days long but due 
to technical problems passage four was reduced to four days. This was 
maintained in the passages for the other two horses for consistency. 
 
The four cell types followed the same replication profile pattern (Figure 4.5A). 
The Ct values at the point of infection for each condition were within 0.87 Ct 
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values of each other after which they were undetectable until day 1 when the 
Ct dropped until day 5 when EIAV was detected in the MoDCs. Following this 
the Ct slowly rose for each cell type, indicating virus loss (Figure 4.8A). This 
infection was subsequently carried out using blood from the remaining two 
horses (using Equine IFNγ). The cells appeared to be of poor morphology 
during the second and third passages, which could be due to the carryover of 
toxic products from the homogenate. To try and reduce this effect, instead of 
transferring the entire well volume between passages, an extra 150ul was 
taken from each well and frozen at the end of the first and second passage. 
The replication profile for horse 2 (Figure 4.8B) and horse 3 (Figure 4.8C) 
were similar to horse 1 with EIAV being detected in all cell types (within 1 
cycle) before being undetectable until days one to five.  
 
The Ct values then decreased over the first passage before stagnating in 
passage two and three. There was a sudden unexplained Ct decrease in M1  
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Figure 4.8: Effect of macrophage activation state on the replication 
profile of EIAVDEV in eqMoMϕ from the three horses. M1, M2, 
inactivated eqMoMϕ or MoDC were infected with EIAVDEV. TCSN was 
taken to measure viral replication by RT-PCR after inoculation of the 
medium (infect), after washing off the inoculum (day 0) and days1,2 and 5 
of the first passage. Due to the volume of TCSN removed the whole 
volume was layered onto the second passage and made up to 1ml. 
Passage one and three was 6 days, passage two was four days. A, horse 
1; B, horse 2; C, horse 3. 
A 
B 
C 
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macrophages from horse 2. Overall M1 macrophages seemed to generate the 
smallest Ct decrease (except in horse 3) and the dendritic cells consistently 
ended with lower Ct values compared to the other cell types but there was a 
lot of variation between the horses and cell types. The activated macrophages 
and DCs did not produce a result as significant as non-activated eqMoMϕ. 
 
4.2.6 Cytokine effects on EIAVWYO replication: 
To reduce the variation in growth profiles of EIAVDEV between infection 
experiments the system was broken down into individual cytokines to 
investigate which if any produced reproducible EIAV infections characterised 
by a stable high level of replication. Rather than looking at defined cells, 
monocytes were stimulated with individual cytokines to see if any generated a 
cell which could efficiently and reproducibly support EIAV replication. Initially 
this was investigated with EIAVWYO. Monocytes were isolated and incubated 
with a cytokine for 18 hours before infecting for five days. Unfortunately due to 
the varying number of monocytes isolated from each isolation round not all 
cytokines could be covered by single Mo isolations and so were covered in 
subsequent Mo isolations (Table 4.6). 
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Table 4.6: Change in Ct associated with infection of Mo stimulated by single 
cytokines. Mo from each of the three horses were stimulated overnight with individual 
cytokines and infected with EIAVWYO TCSN. The table shows the change in Ct value 
between day 0 (after washing off the inoculum) and day 5. Due to variation in the number of 
cells isolated from each horse not all cytokines could be covered by individual Mo isolations.  
ND: Not Done 
 Cytokine Horse 1 Horse 1 Horse 1 Horse 2 Horse 3 
IL-4 (2ng/µl) -12.95 -9.24 -14.26 -10.34 -9.55 
IL-6 (10ng/ml) ND -7.78 -1.53 -11.46 -9.33 
IL-10 (10ng/µl) ND -4.84 -5.84 -7.31 -7.24 
IL-1β (10ng/µl) ND -1.39 -0.53 -2.77 0.22 
LPS (10ng/ml) ND 11.24 -2.95 -1.37 0.18 
IFNγ (100ng/ml) ND -4.27 -3.53 -0.54 -1.84 
TNFα (20ng/µl) ND -0.59 -2.08 -0.74 -0.19 
POLYI:C (2µg/ml) ND -1.79 -3.25 0.08 0.13 
PGE2 (1000ng/ml) ND -7.52 -7.75 -6.04 -1.53 
MCSF (50ng/ml) ND ND  -1.54 -7.9 -2.05 
GMCSF (8x10
4
U/ml) ND -5.17 -3.79 3.61 -3.03 
Serum (10%) ND -10.71 -3.52 -9.8 -0.9 
Dexamethasone (10µg/ml) ND -5.56 -5.56 -4.28 -2.92 
None -9.22 -8.54 ND  -11.22 ND  
 
 
Although there was a lot of variation between cytokines used and between 
replicates of the same cytokine, IL-4 had the most consistent, high Ct value 
change and so was carried forward and tested using EIAVDEV. IL-6 was also 
carried forward since it developed some high Ct value decreases but was not 
as consistent as IL-4. When no cytokine was used, a consistent large drop in 
Ct value was also seen. It was further tested whether increasing the IL-4 
concentration would result in increased virus replication. The concentration 
was increased to 10ng/µl and 200ng/µl. The wash step was also tested using 
the realtime PCR to ensure the removal of virus during the wash step and was 
found to be successfully removing similar levels of virus for each well (Table 
4.8). 
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Increasing the IL-4 concentration did not further improve the result with 
EIAVWYO since the Ct at each time point and the overall Ct change for IL-4 
(2ng/µl, 10ng/µl and 200ng/µl) were all within 1 Ct value. Regarding EIAVDEV, 
IL-6 and the cells with no cytokine did not contain detectable virus on day 0 so 
that a change in Ct could not be precisely calculated but IL-4 seemed to have 
a better effect on EIAVDEV replication considering the starting Ct was within 
0.10 Ct of each other and finished with up to a 6.08 (IL-4 vs IL-6) and 4.92 (IL-
4 vs no cytokine) cycle difference which equates to approximately a 100 fold 
difference (Table 4.7). 
Table 4.7: The Ct values for a five day infection of single cytokine stimulated Mo with 
either EIAVDEV or EIAVWYO. Using cells from horse 1 the effect of increasing the IL-4 
concentration was tested on EIAVWYO, and IL-4 was compared with IL-6 on EIAVDEV 
replication. Cells were infected with virus after incubation with a single or no cytokines. The 
Ct of the medium after inoculation (VM) was measured as was the Ct of the 1ml of medium 
used to wash the cells (wash). 1ml of fresh medium was then placed into each well (day 0) 
and the cells incubated for 5 days. ND: Not detected, #: Because no Ct was detected on day 
0 a Ct difference cannot be calculated.  
Virus Cytokine VM wash Day0 Day5 Change 
EIAVWYO 
IL-4 22.45 27.55 32.26 19.31 -12.95 
IL-4 (x5) 21.75 27.67 32.51 21.15 -11.36 
IL-4 (x100) 21.92 27.47 33.31 21.31 -12 
none 24.26 27.9 30.97 21.75 -9.22 
EIAVDEV 
IL-4 26.33 30.57 32.82 27.35 -5.47 
IL-6 26.38 30.17 ND 33.43 # 
None 26.28 30.12 ND 32.34 # 
 
4.2.7 Detection of viral nucleic acid in IL-4 stimulated monocytes: 
The lack of success with IPX staining for proteins meant another means of 
further demonstrating viral replication was required. Other than protein, the 
detection of viral RNA and proviral DNA within cells would complement the 
data generated for free viral RNA in TCSN and provide further evidence of 
active viral replication. 
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4.2.7.1 Viral RNA staining and flow cytometry 
While the PCR testing has demonstrated the presence of viral RNA a further 
step would be to show the presence of viral RNA within the cells. The staining 
of cells for viral RNA (after fixing in solution) and analysing by flow cytometry 
represents a quantifiable in situ hybridization technique to show that the cells 
are being infected with EIAV. IL-4 stimulated monocytes from horse 1 were 
fixed after a five day infection with EIAVWYO and hybridized with RNA probes 
against EIAVWYO. The probes were then bound to fluorescent probes and the 
cells measured using a flow cytometer. Controls included a positive (targeting 
ribosomal RNA) and two negatives (mock-infected with and without dye 
conjugated probe). Staining of the cells initially resulted in high amounts of 
debris. This indicated that either cells were not surviving the process or debris 
was not being removed during the wash steps. The cell events were too low 
to be able to discern any patterns in fluorescence for the remaining cells. 
 
For the second round, aspiration of waste from the tubes after washing was 
carried out as close to the meniscus as possible to remove debris. Also the 
infection (using cells from horse 1) was reduced to three days to increase the 
cells physiological fitness. A fixable viability dye was also used to assess the 
cells. The viability stain indicated that 75% of cells were viable before fixation 
started. The number of cells analysed ranged from 157 to 1207. The positive 
control indicated 36.45% of 1207 cells infected with EIAVWYO were positive for 
mRNA coding for ribosomal protein RPL12a whereas only 19.08% of 498 
cells of the mock infected were positive. Infected cells stained with the EIAV 
probe were carried out in duplicate and showed 12.64% (451 events) and 
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7.99% (513 events) of the cells were positive. Negative cells stained with the 
EIAV probe showed 5.10% of 157 events were positive. The relative failure of 
the positive control, the similarity of the percentages and the variation 
between the number of events make it difficult to assess the actual amount of 
viral RNA present. A third repeat produced similar results.  
 
A new protocol was used involving multiple RNAse inhibitors (horse 1 cells). 
Again low event numbers were seen but much higher levels of fluorescence 
was present across all samples. 9.87% of infected cells were positive (481 
events) whereas 16.70% of mock infected cells registered as positive (792 
events). This made differentiation of positive and negative cells impossible. 
The protocol was repeated once more using cells from horse 3 but yielded 
similar results indicating the use of a single RNAse inhibitor may be better. 
 
4.2.7.2 Detection of proviral DNA in IL-4 stimulated monocytes: 
A final method of showing viral replication was the detection of proviral DNA in 
cell extractions. Retroviruses replicate through a DNA intermediate which is 
inserted into the host genome. The presence of viral DNA in the cells would 
be a strong indicator of viral replication. Using cells from horse 1, three wells 
were infected with EIAVWYO. After the inoculum was washed off, the TCSN 
was removed and DNA was extracted from the cells after washing the inoclum 
off and on day four and day eight. The pol realtime RT-PCR was then used to 
detect viral RNA in the TCSN. The pol realtime was also used to detect 
proviral DNA in the cells using a no-RT mastermix (Table 4.8). 
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Table 4.8: Detection of proviral DNA in eqMoMϕ. eqMoMϕ were infected with EIAVWYO 
TCSN for eight days. After infection (day 0), on day 4 and day 8, TCSN was tested for free 
virus RNA and DNA was extracted from the cells and tested for proviral DNA. ND: Not 
detected  
Nucleic acid detected 
Days post infection (Ct) 
Day 0 Day 4 Day 8 
Proviral DNA (cells) neg 24.80 20.61 
Free viral RNA 
(TCSN) 
29.98 17.79 15.20 
 
On day 0 (as soon as the inoculum was washed off and fresh media added) 
no proviral DNA was detected. RNA was detected but at a high Ct (29.98). On 
day four proviral DNA was detected in the cells and the free viral RNA had 
dropped from 29.98 to 17.79 (-12.19) equating to a 10,000 fold increase in 
virus. Both RNA and DNA again decreased during the final four days. 
 
4.2.8 Accumulation of mutations in EIAVDEV in differentiated cell: 
EIAVDEV from the end of the third passage on horse 2 eqMoMϕ (Figure 4.6) 
was inoculated into a T25 flask of horse 1 monocytes incubated with IL-4 for 
12 hours (making it passage 5). This was carried over onto another flask of 
horse 1 eqMoMϕ (passage 6). To investigate viral mutation during passaging 
through this cell system RNA was extracted from the second and sixth 
passage and the LTR, gag and env were sequenced. These were then 
compared against the MiSeq data of the original tissue to see if mutations 
were present in the original viral populations or whether they are new 
mutations or mutations from between the passages. The LTR-tat (Dong et al., 
2012) PCR was used to amplify part of the LTR. The three sequences were 
identical, however the LTR-tat PCR covers the U5 region of the LTR only and 
mutations are most likely to occur in the U3 region. Multiple PCRs were 
designed to cover the region but they failed to amplify the region. The gag 
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gene was covered by the same PCRs used to initially sequence the Devon 
case (Section 3.2.3): F3IRE1879, IRER2, and Pol1. The ENV was covered by 
primers designed to cover this region in 5 segments (ENV1-5). The gag 
(Table 4.9) contained six nucleotide changes, three of which were 
synonymous. The two non-synonymous mutations exchanged an acidic 
residue for another acidic residue (E to D; position 102), and a polar residue 
to a non-polar residue (S to G; position 259) but neither mutation occurs in a 
functional motif. Three of the mutations were present as a low level variant in 
the MiSeq data indicating a pre-existing viral variant becoming dominant in 
the cell culture. The remaining three mutations can be seen in one of the 
passage traces indicating a gradual change between the variants. For 
example, at position 247 only a thymine is present in the MiSeq data, then a 
cytosine is present in the passage 2 Sanger trace before becoming dominant 
in passage 6. Similarly at position 259 only an adenine is present in the MiSeq 
data and passage 2 but populations with a guanine at this position are present 
by passage 6. This can also be seen in the three mutations observed in the 
pol fragment (Table 4.9). In two cases a low level variant in the MiSeq data 
becomes dominant by passage 2. In the other mutation (position 1571) A 
thymine is present in the MiSeq data but disappears in passage 2 before 
becoming dominant in passage 6. The mutations present in the pol were all 
synonymous. 
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Table 4.9: The variants present in the gag-pol PCR fragment. EIAVDEV was carried 
through six passages in eqMoMϕ, then the gag was sequenced for the end of passage 2 
and 6 and compared to the original MiSeq data for the tissue. The mutated base is 
highlighted red in the codon. The MiSeq column displays each base that was present at that 
position in the MiSeq data and the number of times it appeared. The position of each 
highlighted nucleotide is in reference to the EIAVDEV genome. 
Gene Position Codon 
Tissue 
(MiSeq) 
Passage 2 Passage 6 
Gag 
102 GAA (E) 
15 A (E) 
8 T(D) 
T (Clear trace) T (Clear trace) 
247 TTG (L) 25 T (L) 
T (C present in 
trace) 
C (Clear trace) 
259 AGT (S) 30 A (S) 
A (G present in 
trace) 
R (A in one trace, G in the 
other) 
268 TTA (L) 30 T (L) T (Clear trace) W (A and T  in trace) 
816 GGC (G) 
25 C (G) 
3 T (G) 
T (Clear trace) T (Clear trace) 
1128 AAG (K) 
16 G 
7 A 
G (Clear trace) A (Clear trace) 
Pol 
1411 AAA (K) 
21 A (K) 
5 G (R) 
G (Clear trace) G (Clear trace) 
1421 CAA (Q) 
19 A (Q) 
5 G (Q) 
G (Clear trace) G (Clear trace) 
1571 GGT (G) 11 T (G) A (Clear trace) T (Clear trace) 
 
The env contained far more mutations then the gag with thirty one in gp90 
(Table 4.10) and eleven in gp45 (Table 4.11). Regarding gp90, ten mutations 
were synonymous and twenty-one were non-synonymous, six of which 
exchanged an amino acid for an amino acid of similar structure or properties. 
Similar to the population analysis of EIAVNEW (section 3.2.8, page 107), the 
majority of mutations were located within a variable region, notably V3 which 
contained twelve mutations. Eight mutations were present in the MiSeq data 
and so present in the original viral population. Sixteen mutations however 
were only present as mixed populations in passage 2. Unfortunately the depth 
of much of the env was low in the MiSeq so the variants may have been 
present in the tissues but not detected. Interestingly there was a deletion 
present in passage 2 but not in passage 6 or the tissue. It was six base pairs 
and so maintained the reading frame. 
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Gp45 on the other hand contained eleven mutations, none of which were 
located in any motifs. Six of the mutations were present in the MiSeq data and 
so the original tissue, but again a higher coverage depth would be needed to 
confirm. 
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Table 4.10: The variants present in gp90. EIAVDEV was carried through six passages in 
eqMoMϕ, then gp90 was sequenced for the end of passage 2 and 6 and compared to the 
original MiSeq data for the tissue. The mutated base is highlighted red in the codon. The 
MiSeq column displays each base that was present at that position in the MiSeq data and 
the number of times it appeared.The column V? shows which variable region (if any) the 
mutation is located in. N, None; GLY, glycosylation site. The NA position is in reference to 
the EIAVDEV genome. 
Position Codon 
Tissue 
(MiSeq) 
Passage 2 Passage 6 V? 
26 TTT (F) 
23 T (F) 
17C (F) 
T (Clear trace) C (Clear trace) N 
36 ATC (I) 
32 A (I) 
10 G (V) 
A (Clear trace) G (Clear trace) N 
297 CTA (L) 
26 C (L) 
14 T (L) 
1 A (N) 
T (Clear trace) C (Clear trace) N 
327 ATA (I)  
17 G (I) 
5 A (I) 
R (G and A in trace) A (Clear trace) N 
499 GAG (E) 31 G (E) R (A and G in trace) G (Clear trace) N 
584 TTA (L) 
20 A (L) 
1 G (L) 
R (A and G in trace) G (Clear trace) V3 
588 TTA (L) 15 T (L) W (A and T in trace) T (Clear trace) V3 
589 TTA (L) 15 T (L) Y (C and T in trace) T (Clear trace) V3 
590 TTA (L) 15 A (L) W (A and T in trace) A (Clear trace) V3 
591 GAT (D) 15 G (D) K (G and T in trace) G (Clear trace) V3 
594 TCG (S) 
14 T (S) 
1 C (P) 
W (A and T in trace) T (Clear trace) V3 
596 TCG (S) 22 G (S) K (G and T in trace) G (Clear trace) V3 
597 AAC (N) 
13 A (N) 
9 G (D) 
W (A and T in trace) A (Clear trace) V3 
601 GGA (G) 22 G (G) R (A and G in trace) G (Clear trace) V3 
612 AAG (K) 
15 A (K) 
6 G (E) 
M (A and C in trace) A (Clear trace) V3 
626 AAG (K) 19 G (K) R (A and G in trace) G (Clear trace) V3 
632 TCT (S) 20 T (S) K (G and T in trace) T (Clear trace) V3 
731 GAC (D) 
11 C (D) 
4 T (D) 
Y (C and T in trace) C (Clear trace) V4 
857 TCG (S)  
12 G (S) 
1 A (S) 
S (C and G in trace) G (Clear trace) V5 
932 GAT (D) 4 T (D) C (T present in trace) T (Clear trace) N 
952 GAT (D) 6 A (D) R (A and G in trace) A (Clear trace) V6 
958 GAA (E) 
7 A (E) 
1 G (G) 
R (A and G in trace) A (Clear trace) V6 
962 AAA (K) 8 A (K) C (A present in trace) A (Clear trace) V6 
966 TCA (S) 9 T (S) G (Clear trace) T (Clear trace) V6 
976 AGG (R) 9 G (R) A (G present in trace) G (Clear trace) V6 
988 GAA (E) 
18 A (E) 
1 C (A) 
C (A present in trace) A (Clear trace) V6 
1069 TCC (S) 9 C (S) C (Clear trace) T (Clear trace) GLY 
1132-
1138 
Indel 
AAATAA (6 
depth) 
Deletion (Clear trace) AAATAA (Clear trace) V7 
1143 AAT (N) 3 A (N) G (A present in trace) A (Clear trace) V7 
1155 GCT (A) 3 G (A) G (Clear trace) A (Clear trace) V7 
1156 GCT (A) 3 C (A) C (Clear trace) A (Clear trace) V7 
1246 CGA (R) 5 G (R) R (A and G in trace) G (Clear trace) N 
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Table 4.11: The variants present in gp45. EIAVDEV was carried through 
six passages in eqMoMϕ, then gp45 was sequenced for the end of passage 
2 and 6 and compared to the original MiSeq data for the tissue. The 
mutated base is highlighted red in the codon. The MiSeq column displays 
each base that was present at that position in the MiSeq data and the 
number of times it appeared. The NA position is in reference to the EIAVDEV 
genome. 
Position Codon Tissue 
(MiSeq) 
Passage 2 Passage 6 
1538 AAA (K) 11 A (K) R (A and G in trace) A (Clear trace) 
1598 AAA (K) 19 A (K) 
7 G (K) 
R (A and G in trace) A (Clear trace) 
1619 GAG (E) 19 G (E) 
11 A (E) 
R (A and G in trace) G (Clear trace) 
1769 ACG (T) 26 G (T) A (Clear trace) G (Clear trace) 
2022 AAA (K) 24 A (K) R (A and G in trace) A (Clear trace) 
2118 AGA (R) 15 A (R) 
5 G (G) 
R (A and G in trace) A (Clear trace) 
2200 AAA (K) 17 A (K) 
12 C (T) 
C (A present in trace) A (Clear trace) 
2219 GGA (G) 19 A (G) 
15 G (G) 
R (A and G in trace) A (Clear trace) 
2283 AAG (R) 27 A (R) 
1 G (E) 
A (G present in trace) G (Clear trace) 
2288 AAG (K) 25 G (K) 
1 T (N) 
G (Clear trace) A (Clear trace) 
2375 AAG (K) 15 G (K) 
13 A (K) 
1 T (N) 
G (Clear trace) G (Clear trace) 
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4.3 Discussion: 
4.3.1 EIAV replication in EDerm cells: 
The infection protocol was first tested using EIAVWYO and Ederm cells since 
EIAVWYO replicates in Ederm cells (Malmquist et al., 1973). Virus replication 
was measured by the pol realtime RT-PCR and showed a gradual decrease in 
Ct value. The majority of replication (largest drop in Ct value) took place 
between days 2 and 36, after which the Ct value did not change substantially 
and the cells began to die off. It is possible that the culture could have been 
maintained by seeding in fresh Ederm cells and replacing part of the media at 
regular intervals to prevent build of toxic products or large pH fluctuations. 
Setting up of the system was problematic because the cells ordered from the 
CTC (APHA, Weybridge) were of a single batch and would proliferate for a 
approximately three days before stagnating and dying off. Different growing 
conditions were tried but ultimately failed. Cells were then sourced from the 
ECACC (PHE, Salisbury) and grew well in supplemented DMEM. By this point 
however the macrophage system had been set up so attention was focused 
on to the macrophages as they are the cells infected in vivo and the main aim 
of this project. 
 
4.3.2 EIAV replication in myeloid cells: 
The development of eqMoMϕ and MoDC differentiation (Section 4.2.1); and 
activation systems (Section 4.2.5), and the use of individual cytokines 
(Section 4.2.6) were based on previous work with porcine monocytes, 
macrophages and dendritic cells and their interaction with PRRSV (Singleton, 
2013). Cytokines and their function are similar across mammals (Pederson et 
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al., 2002). Since in depth work with equine cells has yet to be carried out the 
porcine systems were used as templates.  
 
Initially eqMoMϕ and MoDC were differentiated by titrating the appropriate 
cytokine on Mo and incubating them together for 72 hours. Differentiation was 
confirmed by morphological characteristics such as expansion and 
granulation for eqMoMϕ; and clustering and dendrite formation for MoDC. The 
Mϕ and DC populations within a horse are not homogenous, and it is not 
known if EIAV infects specific subsets of Mϕ or Mϕ in general since no 
phenotypic characterisation of Mϕ infected in vivo has been carried out. This 
system was used as an initial starting point to set up an EIAV replication 
system. Phenotypic characterisation of the eqMoMϕ and MoDC was not 
carried out because the aim was to generate a cell capable of supporting 
EIAV replication. Characterisation of the cells could be carried out once a 
suitable system has been set up for comparison with other cells which do not 
support EIAV replication as well. EIAVWYO proved capable of replicating in the 
eqMoMϕ, with each infection producing a significant change in Ct value 
between -10.22 and -13.88 in three days.    
 
Since EIAVWYO seemed to be successfully infecting the eqMoMϕ the system 
was used with EIAVDEV because the tissues had the highest viral load of the 
other British cases (Table 3.4). The infection was expanded to three passages 
of seven days to maximise the amount of virus present in the cells. However, 
the eqMoMϕ start to die off after five days so the virus had to be passaged 
onto new cells. There was a clear distinction between the growth profiles of 
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EIAVWYO and EIAVDEV. EIAVWYO showed a clear drop in Ct value over the first 
and second passage and to a lesser extent in the third passage. EIAVDEV on 
the other hand showed no Ct value drop until during the third passage. To test 
reproducibility, eqMoMϕ from the remaining two horses were infected with 
EIAVDEV. The replication profile showed a similar pattern but viral replication 
mostly occurred during the second passage. This overall finding was 
surprising because EIAVWYO is fibroblast adapted and so was not expected to 
replicate as efficiently in eqMoMϕ as EIAVDEV but this was not the case. 
However, as mentioned earlier (Section 3.3.8), the lack of a method to 
absolutely quantify the virus means it is likely that there is more virus present 
in the EIAVWYO TCSN then in the EIAVDEV homogenate. The development of a 
realtime PCR with known primers would allow better understanding of its 
efficiency.  
 
The successful isolation of EIAVDEV prompted a test of the eqMoMϕ system 
using an asymptomatic case, EIAVNORTH. To compensate for the lower viral 
load of the tissue the inoculum volume was increased but no virus was 
detected after the inoculum was washed off the cells. It is likely there is not 
enough virus to start a productive infection and probably overcome the toxicity 
of the tissue homogenate. Only small amounts of tissue were taken during the 
post mortem of each horse preventing high numbers of isolation attempts. To 
see if it was possible to concentrate EIAVNORTH to produce a Ct value similar 
to that of the symptomatic cases an extra 50mg was homogenized in 5ml and 
concentrated down to 1ml. This lowered the Ct value by 1.14 Ct values (>2 
fold increase) but a higher concentration is likely required to start a productive 
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infection. Isolations with EIAVNORTH were not commenced until a more suitable 
cell system was in place.  
 
To try and refine the system for optimized replication, eqMoMϕ with different 
activation states were infected. The classical Mϕ activation states of M1 and 
M2 were used and were stimulated according to Singleton (2013). MoDC 
were also used since they are of the Mo lineage and are likely to support 
EIAV replication. This was carried out in cells from three horses and unlike the 
first eqMoMϕ infection; most of the replication seemed to occur in the first 
passage before stagnating in the second passage. The third passage even 
showed an increase in Ct value indicating a loss of virus. The M2 Mϕ were 
most consistent in the three horse’s cells at producing the lowest Ct value, as 
were the dendritic cells. However, there was still variation in the other cell 
types and the dendritic cells were not always detected implying a lack of viral 
replication. Although the virus appears to be replicating in each cell type, the 
growth profile varied. Regarding the unstimulated eqMoMϕ infections the 
majority of replication occurred during the third passage. When horse two and 
three were used replication was best in the second passage. Then when 
TCSN was taken from this infection and used to infect unstimulated eqMoMϕ 
from all three horses replication was good in the first passage. Whilst it is 
possible this variation is due to viral adaption it would be expected that a virus 
of increased fitness would replicate well in all three passages rather than the 
first only. However, from a lentiviral standpoint it is possible that increased 
fitness results in a virus more able to conceal itself by integrating and not 
replicating until the cell begins to die or some other trigger. Alternatively the 
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variation could be caused by the use of primary cells. There were no patterns 
between successful experiments and which horse’s cells were used. Other 
laboratories have found a large variation in the cells taken from different 
horses and from the same horse at different times, this, with the need for a 
system that requires less maintenance has driven a need for a eqMoMϕ cell 
line (Nakajima & Sugiura, 1994; Werners et al., 2004), but this has yet to be 
become available. 
 
Overall there was not a significant difference in the virus replication in Mo, 
eqMoMϕ of various activation states or MoDC. The lowest Ct achieved was 
always around twenty five in each experiment, although this was achieved in 
different passages. To further evaluate the cell culture system, the effect of 
individual cytokines on the ability of monocytes to support EIAVWYO replication 
was investigated. Each cytokine was tested in each horse. Mo isolations 
yielded varying numbers of cells, independent of the horse, requiring multiple 
Mo isolations in order to cover all the desired cytokines. As mentioned 
previously, this variation is expected in primary cells and is likely a cause of 
the variation in viral replication seen in the previous experiments, so cytokines 
that consistently caused a significant Ct value drop were sought. The 
unstimulated Mo produced a larger, more consistent Ct drop than the majority 
of cytokines tested indicating a suppressive effect, especially with IL-1β, TNFα 
and poly I:C. The only cytokine to consistently have a positive effect on 
replication was IL-4. IL-6 and serum also caused significant Ct drops, but only 
in one or two of the different horse’s cells. The effect of IL-4 was then tested 
on EIAVDEV. Although it produced a better effect than IL-6 or with no cytokine, 
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the effect was not as great as with EIAVWYO. It seems that as well as being 
able to replicate well in fibroblasts, EIAVWYO is generally better able to 
replicate than other EIAV field strains. The original EIAVWYO was highly 
virulent in vivo (Malmquist et al., 1973) and so it is possible that its adaption to 
cell culture reduced its virulence in vivo but not necessarily its ability to 
replicate in equine Mϕ (Carpenter & Chesebro, 1989). Its ease of use and 
ability to replicate well in a variety of cell types are what made it attractive to 
work with over other clinical cases which are difficult to isolate and initially 
grow, as seen with EIAVDEV. This would be interesting to test with EIAVNEW, 
which is highly virulent compared to the other British cases (Discussed in 
section 3.3.2). 
 
4.3.3 Detection of EIAV replication: 
The pol realtime RT-PCR was used to monitor the viral load in all 
experiments. This was done by comparing the Ct value of the TCSN after 
washing off the inoculum and adding fresh medium and the various time 
points. If a drop in the Ct value between the two time points occurred the viral 
RNA had increased suggesting viral replication. This could be seen clearly in 
each case with EIAVWYO and most cases with EIAVDEV. However for actual 
proof, a further method is required to independently verify the presence of 
viral replication.  
 
To provide further confirmation of viral replication, IPX staining for p26 was 
used to show the presence of viral proteins within the cells. The majority of 
previous experiments utilising antibodies against EIAV were carried out by 
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laboratories with access to an infected horse, able to isolate polyclonal 
antibodies (Leroux et al., 2001; Schiffer-Evans et al., 1984). Since the culture 
system is meant to be easily accessible and reproducible, commercially 
available antibodies were used. Four attempts at staining were made which all 
failed to definitively stain EIAV proteins. The final stain resulted in large dark 
stained cells which could be the result of virus infection but could also be 
artefacts of cell culture. The high background and lack of specific staining 
could be due to a lack of virus in the cells or a bias of infected cells dying off. 
There is little data on the extent of EIAV infection in cell culture. It is possible 
that the replication seen with the RT-PCR is the product of a small number of 
infected cells, in which case the results seen by the IPX stain could be 
accurate. Maury (1994) infected eqMoMϕ and found that 95% of the cell 
culture was positive (using the same antibody) after twelve days of infection. 
With very little information on the kinetics of EIAV infection it is difficult to 
estimate what the percentage of cells infected on day seven would be, but it 
may be that the number of inserted proviruses increases the longer the 
infection, so it may be that few cells were infected by seven days. Other 
laboratories which use eqMoMϕ have used much higher serum 
concentrations in their media (up to 50%), seeded the cells at much higher 
densities and used bovine serum in preference to horse serum (Nakajima & 
Sugiura, 1994; Maury, 1994; Carpenter & Chesebro, 1989). These alterations 
could yield more longevity from the eqMoMϕ, resulting in better virus 
detection. Alternatively methods of artificially concentrating protein within the 
cell could be used such as brefeldin A or monensin. Methods of protein 
detection other than IPX staining could be used but their success would be 
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questionable. The use of alkaline phosphatase instead of horseradish 
peroxidase would result in a high background due to the macrophages own 
esterases. Alternatively the use of fluorescently tagged antibodies could be 
used but the low number of fixed cells and possible bias of cell detachment 
mean methods that require cell fixation to a plate may not be suitable. RT 
assays have been used previously but they have been found to not be as 
sensitive as IPX staining (Maury, 1994). 
 
As the IPX staining did not reliably detect virus, an RNA in situ hybridization 
kit was used to detect EIAVWYO viral RNA. Unfortunately the number of cells 
remaining in each sample was very low. The kit is not optimised for eqMoMϕ 
or the equine system considering the majority of cells are lost. The kit 
specifies that only physiologically fit cells can be used so the infection time 
was reduced to increase the fitness of the cells and increase the number of 
cells in the final count, but this proved insufficient to significantly raise the final 
cell count. A viability dye was also included and showed the majority of cells 
were alive at the point of fixing. This could indicate that it is the fixation 
process destroying the cells. Since the dye only stains dead cells, if the dye 
also failed it would seem as if the majority of cells were viable. Five attempts 
were made in total, three of which yielded little staining (including the positive 
controls) and two yielded high levels of background staining (including the 
negative controls). In each case though the positive control did stain a number 
of cells and the virus stain stained more cells than the negative control, 
suggesting the presence of viral RNA presence in these cells. Whilst the 
staining was not perfect it did indicate virus infection, and as mentioned 
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before, with little knowledge on which proportion of cells are infected at five 
days it is possible the small number of infected cells seen are the only 
infected cells. If the cells could be kept longer to allow a higher proportion of 
cells to become infected it is possible a much higher number of infected cells 
would be seen in the stain. 
 
Lentiviruses replicate through the integration of proviral DNA into their host. 
As a final method for showing replication of EIAVWYO, the presence of proviral 
DNA was analysed in infected eqMoMϕ. Prior to extraction, the cell surface 
was washed to remove free virus to prevent its interference and a PCR 
mastermix lacking a RT was used to ensure only DNA was detected. After 
infection of the cells one well was immediately extracted to ensure there was 
no carryover of proviral DNA in the inoculum (no DNA is packaged into EIAV 
virions). No provirus was detected confirming specificity of the PCR and 
showing that the inoculum contained no proviral DNA. The proviral DNA was 
then detected at four and eight days post infection (24.80 and 20.61 
respectively). The drop between day four and eight suggests viral replication 
since no DNA was present in the starting inoculum the only method of 
producing it is through the entry and integration of virus into cells. 
Superinfection is rare in lentiviruses with cells becoming refractory to further 
infection once successfully infected by a virus (Maury et al., 2003). Viral RNA 
was also detected in the TCSN with a high Ct after washing (29.98) and then 
significantly lower at four and eight days (17.79 and 15.20 respectively). Being 
a lentivirus, for RNA genomes to be produced an integrated proviral 
intermediate is required. Thus the increase in viral RNA should be a marker of 
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viral replication. Increasing the duration of the DNA integration investigation 
would also be useful in assessing if there is an initial increase in provirus 
levels followed by either continued increases or a plateau. This would show 
whether the free virus in the TCSN is a product of a pool of cells infected early 
on, or due to a gradual spread of infection through the cells. Ideally the 
proviral DNA detection would need to be repeated but due to time constraints 
this was not possible. 
 
Together, significant increases in viral RNA, the presence of viral RNA in cells 
and the production of proviral DNA after infection show viral replication. 
Although it would have been ideal to show evidence of protein synthesis the 
lack of available antibodies and problems with cell culture made it difficult. 
The methods focused on the detection of viral nucleic acid. The pol RT-PCR 
was used to show consistent increases in viral RNA in the TCSN for both 
EIAVWYO and EIAVDEV, and also showed an increase in the presence of 
proviral DNA within the cells for EIAVWYO. The drop in Ct of 12 cycles equates 
to approximately a 10000-fold increase which is likely due to active virus 
replication. Also, the inability to detect EIAVNORTH after initial inoculation 
shows that if the virus is not able to start a productive infection the virus 
doesn’t persist in the cell culture at detectable levels and the virions may just 
break down. The gradual increase of both proviral DNA in the cells and 
proviral DNA within the cells also strongly implies viral replication. 
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4.3.4 EIAV isolation from British cases: 
To isolate EIAVDEV, spleen tissue was homogenised and layered onto 
eqMoMϕ. Replication was detected by PCR and the supernatant, when 
layered onto other cells caused infection. This was also attempted with 
EIAVNORTH but no virus was detected after inoculation. This could be a 
combination of either not enough virus and/or the presence of toxic products 
from the homogenate inhibiting the start of a productive infection. To 
overcome the low level of virus, attempts to concentrate the virus using 
centrifuge filters only reduced the Ct value by 1.14 compared to the 
homogenate and 0.14 when compared to the first EIAVNORTH homogenate. To 
try and further reduce the Ct to that of a symptomatic case it may be 
necessary to homogenize a larger section of tissue in a high volume of 
solution. This may have a better effect when concentrated to a small volume 
rather than reducing a relatively small volume to a small volume (for example 
5ml to 200µl rather than 1ml to 200µl). The small amount of tissue taken from 
each horse limits the amount of isolation attempt repeats so the isolation was 
not attempted again on the eqMoMϕ, but now a system has been developed 
with IL-4, these cells could be used to try and isolate EIAVNORTH. Also with the 
foundations for a cell system in place, isolation of the other asymptomatic 
cases could be attempted:  the first candidate would be EIAVWILT2 as this had 
a relatively low Ct compared to the other asymptomatic cases. Asymptomatic 
viruses are more difficult to isolate than symptomatic viruses (Langemeier et 
al., 1996), whether this is because the immune system is better at 
suppressing them or due to them not replicating as efficiently is unknown. If it 
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is the latter, isolation will be more difficult since a higher starting virus titre will 
be needed compared to the symptomatic viruses. 
 
4.3.5 Adaption of EIAV in cell culture: 
To investigate the adaption of EIAVDEV in the new cell culture system it was 
passaged four times through eqMoMϕ and twice through IL-4 stimulated Mo, 
making a total of six passages. PCR was used to amplify the LTR(U5), gag 
and env. The LTR was identical but considering the functional motifs are 
mostly in the U3 region it would have been interesting to amplify this region. 
Primers designed to amplify both the 5’ and 3’ LTR were designed but none 
amplified product. The gag PCRs (GAGbold, R2 and POL1) and env PCRs 
(DevENV1- DevENV5) did amplify products for sequencing. The gag 
contained six mutations, three of which were present in the tissue. The 
majority of mutations were present in the env, or more specifically gp90. Thirty 
one mutations were present in gp90 the majority of which were non-
synonymous. Without the immune system suppressing some viral populations 
it is expected that a large number of populations would be able to replicate in 
tissue culture. It is likely that rather than the env dictating the successful viral 
populations it is the LTR, considering it contains the promotor region. The cell 
system more closely mirrors the in vivo environment than Ederm cells, so 
although the cells should not cause the virus to adapt, pressures that would 
be present in vivo are absent in the system and so the virus may still evolve in 
ways not necessarily seen in vivo. Most mutations occurred in the designated 
variable regions. The majority of the mutations detected were in passage 2, 
however they were neither present in passage 1 or passage 6. This could 
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indicate that the mutations arose within the first two passages before being 
lost by the sixth passage. Unfortunately the MiSeq coverage in many areas of 
the env is very low. This low coverage makes it likely that even significant 
variants in the tissue may have been missed. To confirm that the mutations 
seen in the passages are definitely not present in the original tissue a greater 
depth of coverage would have to be achieved. For a variant within an 
amplicon to be detected by Sanger sequencing the prevalence needs to 
exceed 20% (Zagordi et al., 2010). This is a high prevalence to achieve by the 
second passage, thus it seems likely that these variants are present in the 
original tissue, but the depth of coverage is insufficient to detect them. To 
confirm whether mutations present were generated in the cell culture system 
or were already present as a minor population a greater depth NGS run is 
needed. Also to better confirm the presence of variants in later passages the 
use of NGS could be used. The high level of virus and low level of tissue 
nucleic acids relative to the original tissue would probably result in a higher 
depth of coverage of the virus. 
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5.0 General Discussion: 
5.1 Detection and sequencing of EIAV: 
Currently detection of EIAV relies on either mandatory testing at events or 
border crossings, for example due to suspicious paperwork or the horse 
displaying symptoms. The proportion of horses that are exposed to mandatory 
testing is small since these horses are usually high value competition horses. 
The remaining less mobile horses are by far more numerous and can go their 
whole life without being tested for EIAV (Leroux et al., 2004). In the USA, 
many cases were discovered due to the testing of horses on properties for the 
first time due to the sale of the property (Issel et al., 2013). Indeed, since the 
advent of the Coggins AGIDT in 1970 (Cook et al., 2013) the disease burden 
of EIAV was perceived to be falling worldwide. As the incidence of EIAV falls, 
small numbers of false negatives become more dangerous. The AGIDT is a 
subjective test with low sensitivity (Issel et al., 2013) leading to 
recommendations to increase the sensitivity of EIAV testing by including an 
ELISA and immunoblot in a three-tiered diagnostic system (Scicluna et al., 
2013). A highly sensitive diagnostic approach is important due to the lack of a 
vaccine, meaning that control and eradication is reliant on the euthanasia or 
lifelong quarantine of infected animals. A vaccine against EIAV has been used 
previously with success in China in the 1970s, but it was live attenuated, 
which is problematic as vaccinated animals would test positive on the AGIDT, 
heterologous protection is poor (Craigo et al., 2007; Craigo et al., 2013) and 
the vaccine strain continues to vary and mutate in the host, altering protection 
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(Craigo et al., 2010). Previous work has investigated the possibility of an 
inactivated or subunit vaccine but was not promising (Issel et al., 1992). Either 
way the serological nature of the diagnostic tests makes distinguishing 
between a naturally infected animal and a vaccinated animal impossible 
without a DIVA vaccine (differentiation of infected and vaccinated animals). A 
molecular method would overcome all of the problems associated with 
antibody detection as well as being cheaper, faster and easier to perform and 
interpret.  
 
The inclusion of the three British EIAV genomes adds three new phylogenetic 
groups to the full genome sequence phylogenetic tree (Figure 3.2 page 90). 
This brings the total number of field strain full genomes to ten sequences 
across six phylogenetic groups (four are Irish sequences from the 2006 
outbreak). Each new sequence has shown a similar nucleic acid divergence 
of ~30% from each of the other sequences indicating a maximum level of 
divergence, but, the addition of each new sequence has reduced conserved 
regions in an alignment. Alignments of EIAVWYO and EIAVLIA contain 
conserved regions that are disrupted by EIAVMIYA and EIAVIRE. Conserved 
regions of these sequences are again disrupted by the inclusion of EIAVDEV, 
EIAVCOR and EIAVNEW. Even though a successful PCR only requires two 
conserved areas in reasonably proximity, the asymptomatic British cases may 
belong to different groups and so may introduce more variation. The design of 
a reliable molecular detection method requires further full genomes since 
EIAV may vary to an extent that multiple PCRs are required to cover all 
groups, but this needs to be confirmed with further sequencing.   
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The full genomes EIAVIRE and EIAVMIYA were sequenced by primer walking 
using PCRs developed from alignments of existing viruses (Quinlivan et al., 
2013; Dong et al., 2013). This approach was attempted in this work with 
EIAVDEV but only the gag and pol could be covered by this method. NGS was 
used with greater success but was unable to generate the sequences for the 
asymptomatic cases, although reads from EIAVWILT2 were used as a base to 
design PCR primers. Thus a combination of PCR/Sanger sequencing and 
NGS is likely to be the best method for the asymptomatic cases until a better 
sequencing or culture method that is capable of isolating asymptomatic 
viruses is developed. The asymptomatic British cases would be interesting as 
they may be unrelated to the other EIAVs and so would add to the EIAV FGS 
alignment. Also sequencing of the asymptomatic cases would allow the 
search for common motifs in the asymptomatic sequences that may confer 
this phenotype. Work has already mapped virulence determinants to the 
LTR(U3), gp90 and S2 (Payne & Fuller, 2010) and much work has been 
carried out with low virulence relatives of EIAVWYO (Zheng et al., 2000; 
Rwambo et al., 1990; Liang et al., 2006), but the presence of motifs and 
experiments utilizing asymptomatic field viruses has yet to be carried out. 
 
5.2 Culture of EIAV: 
Previous research into EIAV has utilized a variety of cells and viruses. 
Methods of isolating and using equine leukocytes which contain the cells 
naturally infected by EIAV have existed since the 1960s (Kobayashi & Kono, 
1966), but due to the laborious and technical nature of the isolation, 
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maintenance and infection, alternatives were sought in a number of cell lines. 
Similarly the virulent EIAVWYO was isolated in 1941 (Kobayashi & Kono, 1966) 
and found to easily infect a variety of cell types, adapting after five passages 
(Carpenter & Chesebro, 1989).  The continued use of EIAVWYO is due to a 
combination of a small research community and a lack of other isolated 
viruses to use. Even when adapted EIAVWYO is able to replicate well on both 
Mϕ and fibroblasts (Carpenter & Chesebro, 1989) indicating the presence of a 
number of populations able to replicate in the different cell types. Whilst other 
field viruses have been used, their origin is not always clear (Carpenter & 
Chesebro, 1989; Moore et al., 1970; Carpenter et al., 1987) and 
asymptomatic or avirulent viruses are usually the result of attenuation of 
virulent strains using cell culture or genetic engineering (Rwambo et al., 1990; 
Zheng et al., 2000). This led to the majority of EIAV knowledge being based 
on experiments utilizing fibroblast cell lines and EIAVWYO or one of its many 
derivatives and thus methods of culturing EIAV are ideally suited to viruses 
that replicate well in cell culture (Maury, 1994; Raabe et al., 1997). This has 
provided a lot of information regarding EIAV replication and genetics however 
adaption of the virus in tissue culture has led to concern about the true 
understanding of in vivo EIAV behavior (Carpenter & Chesebro, 1989; Maury 
et al., 2005; Craigo et al., 2013). So here, in order to develop a cell system 
capable of reproducibly supporting efficient EIAV replication, equine Mo were 
differentiated into eqMoMϕ. The system was tested with EIAVWYO and then 
EIAVDEV was successfully isolated. However the EIAVNORTH asymptomatic 
case could not be isolated. Asymptomatic viruses have proved difficult to 
isolate compared to their symptomatic relatives (Leroux et al., 2001; 
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Carpenter & Chesebro, 1989) so an improved system is needed to 
successfully isolate the asymptomatic British strains. Also EIAVDEV replicated 
to a lower level than EIAVWYO in the traditional eqMoMϕ and there was 
variation in the level of viral replication and survivability of cells. Thus a more 
reproducible system was sought so the effect of individual cytokines was 
explored and IL-4 was found to consistently induce a significant Ct drop. 
Unfortunately, there was not enough time to test the system with the 
asymptomatic cases for inclusion in this thesis. 
 
As mentioned previously (Section 3.3.2), mild EIAV symptoms are non-
specific and may actually be caused by another infecting agent. These other 
infecting agents could be present in the post mortem tissues and co-isolated 
with EIAV, and may also be present in the monocytes from the donor horse. 
When attempting to isolate EIAV from homogenized tissue it is possible a 
hitchhiking micro-organism could also grow in the cell culture. For example, 
equine herpesviruses (EHV) 1, 2 and 4 were found to latently infect high 
numbers of donor horses and be isolated from leukocytes. Although a slow 
replicating virus, EHV is capable of causing cytopathic effects in leukocyte 
cultures after approximately a week in culture, but the use of autologous heat 
treated serum inhibits their growth negating their impact (Kemeny & Pearson, 
1970; Kono & Kobayashi, 1964; Nakajim & Sugiura, 1994). An added 
advantage of carrying out NGS on the horse post-mortem tissues is the ability 
to identify other viruses that may be present, and so identify possible 
contaminants. This was done briefly with EIAVDEV and 142096 reads mapped 
to Theileria equi genes (AY534882 & JQ390047) corroborating the 
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epidemiology report (DEFRA, 2011) and 96 reads mapped against a EHV-2 
genome (NC_001650) indicating its presence. The variation in the eqMoMϕ 
cultures here and their relatively short lived nature is more likely due to the 
donor horses and culture conditions than contaminants since the eqMoMϕ 
survived for similarly short periods regardless of which donor horse was used 
and whether the cells were infected or not. Many previous experiments 
utilized leukocytes for several weeks without total loss of the monolayer by 
using high serum concentrations and seeding densities (Raabe et al., 1997; 
Kobayashi & Kono, 1966; Maury, 1994). Regarding the donor horses, there is 
no connection between a horse’s age or its haematology and the quality of 
leukocytes isolated from the horse (Kobayashi & Kono, 1966). The variation 
between horses and over time from the same horse can make cell isolations 
unpredictable with variation between cells becoming more apparent over 
longer culture periods (Kobayashi & Kono, 1966; Werners et al., 2003). Thus 
a method that is reproducible independent of the horse used for cells is 
important, a cell line capable of supporting EIAV replication without causing 
adaption would overcome the need to isolate and differentiate primary cells. 
 
5.3 Future perspectives: 
The whole procedure of sequencing consists of four broad stages; sample 
selection, nucleic acid extraction, sequencing and data analysis/ 
bioinformatics. The improving of one or all of these steps is critical to 
improving the ability to sequence EIAV from clinical samples. The sequencing 
success of EIAVNEW (Ct 27.34, RNA 90.6ng/µl) compared to EIAVDEV (Ct 
23.84, RNA 327.3 ng/µl) and EIAVCOR (Ct 25.10, RNA 826.7 ng/µl); and 
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relative failure of EIAVWILT2 (Spleen: Ct 26.72, RNA 566.5 ng/µl; Serum: Ct 
27.43, RNA 69.9 ng/µl) and EIAVNORTH (Ct 31.56, RNA 72.3 ng/µl) presents 
an array of questions. Why was there such disparity between the results of 
EIAVNEW and EIAVWILT2 serum when the Ct value and RNA content were 
similar? As mentioned previously (Section 3.3.2, Page 115), the serum may 
have provided an advantage over spleen when the Ct values were similar but 
total RNA was much higher. This may account for the differences between 
EIAVDEV, EIAVCOR and EIAVNEW. However this method is reliant on the 
commercial real time RT-PCR kit for viral quantification, which was used due 
to a lack of other quantitative PCR, but since the primers are unknown it is 
possible primer mismatches may have reduced the sensitivity of the PCR 
increasing the Ct of samples with high abundance. An alternative realtime 
PCR would need to be developed to more accurately quantify the virus in 
extracts. The sequencing of the other British EIAV genomes would provide 
better insight into where to design primers in the EIAV genome. A more 
accurate detection method would also allow for a more in depth assessment 
of the different tissues. A major limitation of this work has been the small 
amount of tissue taken from each tissue of the British horses. This is 
problematic when viral compartmentalisation of the virus may occur in the 
host which may restrict combining sequences from different tissues to create 
a consensus. However, the other tissues of the symptomatic cases may 
provide an opportunity since they are likely to contain lower levels of virus 
than the spleen (Harrold et al., 2010). They may contain similar levels to the 
spleen of asymptomatic cases and so could be used to test sequencing 
strategies without using the tissues of interest. This would however be 
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restricted to tissues of similar structure since extractions and enrichments of 
the spleen may differ to, for example, those from an eye. 
 
The type of sample selected impacts upon the method used to extract the 
viral nucleic acid, for example, between tissues and body fluids. The lack of 
tissues from the Newmarket case and serum from the Devon or Cornish 
cases necessitated the use of different extraction methods. When dealing with 
low level viruses, enrichment is required, especially with RNA viruses where 
the use of isolates and PCR amplification may not be feasible and may skew 
the populations. Whilst methods of enrichment are mostly developed for 
bacterial or cellular porposes, methods for RNA virus enrichment are starting 
to be developed (Logan et al., 2014). Testing of these methods could provide 
more success with the asymptomatic cases but trials would need to be carried 
out with tissues. Considering the finite level of EIAV tissues the negative 
tissues could be spiked with EIAVDEV and used to screen sample types and 
extraction protocols for sequencing success. 
 
The choice of sequencing platform can have a large impact on the coverage 
and return of full genome sequencing. As discussed in section 3.3.6 (Page 
127) sequencing technology is always advancing and providing opportunities 
for increased coverage and read length whether it be in the form of a new 
library preparation kit or new sequencing platform. To increase the chance of 
sequencing EIAV, newer MiSeq kits offering longer read lengths could be 
used as well as new sequencers such as the SOLiD or Ion Torrent platforms. 
The continuous advance and increased output of NGS however, requires a 
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suitable computing approach in order to get the most out of the data, 
especially since NGS is still expensive. As discussed in section 3.3.7 (Page 
128) the way forward at present is training in linux-based systems with the 
addition of quality checking and dedicated programs for SNP analysis. This 
would require a longer term approach given the steep learning curve involved 
with linux-based systems, but considering user friendly windows and iOs 
based programs are expensive and in slow development it is the best way 
forward at the present time. 
 
The sequencing of the asymptomatic cases remains a challenge but is 
important because they could be used to look for common elements in the 
asymptomatic genomes that confer their status. A greater understanding of 
the differences between asymptomatic and symptomatic viruses may yield 
information that affects the control of EIAV. EIAVWILT2 could be completed by 
PCR now that a loose skeleton of reads covers the genome. If successful, the 
addition of a British asymptomatic genome to the alignment could allow the 
generation of more successful primers to sequence EIAVWILT1, EIAVNORTH and 
EIAVDEV2.  
 
With the development of the IL-4 stimulated Mo, the isolation of the other 
British viruses may be possible. Renewed attempts at isolating the 
asymptomatic viruses could be undertaken starting with EIAVWILT2 since it had 
the lowest Ct value of the asymptomatic cases. The growth of the 
asymptomatic cases in eqMoMϕ culture would also provide an opportunity to 
sequence the virus with a much reduced host background compared to the 
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tissue extracts. Further comparison between the evolution of the virus in vivo 
and in the eqMoMϕ system would need to be carried out to assess the rate of 
variation in the different conditions. Fewer variants are present in the Sanger 
sequencing traces of EIAVDEV during six passages than present in the 
EIAVNEW population analysis indicating that mutation may be minimal. To 
confirm, regular use of NGS with a high depth of coverage would need to be 
carried out on the tissue and passages of the same virus to investigate the 
change in viral populations. Together these would allow an insight into the 
rate of mutation of EIAV in the eqMoMϕ system. This could then be compared 
with the other cell lines used to assess the impact of the different cell types, 
allowing an insight into the variation that occurs in the cell culture system 
compared to the original tissue, to see if the variation of virus populations 
declines as a result of cell culture. Passaging could be carried out in the 
Ederm cells alongside the myeloid cells and their sequences and mutation 
rates compared. Further to this other cell lines were obtained from Friedrich 
Loeffler Institute (Germany); equine foetal liver fibroblasts, equine skin sarcoid 
fibroblasts, equine embryonic lung fibroblasts and more equine dermal 
fibroblasts, which could also be compared to the myeloid and Ederm cells.  
 
With a system in place, work can be carried out to start comparing the 
replication kinetics of the different viruses; successful isolation of the 
asymptomatic cases would allow their sequencing for comparison on the 
genomic level as well as comparison of their growth kinetics and virulence 
with the symptomatic cases. The cells themselves could also be 
phenotypically characterised and compared to cells that negatively impacted 
197 
 
on EIAV replication to explore what factors are required to enhance EIAV 
replication. 
 
Much work still needs to be done towards developing a cell culture system for 
EIAV. The use of the IL-4 stimulated monocytes seemed to provide a 
reproducible system but the problem of variation between cell isolations and 
the short-lived nature remains. The ultimate aim would be to characterise a 
suitable cell for EIAV infection and then transform the cells to immortalise 
them (Raabe et al.,1998). Using individual cytokines IL-4 produced the best 
effects but further work could be carried out to determine if combinations of 
cytokines could have a synergistic (or antagonistic) effect on EIAV replication, 
for example initially M-CSF and serum were used and these M0 macrophages 
seemed to generate larger Ct drops more consistently than M-CSF or serum 
alone. In the absence of immortal cells further improvements to the culture 
system could be made, such as using trying different concentrations of serum 
in the culture medium and seeding at different densities. The cells could then 
be observed for various periods of time to ascertain any differences. 
 
 
The IL-4 stimulated monocytes and NGS pipeline represent a first step in 
creating a cell culture system capable of reproducibly and efficiently 
supporting EIAV replication of novel field viruses and the ability to carry out 
full genome sequencing of viruses from low viral load tissues respectively. 
Improvements to both methods have been identified and once in place the cell 
culture system would allow a much wider variety of EIA viruses to be used in 
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the study of EIAV biology and ultimately lead to a greater understanding of the 
virus.  Continued work to sequence and isolate the asymptomatic viruses 
could then lead to a comparison of the symptomatic and asymptomatic 
viruses behaviour in cell culture, and attempts to correlate the behaviour with 
a genetic determinant as well as provide an insight into a possible molecular 
detection method. 
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7.0 Appendices: 
Appendix 1: Primer sequences (Table 12.1, from the literature; Table 12.2, 
Designed from alignments; Table 12.3, Designed from specific virus 
sequences) 
Table 12.1: Primers taken from the literature. The primer names are shown with their 
sequence and source. Tm, melting temperature (°C); F/R, the direction of the primer (forward 
or reverse); NSTD indicates a nested primer.Table continued on next page. 
Target Primer PCR F/R Sequence Ta Source 
FGS 1F R1 F 
TGTGGGATTAAATAATGAGTA
CTTG 
59.8 
Quinlivan et al, 
2013 
 
854R 
 
R TGTTTCCAGCCCCATCTATC 63.7 
Quinlivan et al, 
2013 
 
380F R2 F CCCTAGGACAGCAGAGGAGA 63.5 
Quinlivan et al, 
2013 
 
1530R 
 
R AGCGCTCTTGCCAATAACAT 63.6 
Quinlivan et al, 
2013 
 
1264F R3 F GAAGCCCAAGGCTCAAAATA 62.9 
Quinlivan et al, 
2013 
 
2091R 
 
R ATTTCCTCCAACTCCCACAA 63.3 
Quinlivan et al, 
2013 
 
1483F R4 F GGATATTGGCACCACGAAAC 64 
Quinlivan et al, 
2013 
 
2574R 
 
R ATATGCGTCCCCAATATCCA 63.7 
Quinlivan et al, 
2013 
 
2378F R5 F AGGCCGAAGACAATAATCCA 63.3 
Quinlivan et al, 
2013 
 
3632R 
 
R ACAGGTCCCAGCAACTTTTG 64 
Quinlivan et al, 
2013 
 
3449F R6 F ATGCGTGGCTTCCAGAAATA 64.4 
Quinlivan et al, 
2013 
 
4450R 
 
R CAGGCCCAGATCCTTGTTTA 63.9 
Quinlivan et al, 
2013 
 
4032F R7 F GCCTCAGCAGAGTTTTGGAT 63.3 
Quinlivan et al, 
2013 
 
4570R 
 
R TTGCCAATAGCGTAGCATGT 63.1 
Quinlivan et al, 
2013 
 
4396F R8 F GCAAAGCAGATAACCCAGGA 64 
Quinlivan et al, 
2013 
 
5513R 
 
R TCGGGATCATTTCTTCTTGG 63.8 
Quinlivan et al, 
2013 
 
5356F R9 F GGGAGTCCAAACCCCTATTG 64.3 
Quinlivan et al, 
2013 
 
6601R 
 
R CTGCCATTCTTGCATTTCTG 63.3 
Quinlivan et al, 
2013 
 
6440F R10 F 
AACACAAGGGAAATAAATAAT
GCT 
60.5 
Quinlivan et al, 
2013 
 
7356R 
 
R GATGCACGTTTGTGATGGAG 64.3 
Quinlivan et al, 
2013 
 
7177F R11 F TGCAAATTGGATTCCTGGAT 64.1 
Quinlivan et al, 
2013 
 7912R  R 
GCAAGGCATTGTAACATGAG
A 
62.6 
Quinlivan et al, 
2013 
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7543F R12 F ACTCGCCAACTACGAGGAGA 63.9 
Quinlivan et al, 
2013 
 
8254R 
 
R ACTGTAGGATCTTAACCAAGAG 55.7 
Quinlivan et al, 
2013 
GAG Ire450 
GAG
bold 
F 
ATGGGAGACCCTTTGACATGG
AGCAA 
74.5 
Boldbaatar et 
al, 2013 
 
Ire450-B 
 
F 
ATGGGAGACCCAGTGACATGG
AGCAA 
75.8 
Boldbaatar et 
al, 2013 
 
Ire1879 
 
R 
CTCCCACAAACTGTTCAGGTTG
AGATCCT 
73 
Boldbaatar et 
al, 2013 
 
EIAV450-
C 
GAG
quin 
F 
ATGGGAGACCCATTGACATGG
AGCAA 
75.4 
Quinlivan et al., 
2007 
 
EIAV208 
 
R CGGTCTGAGTCCCTTCTCTG 64 
Quinlivan et al., 
2007 
GAG 
EIAV 
DNAITA F 
GAG F GACATGGAGCAAAGCGCTCA 68.8 
Cappelli et al, 
2011 
 
EIAV 
DNAITA 
R 
 
R CTGCCCAGGCACCACATCTA 68.5 
Cappelli et al, 
2011 
 
EIAV 
DNAITA 
NSTD F 
 
F TGTGGGCGCTAAGTTTGGTG 68.1 
Cappelli et al, 
2011 
 
EIAV 
DNAITA 
NSTD R 
 
R TTTCTGTTTCCAGCCCCATC 68.1 
Cappelli et al, 
2011 
LTR 
EIAVltr-
1F 
LTR F GACAGTTGGGCACTCAGATT 61.8 
Dong et al, 
2012 
-tat 
EIAVltr-
1R  
R CAGGAACACCTCCAGAAGAC 61.3 
Dong et al, 
2012 
 
EIAVltr-
2F  
F ATTCTGCGGTCTGAGTCCCT 65.1 
Dong et al, 
2012 
 
EIAVltr-
2R  
R TAAGTTCTCCTCTGCTGTCC 58.6 
Dong et al, 
2012 
FGS 
EIAVcom
1F 
EIAV
com1 
F 
TAGCCTGCTGAACCTGGCTGA
T 
65.9 
Dong et al., 
2013 
 
EIAVcom
1R  
R GCAGAGAAGGGACTCAGACC 63 
Dong et al., 
2013 
 
EIAVcom
2F 
EIAV
com2 
F GAACATGGTGGGCGATCTCT 66.4 
Dong et al., 
2013 
 
EIAVcom
2R  
R ACAACATGGAATAGTAAGAG 50.6 
Dong et al., 
2013 
 
EIAVcom
3F 
EIAV
com3 
F ACAAGGACCTATCCCTATGA 57.5 
Dong et al., 
2013 
 
EIAVcom
3R  
R ATGTCTCCTTCAGGTAACGA 58.8 
Dong et al., 
2013 
 
EIAVcom
4F 
EIAV
com4 
F ACAAGAAAACTTTCCCTGTG 58.3 
Dong et al., 
2013 
 
EIAVcom
4R  
R TTAAGGCAATATAGGACATC 53.4 
Dong et al., 
2013 
 
EIAVcom
5F 
EIAV
com5 
F GGCACTGAAATATCTAGGGG 60 
Dong et al., 
2013 
 
EIAVcom
5R  
R CTAAGACCCCAAGAAACACC 60 
Dong et al., 
2013 
 
EIAVcom
6F 
EIAV
com6 
F ACAAGGAATATTATGGGCAGG 61.5 
Dong et al., 
2013 
 
EIAVcom
6R  
R CTTCTGGGGGTATTTGCTTCC 65.5 
Dong et al., 
2013 
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S 
SBV-S-
382F 
SBV 
PCR 
F TCAGATTGTCATGCCCCTTGC 56 Bilk et al., 2012 
S 
SBV-S-
469R 
 R TTCGGCCCCAGGTGCAAATC 56 Bilk et al., 2012 
S 
SBV-S-
408FAM 
Prob
e 
N
A 
FAM-
TTAAGGGATGCACCTGGGCCG
ATGGT-BHQ1 
 NA Bilk et al., 2012 
 
Table 12.2: Primers designed from sequence alignments. The primer names are shown 
with their sequence and source. Tm, melting temperature (°C); F/R, the direction of the primer 
(forward or reverse). Location is given relative to EIAVWYO. Table continued on next page. 
Target Primer PCR F/R Sequence Ta Location 
GAG F1 F1 F TACAGTTGGCGCCCGAACAG 70.4 308-327 
GAG R1 
 
R CAGAAGTACAGTCTACTGATA 48.2 977-957 
GAG F1NSTD 
 
F CAGCAGAGGAGAACTTACAG 56.8 385-404 
GAG R1NSTD 
 
R 
TTTACCCAGGTAGTATATCCT
CT 
56.5 900-878 
GAG F2 F2 F 
AGGATATACTACCTGGGTAAA
TAC 
55.2 880-903 
GAG R2 
 
R 
TTCTGGCCTTAAATGTCTCAT
AGC 
64.2 
1450-
1426 
GAG F2NSTD 
 
F 
TGTACTTCTGAGGAAATGAAT
GC 
62 968-991 
GAG R2NSTD 
 
R 
GCAGGTTCCATCTGTCTTTCT
CT 
64.7 
1888-
1865 
GAG F3 F3 F 
TTGATCAGTTTAGGCAGACTT
ACAG 
62.4 
1191-
1216 
GAG R3 
 
R 
GTTAATACTGAAGTATCTGCT
CCTG 
59 
2015-
1990 
POL 
EIAV 
FwPol1 
POL1 F GTCAATGTAAAGCTCTCAAAG 55 
1736-
1756 
POL 
EIAV 
RvPol1  
R 
ATCCTCTGGATATTTCAGTTC
C 
58 
2509-
2488 
POL 
EIAV 
FwPol2 
POL2 F AATGGCCACTCACTAAGGAG 58 
2300-
2319 
POL 
EIAV 
RvPol2  
R ACCCCTGAACTCATCCATGT 58 
3041-
3022 
POL 
EIAV 
FwPol3 
POL3 F AAAGGGTTTTGAGACGCCTG 58 
2862-
2881 
POL 
EIAV 
RvPol3  
R CTTTCTGTTGCCACATGTTG 56 
3362-
3343 
POL 
EIAV 
FwPol4 
POL4 F ATGAGGGCTAATAAAGGATGG 57 
3292-
3312 
POL 
EIAV 
RvPol4  
R 
AGAAGTCAAACCCTGCATCTT
C 
60 
3961-
3940 
POL 
EIAV 
FwPol5 
POL5 F TGGGTACCAGGTCACAAAGG 60 
3826-
3845 
POL 
EIAV 
RvPol5  
R 
GCCTGCCAATGATTAGGAGAT
C 
62 
4487-
4466 
POL 
EIAV 
FwPol6 
POL6 F GCACAAGATGAACATGAGAA 54 
4321-
4340 
POL 
EIAV 
RvPol6  
R GTAATAAATACTTCCCATGG 52 
4901-
4882 
POL 
EIAV 
FwPol7 
POL7 F TACAACTTGCTCTCATTACT 52 
4826-
4845 
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POL 
EIAV 
RvPol7  
R TGCGATGCTGACCATGTTAC 58 
5335-
5316 
GAG F74 
GAGga
p 
F 
CTGYTGAACCTGGCTGATGCT
AGG 
73 354-377 
GAG R1020 
 
R 
CCTGCCTGACCAGGTACTACA
TC 
65.7 
1020-
998 
POL PolF2.1 POL2.1 F AGTAACTATTTTGGGGCGAGA 61.4 
~2171-
2192 
POL PolR2.1 
 
R CTTTTATCTGGTTCCTGATG 56.2 
2637-
2657 
POL PolF2.2 POL2.2 F 
GGAACTGAAATATCCAGAGGA
T 
59.9 
2487-
5009 
POL PolR2.2 
 
R ATTCAGCTTCCARAGAGCCAA 57.1 ~3200 
ENV 5821F ENVs F ATAGCGATCATTGCCAGGAA 64.4 
5821-
5841 
ENV 5059R 
 
R CCTTTGCCCAGGTCTCATTA 63.9 
6059-
6079 
 
Table 12.3: Primers designed for specific viruses. The primer names are shown with their 
sequence and source. Tm, melting temperature (°C); F/R, the direction of the primer (forward 
or reverse). Location in reference to specific genomes. Table continued on next page. 
Target Primer PCR F/R Sequence Tm Location 
LTR 
EIAV 
7751F 
CorLTR1 F 
ATCATGGGACGCTTAA
TAGG 
56 7751 
LTR 
EIAV 
8254R  
R 
TTGTTGAGCTGTGTGA
GTTC 
56 8254 
LTR 
EIAV 
7881F 
CorLTR2 F 
CCAGCTACATCTCATA
TATC 
54 7881 
LTR 
EIAV 
8350R  
R 
TTGGCCATCTGTATAT
CTTC 
54 8350 
ENV DevF5926 
DevENVg
1 
F 
GTGTACAGCCGCCATT
CTTT 
63.9 5926 
ENV DevR6788 
 
R 
TAGCGCTAGCAGCAAT
AGCA 
63.7 6788 
ENV DevF7557 
DevENVg
2 
F 
TATGGACTCCAGGGG
ATAGC 
62.8 7557 
ENV DevR8221 
 
R 
CCAGCAGAGAAGGGA
CTCAG 
64.2 8221 
ENV CorF5490 
CorENVg
1 
F 
GGGGATCTTTTCCTGG
ATGT 
63.9 5490 
ENV CorR5972 
 
R 
TGACTATGATTGTCTG
GATTCCTT 
62.5 5972 
ENV 
EIAV 
8350R 
CorLTR3 R 
TTGGCGATCTGTATAT
CTTC 
54 
8350-
8370 
ENV 
EIAV 
8254R  
R 
TTGTTGAGCTGTGTGA
GTTC 
56 
8254-
8274 
ENV 
EIAV 
7881F 
CorLTR4 F 
CCAGCTACATCTCATA
TATC 
54 
7881-
7901 
ENV 
EIAV 
7751F  
F 
ATCATGGGACGCTTAA
TAGG 
56 
7751-
7771 
ENV CorENVF1 CorENV1 F 
CCAACAAGGAAGACAA
CCTCACT 
65.4 5048 
ENV CorENVR1 
 
R 
TCCTGGCAATGATCGC
TATCT 
65.7 5647 
ENV CorENVF2 CorENV2 F 
CCTGGATGTAGACCGT
TCAATAAT 
63.8 5496 
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ENV CorENVR2 
 
R 
AACCCCTAGATATACT
GGAGGCC 
64.1 6032 
ENV CorENVF3 CorENV3 F 
CCGATCAGATTGTGTG
TACAGC 
64.4 5904 
ENV CorENVR3 
 
R 
TAACACTAGCAGCAAT
AGCAGT 
58.4 6540 
ENV CorENVF4 CorENV4 F 
CGCACTGGATTAGTTA
GATACAAG 
60.6 6450 
ENV UniENVR4 
 
R 
TCGTCGTTGTCCAGAG
GTTTCT 
67.1 
7066/709
5 
ENV CorENVF5 CorENV5 F 
GAGTCATGTGGCGAA
CTGGAT 
66.4 6968 
ENV CorENVR5 
 
R 
GCCTATTAAGCGTCCC
ATGATG 
66.3 7577 
ENV DevENVF1 DevENV1 F 
TCAGCAAGGAGACAAC
CTTCAT 
65.9 5024 
ENV DevENVR1 
 
R 
CTTGACAGTGATCACT
ATCTACAC 
57 5644 
ENV DevENVF2 DevENV2 F 
CTGGATGTAGGCCGTT
CACTAATT 
65.9 5494 
ENV DevENVR2 
 
R 
ACCCAAGAATATTGAT
GGCCCAC 
68.5 6006 
ENV DevENVF3 DevENV3 F 
CCCATTAGGCTATGTG
TACAGC 
62.2 5902 
ENV DevENVR3 
 
R 
TAGCGCTAGCAGCAAT
AGCA 
63.7 5611 
ENV DevENVF4 DevENV4 F 
AACACTGGGTTAGTTA
GACGTAAG 
59.3 6421 
ENV UniENVR4 
 
R 
TCGTCGTTGTCCAGAG
GTTTCT 
67.1 
7066/709
5 
ENV DevENVF5 DevENV5 F 
TGGAGCCATGTTGCTA
ATTGGAT 
68.2 6937 
ENV DevENVR5 
 
R 
CCAACATGCGTCCTAG
TATGA 
62.5 7543 
LTR-
GAG 
Dev5'GSP1 
 
R CATCGCCCACATTATT 54.8 519 
LTR-
GAG 
Cor5'GSP1 
 
R ATGGCTTATTTGCAGG 54.2 510 
LTR-
GAG 
Dev5'GSP2 
 
R 
TTTCTTGGCCTGTCAA
TGTT 
63.3 445 
LTR-
GAG 
Cor5'GSP2 
 
R 
GTTCTTTCCCTGTTAAT
GTATTT 
56.9 ~440 
LTR-
GAG 
Dev5'GSP3 
 
R 
TTTCATAAAGTTGGTG
TCATGG 
61.2 372 
LTR-
GAG 
Cor5'GSP3 
 
R 
GTTTTGTAAGCTGGGT
GTCAT 
60.5 ~350 
LTR CorLTRF CorLTR F 
GGGACGCTTAATAGG
CTATGG 
63.4 7506 
LTR CorLTRR 
 
R 
CTCAGATTCTGCGGTC
TGAGT 
63.6 ~30 
LTR Wilt2F Wilt2 F 
TCCCTGGCTTCACTTG
TCTTG 
66.5 ~53 
POL Wilt2R 
 
R 
ACAGGGAGAGTTTGCT
TTTGG 
64.3 ~2000 
LTR Wilt2_2_F Wilt2_2 F 
CCGAACAGGGACCTG
AGAAG 
66 ~50 
POL Wilt2_2_R 
 
R 
TTCCTGATCCTGTTGC
TCTTCC 
66.6 ~1500 
POL Wilt2_3_F Wilt2_3 F ACCCAGATTTGACCCA 63.8 ~1500 
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GATG 
POL Wilt2_3_R 
 
R 
GGCCCCTATCAGTTTT
TCCA 
63 ~2100 
POL Wilt2_4_F Wilt2_4 F 
GATAGCCCCAAGGCA
CATAA 
63.6 ~1800 
POL Wilt2_4_R 
 
R 
GCAATCTCCATTTTCC
AGACTT 
63.2 ~2100 
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Appendix 2: Bioanalyzer results for SBV 929 extraction 
Bioanalyzer results for the SBV 929 tissue extraction using the 
TRIzol/RNeasy extraction method. A Shows the gel image taken. There is a 
consistent pattern across all the elutions representing the consistent content 
of each elution. B The marker showing peaks (from left to right) at 25, 200, 
500, 1000, 2000, 4000 and 6000 nucleotides. C Sample 7 contains a marker 
that was run in each sample as an indication that the read was successful. D 
The TRIzol® extracted 929 sample with a highly reduced RNA yield compared 
to the elutions. E F G H and I Show each consecutive elution. The RNA yield 
decreases from E1-E4 but then increases in E5. RNA concentrations are 
superimposed onto the graphs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
B 
C 
D 
E 
RNA conc: 35.29 ng/ul 
RNA conc: 908.47 ng/ul 
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RNA conc: 193.24 ng/ul 
RNA conc: 128.83 ng/ul 
RNA conc: 77.18 ng/ul 
RNA conc: 116.58 ng/ul 
Appendix 3: Bioanalyzer results for SBV 544 extraction  
Bioanalyzer results for the SBV 544 tissue extraction using the 
TRIzol/RNeasy extraction method. A Shows the gel image taken. There is a 
consistent pattern across all the elutions representing the consistent content 
of each elution. B The marker showing peaks (from left to right) at 25, 200, 
500, 1000, 2000, 4000 and 6000 nucleotides. C Sample 7 contains a marker 
that was run in each sample as an indication that the read was successful. D 
E F G and H show the consecutive elutions with each elution containing less 
than the one before. RNA concentrations are superimposed onto the graphs. 
 
 
 
 
 
F 
G 
H 
I 
A 
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RNA conc: 111.57 ng/ul 
RNA conc: 139.07 ng/ul 
RNA conc:28.45 ng/ul 
RNA conc: 10.53 ng/ul 
RNA conc: 4.08 ng/ul 
 
 
 
 
 
 
B 
C 
D 
E 
F
 E  
G 
H 
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Appendix 4: Nucleic acid sequence homology tables: 
Tables showing the percentage identity and divergence of the nucleic acid 
sequences of the full genome sequences and partial sequences which only 
contain the gag. 
Full genome sequence (excluding LTRs) 
 
LTR 
 
GAG 
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POL 
 
ENV 
 
tat 
 
S2 
 
 
216 
 
rev 
 
PR 
 
RT 
 
RN 
 
 
217 
 
DU 
 
 
IN 
 
Gp90 
 
 
 
 
 
 
 
218 
 
Gp45 
 
GAG 
 
 
 
 
 
 
 
 
 
 
 
219 
 
MA (P15) 
 
CA (p26) 
 
 
 
 
 
 
 
220 
 
NC (p11) 
 
p9 
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Appendix 5: Amino acid code table: Table showing the general properties of 
each amino acid and its three and single letter code. 
 
Properties Amino acid Three letter code Single letter code 
Non-polar side 
chains 
(Hydrophobic) 
Glycine Gly G 
Alanine Ala A 
Valine Val V 
Leucine Leu L 
Isoleucine Ile I 
Methionine Met M 
Phenylalanine Phe F 
Tryptophan Trp W 
Proline Pro P 
Polar side 
chains 
Serine Ser S 
Threonine Thr T 
Cysteine Cys C 
Tyrosine Tyr Y 
Asparagine Asn N 
Glutamine Gln Q 
Negatively 
charged side 
chains 
Aspartate Asp D 
Glutamate Glu E 
Positively 
charged side 
chains 
Lysine Lys K 
Arginine Arg R 
Histidine His H 
 
 
 
 
 
 
